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ABSTRACT· 
COMPARISON OF THE BEHAVIORAL PHARr1ACOLOGY OF PHENCYCLI DINE TO RELATED 
COMPOUNDS 
Kathl een T. Brady , Ph . D .  
Medi cal Col l ege o f  V irgin ia  - Vi rgi n ia  Commonweal th Univers ity ,  1 981 . 
Major Professor : Dr . R . L .  Bal ster 
Phencycl i d i ne ( PCP )  bel ongs to a cl ass  of drugs with � · u n i que  and  
characteri stic  spectra of pharmacol ogi cal activ i ty .  PCP has recentl y 
become a major drug of a bu s e .  Structural anal ogues of P C P  have al s o  
been reported i n  street u s e .  The fol l owi ng experiments expl ore the 
behavioral pharmacol ogy of PCP a nd several compounds with PCP-l i ke 
activ ity .  
-- -
I n  Experiment I the effects of PCP were compared to three structural 
a nalogues i n  rhesus monkeys tra i ned to l ever press on a fi xed- i nterval 5 -
m i n  schedul e o f  food presentation .  Dos e-response curves a nd potency 
estimates were determi ned for PCP ,  N-ethyl -l -phenylcycl ohexyl ami ne 
( PCE ) , 1 - ( 1 - (2-thi enyl ) cycl ohexyl ) pi per i d i ne (TCP )  a nd ketam ine . 
The e ffects of all  four drugs on response rates were dependent on the 
bas el i ne rate of respond i ng . . High doses of al l four drugs decreased 
overal l response rates . Onset and duration  o f  drug effects were ·a 1 s o. 
determ i n ed and compared . 
I n  Experiments I I  through V I  the drug di scrimi nati on paradi gm was 
used . Animal s were tra i ned to d i scrimi nate PCP ( rats , 3 . 0  mg/kg i . p . ; 
monkeys , 0 . 1 6  mg/kg i .m . ) from sal i ne  i n  a two-l ever drug d i scr i mi nation  
task o n  a fi xed- rati o  32 ( FR 32 )  schedul e of food presentation . After 
rel i a bl e d i scrimi native control of l ever cho ice was establ i s hed , general -
i zati on  tests were conducted every thi rd day . Test periods cons i sted o f  
xi  
a 2 -mi n peri od duri ng wh ich  respond i ng on ei ther l ever was rei n forced 
(rats' ) or res pondi ng was recorded but not re i nforced (monkeys ) .  The PCP 
dose-response determi nation prec�ded general i zation  testi ng  with  other 
compounds . Dose-effect curves for each drug for percent drug-l ever 
a ppropriate res pond i ng and for suppres s i on of operant respond i n g  dur i ng 
test ses s ions were a na lyzed by l i near regres s i o n .  
I n  Experiment I I  the di scrimi native st imul us  properties o f  PCP a nd- -
f i ve other a ryl cycl oal kyl am i nes were i nvesti gated in squirrel monkeys . 
Genera l i zation  testi ng was conducted wi th PCP , PCE , TCP ,  l - ( l -phenyl cycl ohexyl ) 
morpho l i ne ( PCM ) ,  l - ( l _phenyl cyclo hexyl ) pyrro lCd i n� ( PHP ) , and ketami ne . 
Al l drugs produced dose-dependent PCP-appropri ate respondi n g .  The dose 
necessary to suppress o perant respondi ng to fi fty percent o f  veh i c l e  
rates w a s  3 to 8 times l arger than the EDSO for drug- lever a ppropriate 
respond i ng .  
Experiments I I I ,  I V  and V I  were des i gned to expl ore s i m i l ar it ies 
between the di scrimi native stimul us properties of PCP and a ser ies of 
s tructura l ly  d i s s imi l ar compounds . I n  Experiment I I I  the d i s crimi ­
native stimul us properties of dexoxadrol and etoxadrol , both 2 - ( 2 , 2� 
s u bst i tuted 1 , 3 d i oxo l an-4-yl ) p i perid i nes, were studied i n  squi rrel 
monkeys . Both compounds genera l i zed to PCP i n  a dose-dependent manner . 
The dose necessary to suppress operant res pondi n g  to fi fty percent of veh ic le  
rates was 3 to 7 t imes l arger than the EDSO dose · for drug-l ever a ppro-
priate res pond i n g .  
I n  Experiment I V  the d i s crimi nati ve stimulus  properties  o f  stereo­
i s omers of N-al l yl normetazoci ne ,  a benzomorphan opi o i d  wi th  psychoto­
m i meti c p roperties , were i nvesti gated in squi rrel monkeys and rats . 
I n  both spec i es ,  the (+) i somer and the racemic  m ixture produced dose­
d ependent PCP-a ppropr iate respond i ng . The ( -) i somer d id  not  produc e  
PCP-appropriate responding , however i t  wa s  more potent than t h e  (+) 
i somer i n  overa l l  response rate su ppress ion . H i gh  do ses of nal oxone 
(rats , 30 mg/kg ; mon keys , 1 .0 and 3 .0 mg/kg ) did not bl ock the dru g ­
l ev er a ppropriate respond i ng or res ponse rate suppress ion  produced by 
e ither i somer of N -a 1 l ynormetazoc i n e .  
I n  Experiment V t h e  d i scrim i native stimu l u s  properti e s  of ketami� -----­
stereoi somers were i nvestigated i n  rats . Both i somers a nd t he racem i c  
form o f  ketam ine  produced drug-l ever a ppropriate respond i ng and d ecrea s ed 
response rate i n  a dose-dependent manner . There was no s i g n if icant  
potency d ifference between (± ) -ketami ne and e ither of the i somers for 
e i ther of these measures . 
The stereo se1 ecti v i ty of t he d i scrimi nat ive  stimul u s  propert ies  of 
cyc l azocine , another opioid  of the benzomorphan ser ies , i n  squ i rrel 
monkeys was expl ored i n  Experiment VI. The (+) i somer produced dose­
dependent PCP-appropriate respond ing . The (-.) i somer and the racem ic 
m ixture d id not produce PCP-appropriate  respond i ng at any of the dose s  
tested . The (-1 i somer was 300 t imes more potent than the (+1 isom er i n  
ov era l l response rate suppress ion . 
The I'.Ork presented i n  th i s  thesis  suggests that PCP bel ongs  to a 
u n i qu e  c l a s s  of drugs  whIch can have a wide variety of chemi.cal struc.,. 
tures . . The overa 1 p i n the behav i ora 1 pharmacol ogy of PCP and the 
psychotomimet ic  op ioids  of the benzomorphan series is  probably due to 
the act i v i ty of the (+). i somers of these compounds . 
x i i i  
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I .  GENERAL I NTRODUCTION 
The current esca l ation  i n  the abuse of l - (l-phenyl cycl ohexyl ) 
p i per i d i ne ( phencycl i d i ne ;  PCP) has brought an i ncreas i ng amount of 
a ttenti on to the c l ass  of drugs  to whi ch it  bel ongs , the d i s soci ative 
a nesthetics . Recent research has reveal ed thi s group of compounds to 
have a v ery uni que and c haracter ist ic  s pectra of pharmaco l o g i ca l  acti ­
v i ty .  The · research presented i n  thi s d i ss ertation represents a n  attempt 
to further characteri ze the behav ioral pharmaco l ogy of thi s group of 
compounds a nd to make some contr i bution to the body of l i terature con­
cerned w i th the rel ati onshi p of structure to behav i oral acti v i ty .  
Al l compounds referred to i n  this  thes i s  are racem i c  m ixtures un l ess 
otherwi s e  i ndi cated . 
A. H i s tory · of Phencycl i di ne 
Phencycl i di ne ( PCP )  was synthes i zed by Victor Maddox and a s soc i -
ates o f  Parke-Da v i s  and Co . General pharmacol ogical  test i ng ( Chen et 
21 . , 1 959)  i ndi cated that PCP produced surgi cal anesthes i a  i n  monkeys 
wi thout card i ac or respi ratory d epress ion . As a resul t ,  PCP was devel ­
oped by Parke-Dav i s  a nd Co . as an anesthetic a gent . I n  1 957 , c l i ni cal  
tri a l s  revea l ed that doses o f  0 . 2 5  mg/kg i . v .  produced anesthes i a  s uf­
fi c i ent for m i nor a nd s ome major surgery ( Grei fenstei n et �., 1 958 ) .  
Phencycl i di ne vias devel oped for use  i n  humans under the trade ·name 
Serny1 (Munch , 1 974 ) .  Because  o f  post-operativ e  thought d i s turbances 
a nd a g i tation  produced by phencycl i d i n e ,  i n  1 965  c l i ni cal i nvesti gations . 
. 
were d i s conti nued . I n  1 967 , the drug patent was changed to perm i t  the 
manufacture of PCP for veter i na ry use  as a n  a n imal  i mmobi l i zi ng agent 
( Marti n  � 21. ,  1 97 2 ;  Seal a nd Eri kson , 1 969)  under the trade name 
Serynl an  ( Bi o-Ceuti c La boratories , I nc . ) .  At the present time , PCP i s  
not commercia l ly ava i l abl e .  Ketami ne ( Keta l ar ) , a ketone anal ogue o f  
-2 -
PCP ,  i s  p resently marketed by Parke-Da v i s  and Co . a s  a di ssoc iat ive  
anes theti c for veterinary and human u se .  I t  has a very s im i l a r  pharma-
co 1 0g i ca1  profi l e  to that o f  PCP (r1cCarthy.et �. , 1 965; Chen et �. , 
1 966)  but has a s horter durat ion of action and a l ower i nci dence of 
emergence reactions ( Corss en and Domino , 1 96 6 ;  Corssen et �. , 1 968) . 
Reports o f  i l l i c i t  use  of PCP began i n  1 967 on the West Coast  
---------
( Meyers et �. , 1 967/1 968) . At th is  time , i t  was marketed a s  a mi l d  � __ 
psychedel i c  and s o l d  i n  tabl et and capsu l e forms . Because  the effects 
were often unexpected and the dosage cou l d not be  t i trated , there was a 
h i g h  i nc i dence of adverse reactions and PCP l o s t  popul a r i ty · a s  a s treet 
drug ( Bu rns et �. , 1 97 5 ) .  
In  the next few Years , PCP was sti 1 1  found on the s treet , but i t  
was u s ual ly m isrepres ented as  another dru g ,  most  commonl y  as  �9-tetra ­
hydrocannabino1  ( THC ) .  A survey i n  Los Angel es (Lundberg et �., 1 976 )  
reveal ed that .out o f  94  street sampl es of drugs so l d as THC ,  74  con­
tained only PCP, and only 8 . 7  percent of the total  sampl es contain ing  
PCP  were represented correctly as  PCP.  
In  the early 1 970's , there was a marked c hange in PCP s treet u s e  
(Lerner and Burns , 1 978 ) .  Thi s  was probably  due t o  a trend towards 
smoking PCP on l ea f  mater ia l  rather than oral ingestion o f  a tabl et or 
caps u l e .  Th i s  a l l owed the user to more effective ly  control the dosage . 
Between 1 972 and the pres ent time , there has been a steady i ncrease i n  
t h e  number o f  emergency room menti ons i nvo l v ing  P C P  i n  the Drug Abu s e  
Warning Network ( DAWN )  system . The sharpest increase  i n  PCP-related 
emergency room mentions has been in the three· year per i od between 1 97 6  
and 1 979 .  T h e  Drug Enforcement Admi n i s trati on (DEA) h a s  ranked PCP 
s econd only to hero in  i n  its 1 979 pri or i ty ranki ng of efforts against 
\ 
i l l i c i t  drug traffic ( Newmeyer , 1 980) . 
The s l ang  name · of s treet phencycl i d i ne and i ts phys i ca l  form have 
continuous l y  changed s ince i ts emergence as a drug of abu s e .  I t  has 
a ppeared as a powder , a ta bl et , a l ea f  mi xture and a l iqu i d  ( lundberg � 
�. , 1 976 ) . I t  can be taken oral l y ,  bu i nsuffl ati on , or s pri n kl ed on a 
combusti bl e materia l . At the pres ent time , i t  i s  most commonly sol d  as  
PCP , Angel Dust ,  Hog  or Crysta l . To date , at l east  five s tructural 
a na l ogues of PCP have been d i scovered in i l l i c i t  street use ( S hu1 g i n  and 
Maclean ,  1 976 ) .  
B .  Chemis try 
Phencycl i di ne hydrochl oride  ( l - ( l -phenylcycl ohexyl ) pi per i d i ne 
hydroch loride )  i s  a whi te , s tabl e sol id  wi th a mel t i ng poi nt o f  234-
2360C ( Domi no , 1 964 ) .  I t  i s  a wea k bas e  that i s  read i l y  sol ubl e i n  
water ( Domi no , 1 964 ) and h i 9h1y l i pophi l i c  at phys i o l ogica l  pH ( James 
and Schno l l ,  1 976 ) . A recent report (Maayani and Gross , 1 980) i nd i ca te 
that PCP has a rel atively  h i g h  pKa val ue  ( pKa � 9 . 42 at 2 50C ,  pKa = 9 . 20  
a t  370C ) '  a l ow water sol u bi l i ty ( 2 . 2  x 1 0-4M at  230C )  and a h i gh o i l ­
water parti tion coeffi c i ent . PCP i s  prepared by the react ion  o f  1 -
pi peri donocycl ohexanecarboni tri l e  ( PCC)  with  Gri gnard reagent ( S hu l gi n. 
and Maclean , 1 976 ) . The synthes i s  i s  fa i rly  easy whi ch , no doubt , 
parti a l ly  expl a i ns the widespread avai l a bi l i ty and use  of · the  drug . 
I n  addi tion to phencycl i d i ne ,  over th i rty chemi cal l y  s imi l ar 
anal ogues have been synthesi zed (Maddox et �. , 1 96 5 ;  Kal i r  et �. , 
1 969 ;  Wei nstei n ,  et �. , Maayani � �. ,  1 974 ; Geneste et �. , 
1976 ; Shul g i n  a nd Maclea n ,  1 976 ) . Al though s everal  of these anal o gues 
have been di scovered i n  i l l i c i t  street use , there i s  a pau c i ty o f  b io-
l og i cal data on  these compounds . Ketam i n e  i s  the on ly  PCP anal ogue 
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whi c h  has been s u bj ected to extens ive  pharmaco log ical  exami nati on  
( Mc Carthy et � . •  1 965)  and spectra of acti v i ty i s  very s i mi l a r  to  that 
of PCP .  
Mos t  active  PCP  ana l ogues i nvol ve sUbstitutions for the  p i peri di ne 
ri ng  ( i  . e . , PHP. PCE ) a nd l ess  frequently the phenyl ri ng (i . e  TCP ) . I n  
add it ion  t o  structural anal ogues . i t  appears that there may b e  some 
s tructura l l y  u nrel ated chemical s "namely etoxadrol and dexoxadrol 
( Chen ,  1 965)  whi ch share many pharmacolog ical  propert ies ¥/i th PCP . 
A number of s tud ies have i nd i cated pharmaco logical  s i mi l a ri ti e s  
between PCP  and  s everal of i ts anal ogues . PCP , PCE , and Tep have been 
s hown i n  a s eri es of s tud ies by Maayan i  and hi s group to have  both 
a nti chol i nerg ic  and antichol i nesterase  act i v i ty u s i ng receptor bi nd ing  
a n d  bi oassay procedures ( Kl oog et �. , 1 977 ; Maayan i  et  � . •  1 97 4 ;  
-4-
1 973 ; Paster et �. , 1 974 ; Pi ncha s i  et � . •  1 977 , 1 978a , 1 978 b ;  Wei nstei n 
et �. , 1 973 ) .  Gehrmann and Ki l l am ( 1 979 )  found PCP , PCE a nd  ketami n e  
p roduced s im i l ar EEG effects i n  rhesus monkeys . Drug di scrimination  
stud i es ( Jarbe et  �. , 1 97 5 ;  Overton , 1 975 ; Sha nnon , 1 97 9 )  have  shown 
that PCp-tra i ned an ima l s  g eneral i ze to PCE . ketami n e  and s ev eral  
other structural a na l ogues of PCP.  
Pharmacol ogica l  and  behaviora l  characteri zation  of PCP a na l ogues  
and  representatives of other chemical cl asses which may have PCP-l i ke 
effects has rapid ly  devel oped during the yea rs that the res ea rch  descri bed 
in thi s d i s sertation has 'been carri ed out .  These more recent  s tud i es 
wi l l  be di scussed i n  the context o f  the research i n  suceed i n g  chapters . 
C .  Pharmacol ogy 
Genera l  Pharmacology 
The most promi nent effects of PCP  and  other aryl cycl oa l kyl am ines 
-5-
are  on  the central nervou s system . Because the major focu s  o f  my re­
s earc h is  on  the centra l nervous system effects of the aryl cyc l oal kyl ­
ami nes , the general pharmacol ogy of these compounds wi l l  be dea l t w ith  
onl y br i efl y .  Domi no ( 1 964 ) h a s  pu bl i s hed a comprehens ive  rev i ew o f  
t h e  g eneral pharmacol og ica l  act i v i ty of PCP .  
Anesthetic doses of PCP act as  a m i l d  pressor agent i n  man 
( Gre ifenstein et �. , 1 958 ; Johnstone et �. , 1 959)  and s ev eral s pec ie s  
o f  a n imal s ( C hen et  �. , 1 959 ) . T h i s  a ppears to be due to  a cocaine­
l i ke effect in bl ocking  reuptake of the catec ho l ami nes ( Chen et �. , 
1 96 5 ;  O'Donnel l and Wanstal l ,  1 968 ) and to some d irect action on a­
adrenerg ic  receptors ( I l ett et �. , 1 966) . Hypertensive cr i ses have 
been reported i n  PCP overdose  pat i ents ( Eastman and Cohen , 1 97 5 ) . 
I n  humans , anesthetic doses of PCP produce smal l increases  i n  the 
m i nute  vol ume,  rate and depth o f  respiration (Gre i fens·tei n  et �. , 1 958 )  . 
. Anesthet ic  doses of PCP have no marked effect on respiration i n  
s ev eral spec i es o f  l a boratory a n imal s ( Chen et �. , 1 959) , but h i g her 
doses  cause · suppress ion of respiratio n ,  hypotens ion . and bradycard i a . 
No ev idence o f  acute cel l ul ar tox i c i ty was reported i n  the 
f irst  c l i n ical stud i es of PCP (Greifenstein  � �. ,  1 958) . Lerner a nd 
Burns ( 1 978) have reported no evidence of hematol og i c , hepat ic  o r  renal  
tox ic i ty in a study of chronic PCP use  by humans  for per iods o f  t im e  
v arying from 6 months t o  5� years . 
There hav e been a number of recent stu d i es o f  the blOdi spos it ion  of 
PCP .  PCP is  wel l a bsorbed after al l routes of adm i n i strat ion. It is 
ra p idl y metabol i zed v i a  oxidative hydroxyl ation of the r ings  a nd ex-
creted in the urine  as conju gates (Ober � �. , 1 963 ; L i n  et �. , 1 97 5 ;  
Wong  a nd B i eman ,  1 97 6 ) . Di fferent s pec i es produce the same. u r i nary 
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metabol ites in differing amounts . Whil e the biol ogical a ctivity of the 
metabol ites is  l argely u nexpl ored , there have been some reports of 
activity of s everal hydroxyl ated metabol ites in rats , dogs a nd mice 
( Maddox � �. ,  1 96 5 ;  Domino , 1 978 ; Cone et �. , 1 980 ) .  
PCP is highly l ipophilic and distributes rapidly to the brain and 
other tissues . Studies with s everal species have found high concentra­
tions in l un g ,  l iver a nd fat ( Martin et �. , 1 980 ;Bail ey et �. ; 1 97 9 ;  
Law � �. ,  1 979 ) . Al though PCP is rapidly  metabol ized, overdose patients 
frequently s how signs of PCP infoxication for s everal days ( Burns et 
�. , 1 975;  James and Schnol l ,  1 976 ) . James and Schnol l ( 1 976)  reported 
l ow l evel s of PCP persisted in both brain and adipose tiss u e  of rats 48 
hours a fter a singl e i . p .  injection . Misra et �. ( 1 979 )  r eported that 
PCP a nd metabolites pers i sted for prol onged peri ods in rat bra in and 
adipose tissue a fter a singl e injection and s howed accumu l a tion a fter 
mu l tipl e  dosin g .  They a l so reported a high degree of mel a nin binding of  
PCP a nd its metabol ites which impl ies a possibl e l ocal ization in the  
neuromel anin-rich substantia nigra a nd l ocus  coeru l eus . Some investi­
gators ( Misra et �. , 1 976 ; James and Schnol l ,  1 97 :6) suggest that this 
s equestered PCP is a possibl e expl anation for the prol onged and persis- , 
tent cognitive dysfunction several days a fter PCP administration . 
Leighty and Fentiman ( 1 980 )  recently reported s everal common fatty acids 
were conjugated to two metabol ites of phencycl idine in a n  i n  vitro rat 
l iver microsomal system . They suggested this as a mechani sm  by which 
PCP is retained in l ipid containing tissues . 
Another expl anation for the occasional prol onged intoxications with 
, PCP has been offered by s everal investigators ( Done et �. , 1 977, 1 978 ) . 
PCP is a wea k bas e  with a pKa of a pproximately 9 . 20 (Maayani and Gross ,  
1 980) . Because of thi s ,  i t  s houl d become ion i zed i n  the ac id  med i a  o f  
t h e  stomach a nd become trapped there . The current treatment for PCP 
overdose  is aci d ifi cation of the ur ine coupled  wi th 9as tri c suct ion ing  
( Aro now a nd Done , 1 978) .  
Central Nervous System Pharmacology 
Neurotransmi tter Systems 
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Catecho l amine Systems . Whi l e  there have been many recent stud i es 
o f  the effects of PCP on central neurotransmi tter systems , no c l ear 
pi cture has emerged to expl a i n  i ts· neurochemical  mechanism of acti on . 
Leonard and Tonge ( 1 969) reported that PCP produced a decrease i n  rat 
bra i n  norepi nephri ne ( NE )  and a s l i ght i ncrease  in dopam i ne ( DA ) . They 
found that PCP potenti ated reserpi ne- i nduced NE  depl etion , but had no 
effect o n  N E  turnover . Another study by Leonard and Tonge ( 1 970 ) 
reported an i ncrease i n  rat bra i n  tyro s i ne l eve l s  a fter PCP adm i n i s­
trati o n .  Hi tzeman et �. ( 1 973 )  reported that PCP decreased the syn­
thes i s  of DA a nd NE a nd i ncreased the accumul ation of the O-methy1 ated 
metabol i tes of DA a nd N E .  Thi s impl i es that P C P  e i ther i ncrea s es the 
rel ease or d ecreases the reuptake of catecho 1 ami nes from the extraneu-
ronal space .  
Cons i s tent with thi s ,  s everal i nvesti gators have found that PCP 
i nh ibi ts the uptake o f  N E  a nd/or DA in both cort i ca l  s l i ces ( Taube et· 
�. , 1 975) a nd synaptosomes ( Garey and Heath , 1 976 ;  Smi th et �. , 1 97 7 ;  
Arf a nd Kom i s key , 1 980) . Recently ,  Vickroy a n d  Jo.hnson ( 1 980 ) reported 
that PCP s timul ated tyro s i ne hydroxyl ase acti v i ty i n  rat synaptosomes 
wi thout i ncrea s i ng the uptake of 3H-tyro s i ne .  They postu1 a ted . that th i s  
st imu l ation  m ight be  a n  i nd i rect action v i a  t he  rel ease  of DA . Thi s i s  
i n  agreement wi th the fi nd i ngs of Ary and Komi s key (1 980 ) that PCP 
decreased 3H_DA accumul ation i nto synaptosomes by decrea s i n g  uptake and 
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by rel eas i ng prev iously accumul ated DA . Bagchi ( 1 980) a l s o  reported 
that PCP i ncreased the rel eas e  of DA and stimul a ted DA synthes i s  ,i n  rat 
caudate synaptosomes . Doherty et �. ( 1 980 ) found that PCP decreas ed 
the  rate o f  striatal DOPA accumul ation after the , i nh i bi ti on o f  L-aromatic,  
ami no decarboxyl ase  in  the  rat  striatum, but  d i d  not  anta go n i ze the 
i ncrease  i n  DOPA Caused by hal operidol . PCP a l s o  decreased str i ata l  
l evel s o f  DA metabol i tes whi l e  potentiati ng t h e  ha l o peri do l-i nduced r i s e  
i n  D A  metabol i tes . Th i s  work  a l so su pports t h e  i dea that P C P  potentiates 
the synaptic  effects of endogenous DA . I n  contra s t ,  Leel avathi  and 
Smi th -( 1 979) found that PCP g i ven i . p .  to rats had no effect on DA 
uptake i n  the stria tum . 
Raja and Guyenet ( 1 980 )  r eported that i ntravenous PCP i ncreased the 
f i r i ng �ate of dopami nergi c  neurons i n  the substa nti a n i gra of rats 
a nd i nh i b i ted the firing  o f  noradrenergic  neurons i n  the l ocus coeru-
l eus . Marwaha et �. ( 1 980) reported that l o ca l l y  adm i n i s tered PCP 
depressed fi ring  of noradrenergic  rat cerebel l ar Purki nj e  c el l s .  Th i s  
effect was antagoni zed by anti psychoti c  drugs . These s tud i es i nd i cate  
that  PCP  ha s  d i fferent effects on dopami nergic and noradrenergic  systems . 
Th i s  i s  cons i stent wi th the resul ts of Ary and Komi s key (1980 ) di scussed 
prev i ously wh i ch i ndi cate that PCP decreased the accumu lat ion of 3H_N E  
i n to synaptosomes by bl ocking  reuptake whereas the effect o f  PCP on  3H_ 
DA accumul ation is caused by rel easing  prev i ous ly  accumu l a ted 3H_DA as 
wel l as as  by blocking  reuptake of 3H_DA . 
Sev eral  i nvesti gators have shown that PCP produces a ' dose-rel ated 
i ncrease  in i ps i l a teral rotation  in rats wi th el ectrolytic (Kanner et 
�. , 1 975;  Fi nnegan et �. , 1 97 6 )  and 6-0H DA i nduced (Fes s l er et �. , 
1 979 )  l es i ons o f  the substantia n i gra . Thi s  i s  thought to i nd i cate some 
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i nd i rect DA agoni sti c and/or anti chol i nergi c act i v i ty .  The effect was 
a ntagoni zed by a 1 pha-methy1 -para-tyrosine  (AMPT ) , hal operi dol and areco l i ne 
and potentiated by tri hexyphenidyl . A recent study by Gl i ck  et a 1 . 
( 1 980 ) reported that PCP el i c i ted dose-rel ated rotati on i n  na i v e  rats 
wh i ch was d i ssimi l a r  to the rotatory effects of dopami nergic or anti­
c hol i nergic drugs . Stud i es o f  regional bra i n  uptake of l abel ed 2-
deoxy-D-g1 ucose a nd h i ppocampa1 1 es i ons i nd icate that PCP activates a 
hi ppocampal mechan i sm o f  rotation  whereas dopami nergi c drugs d i d  not , 
( Gl i c k  � �. ,  1 980) . 
Ba 1 s ter and Cha i t ( 1 978a ) found that PCP enhanced amphetami ne  
s tereotypy in  rats . Murray a nd Hor i ta ( 1 979 )  reported that PCP produced 
a very characterist ic  stereotyped behav i oral syndrome in rats which  was 
a ntagoni zed by DA receptor block ade . In  add i ti on , Schl emmer et �. 
( 1 978) reported that the DA receptor bl ocking agent pimozi de antagoni zes 
s tereotyped behav ior produced by PCP chroni cally adm i n i s tered to stump­
ta i l ed monkeys . Several i nvesti gators ( Garey et �. , 1 980 ; Castel l ani  
and Adams , 1 980) reported that hal operi dol antagonized PCP- i nduced motor 
dys functions in rats . Both these i nvest igations a l s o  found that PCP 
motor dysfunction was antagoni zed by l ow doses of the DA agon i s t  a pomor­
ph ine  but potenti ated by h igh doses Of the 'drug . They suggest a pre­
synaptic  mechanism for th i s  effect . 
Genera l l y ,  the l i terature suggests that PCP acts a a catechol ­
ami nergi c agon i st .  I n  the noradrenergic  system , it  i s  l i kely that PCP 
acts by bl ocki ng reupta ke of N E .  The effect o f  PCP o n  the dopami nergic 
system i s  probably the resul t of bl ocki ng reuptake and  caus i ng rel ease 
o f  DA. 
Sertonergi c systems . The effects of PCP on 5-hydroxytryptamine  
... . - .. 
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( 5HT)  functi on are even more confu s i ng .  Tonge and Leonard ( 1 969 )  found 
that in rat bra i n ,  PCP el evated 5HT l evel s and i n i t i al ly depress ed but 
l ater el evated the l evel s of the major metabol i te of 5HT , 5-hydroxy i n­
dol eacetic  ac id  ( 5-H IAA) . They fou nd that PCP had no effect on the two 
enzymes i nvol ved i n  the synthes i s  and metabol i sm o f  5HT ,  but that trypto� 
phan concentration was i ncreased . I n  l ater studi es by these same i nves­
t i ga tors ( Tonge and Leonard , 1 971 , 1 972 )  opposi te " resul ts on 5-HT and 5-
H I AA l evel s were obta i ned in d i fferent sets of rats of the same s tra i n .  
I t  i s  pos s ibl e that this  i s  due t o  the fact that the d i fferent grou ps 
had d i fferent control l evel s of 5-HIAA .  
Sev eral i nvestigations ( Sm ith  e t  �. , 1 977 ; Lee1 avathi a n d  Smi th , 
1 979 )  have i nd i cated that PCP bl "ocks the uptake o f  3H-5HT i n  synapto­
somal preparations from rat bra i n s .  Mart i n  et �. ( 1 979 )  "reported a 
s erotonergic syndrome of behav ioral effects produced by phencycl i d i ne i n  
t h e  "rat which  wa s antagoni zed by sertonergic antagon i sts . Jarbe et �. " 
( 1 975 )  found that depl etion of bra i n  5-HT d id  not bl ock  the d i scrimi-
nati ve  s timulus  properti es o f  PCP ,  but  it  i s  u ncl ear how compl ete the 5-
HT depl etion was .  
Chol i nergi c systems . Leonard and Tonge ( 1 970 )  found no change i n  
a cetyl chol i ne eACh)  or chol i nesterase  (AChE)  activ i ty i n  rat bra i n  a fter 
P CP admi ni strati on .  Domino and W i l son ( 1 972 ) , u s i ng hemichol i n i u m ,  
obta i ned evi d�nce that PCP may i ncrease  ACh turnover a n d  u t i l i zat ion  
wi thout a ffecti ng who l e  bra i n  l evel s .  Hsu � �. ( 1 980)  reported that 
an  acute dose o f  PCP i ncreased chol i ne acetyl transferase ( CAT ) i n  the 
hi ppocampus , decreased CAT in the cerebel l um and i ncreased AChE in a l l  
parts o f  the rat bra i n .  
Maayan; � �. ( 1 974 ) have demonstrated theoret ica l ly a nd experi -
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mental l y  that PCP a nd ACh have s im i l ar el ectrostatic  charge di stribution 
patterns a nd that PCP is  a competitive  i nh i b i tor of both the muscar i n i c  
c hol i nergi c receptor a nd the  cho1 i nesterases . Whi l e  these effects wou l d  
tend t o  offset each other, comparison of a ffi n i ty constants ind icate 
that PCP has a higher affi n i ty for the cho1 i nesterases than for the 
chol i nergi c recepto r .  However , the overal l behavi oral effect of PCP 
a ppears to be anti chol i nergi c .  Maayan i  et �. ( 1 974) reported that 
PCP- i nduced anesthes i a  in the gu i nea pig a nd hyperacti v i ty in mice were 
both antagoni zed by tacr i n e ,  an anti chol i nesterase agent . Other studi es 
have  confi rmed that whi l e  PCP has both anti chol i nergic and antichol i ­
nes terase acti v i ty ,  the i n  v i vo acti v i ty a ppears to b e  predomi nately 
a nti chol i nergi c ( We instei n et �. , 1 973 ;  Paster et �. , 1 974 ; K1 00g et 
�. , 1 97 7 ;  Pi ncha s i  et �, 1 977 ; Gl i c k  � �. ,  ·1980 ) .  
A s tudy by Adams ( 1 980) supports thi s  fi ndi ng in reporting that 
PCP-i nduced i ncreases in l ocomotor acti v i ty in the rat were potenti ated 
by a tropi ne and bl ocked by physostigmi ne .  However ,  Cha i t  and Bal s ter 
( 1 979)  reported no effect of atropi ne on PCP-i nduced. suppress i on of 
·operant respond i ng in  squi rrel monkeys a nd only part ia l  antagoni sm o f  
t h e  P C P  effect by physostigmine . 
GABA systems . Leonard and Tonge ( 1 970 ) found no change i n  whol e 
bra i n  l evel s o f  h i stami ne or gl utam ic  ac id  i n  rats gi ven PCP . They d i d  
f i n d  a s i gn if icant depl eti o n  of gamma ami nobutyri c  a c i d  (GABA) which  
correl ated i n  time cours e wi th the  behavi oral  acti v i ty of the  drug . 
Menon � �. ( 1 980)  reported that pretreatment · wi th GABA-potentiati ng 
drugs b locked the l ocomotor s timu l ation by PCP i n  m ice . Mys 1 o bods ky et 
�. ( 1 979 )  reported that i nh i bi tion  of the enzyme wh ich  metabol i zes GAB A 
( GABA-transami nase )  i nhi bi ts the stereotypi c  behav i or and v i gorous 
rotati on  produced by ketami ne i n ' rats . More recently ,  there have been 
r eports that PCP i ncrea sed the acti v i ty of the rate- l im iti ng enzyme i n  
GAB A synthes i s  i n  the hi ppocampus o f  mice  ( Spoer l e i n  et �. , 1 980 ) and 
rats ( Hs u  � �. ,  1 980 ) .  Wood and Hertz ( 1 980 ) reported that ketamine  
i ncreased who l e  bra i n  GABA content i n  m i ce  and  i nhi bi ted GABA upta ke i n  
a n  .i!l v i tro sys tem . I t  a ppears that part of the actions of PCP and 
ketam ine  may be due to GAB A a ntagon i sm in the bra i n ,  poss i bly  through 
bl oc kade of the receptor .  
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There are probably a vari ety of reasons for the apparent confl i cts, 
i n  the resul ts of these neurochemical  stud i es . These range from d i fferences 
i n  assay methods , d ifferent ' drug doses , di fferences ' i n  time from drug 
admi n i stration unti l measurement as  wel l as spec i es , stra i n  and sub-
s tra i n  of s ubj ects used . Whi l e  it i s  l i kely that the pharmacol ogi cal 
profi l e  o f  PCP is due to i ts combi ned effect on  a l l  of the neurotrans­
mi tter systems , it  i s  poss ibl e  that certa i n  d i screte effects may be the 
resul t o f  an effect on a s i ngl e neurotransmi tter system . 
Beha v i oral Pharmaco l ogy 
Human behav ior .  Dur i ng the  t ime  that PCP  was undergoing i nvest i ­
gation  for use  as  a n  a nestheti c i n  humans , there were s everal reports o f  
i ts effects on human vol unteers . I n  an earl y cl i nica l  tr ial , Grei fen­
ste in et �. ( 1 958) found that 0 . 25 mg/kg i .v . produced compl ete anes­
thes i a  without depres s i o n o f  resp i ration or c i rcul at ion .  Muscl e relaxa­
tion was poor a nd many of the pati ents ' eyes remai ned open and v erti cal 
nystagmus was noted . I n  a l l  pati ents there wa� profuse sal ivation . 
Hi gher doses ( 0 . 5  - 1 . 0  mg/kg) produced agitati on  fol l owed by r igid ity ,  
cataton i a  a n d ,  i n  some cases , convul s i ons . They a l so noted some i ns tances 
o f  s evere exci tement and hal l uci  natory d i  s turbances u pon emergence . The 
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type o f  a nes thes i a  produced by PCP and rel ated compounds has su bsequentl y 
been termed "di ssoc iat ive  anesthes ia" ( Corssen and Domi no , 1 96 6 ;  Pender. 
1 971 ) , because rather than  l o s i ng cons i ousness , the pati ent seems, to 
become d i ssoci ated from the envi ronment .  
T h e  subj ective  effects of s ubanestheti c  doses o f  PCP have been 
reported by s everal i nvestiga tors ( Dav ies and Beech , 1 960 ; Luby et ,�. , 
1 95 9 ;  Cohen et �. , 1 960;  Eak!<er and Ami n i , 1 961 ) .  Most commonl y ,  t here 
was an a l teration in body image wi th feel i ngs of estrangment . The 
s ubjects fel t drowsy or i nebri ated wi th a sense of apathy . Di sorga n i ­
z a t i o n  of thought and perceptual  d i stortion were al so reported . 
Obj ecti v e  measurements reveal impa i rment of sensory and cogn i t i v e  
processes by subanestheti c  doses of PCP . Ros enbaum et �. ( 1 959)  reported 
decreased reaction t imes and impa i rment of rotary pursu i t  and weight 
di scrimi nat ion .  Dav i es and Be,ech ( 1 960 ) found PCP impai red the l earn ing  
a nd reca l l  of l earned words and the abi l i ty to  define  proverbs . Cohen  
et �. ( 1 962 ) reported impa i rment of symbol i c  reasoni ng and s equent i a l  
t h i nki ng tasks . Morgenstern et �. ( 1 962) ' found sensory impai rments i n  
a l l modal i ti es .  The most sens i t i v e  were two po i nt d i scrimi nation and 
touch , but there was a l so impairment of v i sual  fi e l ds , audi tory acu i ty , 
pos i ti on sens e ,  taste and v i sual acu i ty .  
S ev eral i nvestigations have compared the effects of PCP to psycho­
t i c processes . Both Ros enbl um et {L. ( 1 959)  and Cohen et {L .  ( 1 962) 
concl uded that the effects of PCP on' thought processes more cl osely 
s i mu l a ted the performance of schi zophren i c  pati ents than d id  the effects 
of other ha l l uci nogens tes ted i ncl udi ng LSD .  Other i nvestigators (Luby 
et �. , 1 959 ,  1 962 ; Levy et {L . , 1 960)  found that PCP gi ven to s c h i zo­
phren i cs exacerbated many of the  symptoms of schi zophren ia . I n  l i ght of  
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thi s ,  it  is  parti cul arly i nterest i ng that ene phenemenen a s sec iated with 
PCP use  i s  the devel epment e f  a schi zephreni ferm state (Ste i n ,  1 973 ; 
Fauman et �. 1 97 5 ,  1 976 ;  Ra i ney and Crewder , 1 97 5 )  wh ich  eften dees 
net a ppear unti l days after i ngestien  ef the drug . The duratien  ef the 
ep i sede  may be frem s everal days to. several weeks even theugh there i s  
n o.  d etectabl e drug i n  the bl eod 9r ur i ne .  Whi l e  reperts e f  thi s phenem­
enon are rare , it is pess i bl e  that it is net recogni zed as PCP-i nduced 
when s een .  The phenomenen dees not appear to. be dose-dependent a nd may 
be due  to abnermal metabe l i sm of PCP,  centaminants ef PCP (Shu l g i n  a nd 
Maclean ,  1 976 ;  Ba i l ey et �. , 1 976 )  or prec i p i tation of a l atent psyche­
pathol ogy . 
Animal behavior . There are dramatic  spec i es ·d i fferences i n  the 
gress  behav ioral effects ef PCP . Chen et �. ( 1 959)  found that PCP 
cou l d  preduce CNS stimu l ation er depress ien  depend ing en the s peci es  of 
a n ima l  a nd dose used.  I n  rodents , hyperacti v i ty was promi nently ob­
s erved . Atax ia  and catal epsy were . s een at the hi ghest dose s  i nd i cat i ng 
some d egree ef central . nerveus system depress ion .  I n  a l l  ether spec i es 
tested , a qu ieti ng or cal m i ng effect was reperted at l ew doses progress i ng 
to a catal eptoid res pons e  and general anesthes i a  at h i gher doses . 
Hi gher deses produced convul s i ens i n  many spec i es . 
Gross behavi oral effects ef PCP i n  subhuman primates resembl e those 
reperted i n  man .  These i ncl ude atax i a ,  nystagmus ,  exces s i v e  sa l i vat ien  
and rhythm ic  mevements (Bal ster a nd Cha i t ,  1 976 ) . The  marked d i fference 
between the effects of these compounds in rodents and  in primates makes 
primate werk in thi s area especi al l y  impertant . 
Cond i ti oned Behav ier .  One way to appreach the study of the central 
n ervous system effects of a compound is to s tudy i ts effects on l earned 
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beha v i o r . · Adey and Dunl op ( 1 960) found that i . p .  i nj ections of both 
PCP a nd peE (1 . 0  - 3 . 0  mg/kg) di srupted cond i t i oned approach performance  
i n  cats for  up  to  24 hours afte� drug admi n i s trat i o n .  Lower doses 
( 0 . 3  - 1 . 0 mg/kg )  d i srupted the performance for s horter periods of time . 
Domi no ( 1964 )  reported that PCP d i srupted cond i t ion  avoidance respondi n g  
i n  rats i n  a non-speci fic manner . I ncrea s i ng doses of PCP ( 1 . 0  - 8 . 0  
mg/kg i . p . ) bl ocked avoidance and escape to · the same extent and caused 
gross di sruption of behavi or. 
Brown and Bass. ( 1 967 ) conduct·ed a study of the effects of i . m .  
inj ecti ons o f  PCP o n  accuracy a n d  response l atency i n  a three-key 
avoi dance paradi gm with  rhesus monkeys . The subjects were requ i red to 
press the key wi th the smal l es t  form to avoid el ectric  shock .  There was 
a dose-dependent i ncrease  i n  response l a tency ( 0 . 05 - 0 . 25 mg/kg ) u nt i l  
a dos e  was  reached at  whi c h  t he  an imal s d id  not  respond at  al l (0 . 5  
mg/kg)  . 
Studies of the effects of PCP o n  . an ima l s tra i ned under a mul ti pl e 
or c ha i ned fi xed-i nterval fi xed-rati o schedu l e  ( F I FR )  of food pres enta ­
t ion  have been conducted with  pigeons (Wenger , 1 976 ) , m i ce (Wenger and  
Dews , 1 976 ) ,  rhesus monkeys ( Bal ster and Cha i t ,  1 976 ) and squi rrel 
monkeys ( Cha i t  a nd Ba l s ter ,  1 976 ) . I n  both  p igeons and mice , PCP was 
found to i ncrease FI  response rates at  l ow doses whi l e  decreasi n g  response  
rates a t  h i g h  doses . The  response rate i nc reases caused by PCP  i n  the  
F I  component were dependent on  the control rate of respond i ng  in  a 
manner cons i stent wi th the rate-dependency hypothes i s  of Dews (1 958 ) . 
Only dose-dependent decreases i n  response rates were seen i n  the FR 
component . I n  rhesus monkeys ( Bal s ter and Cha i t ,  1 976 ) .  PCP produced 
on ly  dos e-dependent decreases in respondi n g  over the doses tested (0 . 2 5  -
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2 . 0  mg/kg , i . m . ) .  Both schedu l e  components were equ a l l y  affected by 
the dru g .  Whi l e  Cha i t  and Ba l ster ( 1 978) a l so reported a dose-re lated 
d ecrease  i n  respond ing  i n  both components of the mul t ipl e schedul e  wi th 
i .m .  i nj ections of PCP ( 0 . 01 - 0 . 60 mg/kg )  i n  squi rrel monkeys , a sma l l  
but cons i stent i ncrease i n  FI  respond i ng was seen with l ow doses o f  PCP . 
The res pons e rate decreases i n  the FI component were consi stent with the 
rate-dependency hypothes i s  (Dews , 1 958)  in  that high rates of respondi ng  
were decreased more than  l ow rates of respondi ng . 
A rev i ew by Bal ster and Cha i t  ( 1 978b) i ncl udes a tabl e wi th est imates 
of the rel ative  potency of PCP for d i sruption of FR performance taken 
from the data in the papers di scussed so far (Ta bl e  1 ) . One observat ion  
they made  was that whi l e  the  squi rrel monkey i s  s l i ghtly more sens i t i ve  
to  the effects o f  PCP  on  o bs ervabl e behav ior than the  rhesus monkey , i t  i s  
3 times l ess  sens i ti ve to the effects of PCP on food rei nforced operant 
respond i ng . 
Cha i t  and Bal ster ( 1 978 ) stud i ed the effects of i .m .  i njections of 
PCP  ( 0 . 20 - 0 . 64 mg/kg ) i n >  s qu i rrel monkeys tra i ned on  a variabl e­
i nterv a l  ( V I ) s chedul e o f  food presentati o n .  They saw smal l response­
rate i ncreases at l ow doses and a dose-dependent decrease i n  respondi n g  
a t  h i gher doses . Murray ( 1 978 ) found that i . p .  i njecti ons of P C P  had a 
s imi l a r  effect on response rates i n  femal e  rats tra i ned to respond on a 
VI schedul e of water presentati o n .  Low doses ( 0 . 2 5  - 1 . 0  mg/kg ) i ncreased 
response rates and h igher doses (2 . 0  and 4 . 0  mg/kg )  decreased response 
ra tes i n a dose-dependent manner . Gl i ck  et �. (1 97 9 )  found that PCP , 
ketami ne a nd PCE a l l  had a bi pha s i c  effect on response rates i n  rats 
trai ned to perform a s patia l  a l ternation task in a two-l ever chamber . 
Whi l e  l ow doses i ncreased response rates and hi gher doses decreased 
TABLE 1 
DOSES OF PHENCYCLIDINE  PRODUC I NG 50% DECREASES I N  FIXED-RATIO 
RESPONDI NG IN VARIOUS SPEC I ES OF LABORATORY AN IMALS 
Spec i es 
Mouse  
P i  g eon  
Squ irrel Monkey 
Rhesus Monkey 
ED 50 
1 0 . 00 mg/kga 
. b 0 . 7 0  mg/kg 
0 . 27 mg/kgC 
0 . 08 mg/kgd 
a .  by i ns pection o f  dose-response curve i n  Wenger and Dews ( 1 976 )  
b .  by i ns pection of  dose-response curve i n  Wenger ( 1 976 )  
c . . reported in  Cha i t  and Bal ster ( 1 978a ) 
d .  by i ns pection. o f  dose-response curve i n  Ba l ster and Cha i t  ( 1 97 6 )  
- 1 7 -
- 1 8 -
response rates , a l l three drugs produced only dose-dependent decreases 
i n  the accuracy of performance in the spatial  a l ternation tas k .  Ba l s ter 
a nd Ba i rd ( 1 979) fou nd that l ow doses of PCP ( 1  and 3 mg/kg i . p . )  produced 
l arge response rate i ncreases in  mice  tra i ned to l ever press on a d i ffer­
ential  reinforcement of l ow rate ( DRl)  schedul e ,  whereas hi gher 
doses resul ted i n  decreased response rates . 
I n  a n  i nterest ing  study of the effects of ketam i ne on FI performance , 
Mel i s ka a nd Trevor ( 1 978 )  found that a l ow dos e  of ketamine ( 7 . 5  mg/kg , 
i . p . )  i ncreased res ponse rates i n  drug-na ive  and drug-experi enced rats , 
bu t a h i g her dose ( 1 5 . 0  mg/kg , i . p . )  decreas ed respond ing  i n  drug-na i v e  
rats a nd i ncreased respond i n g  i n  dru g-experi enced rats . Because  the 
response rate i ncrease  reported i n  thi s l atter group d id  not occur unti l 
30-40 m i n after drug i nj ecti on , they postu l ated that i s  was due  to the 
actions of a ketami ne metabol i te .  Both doses  of ketami ne i ncreased 
s pontaneous l ocomotor acti v i ty i n  a l l  groups tested . Moerschbaecher 
and Thompson ( 1 980) found that PCP decreased response rates and i ncreased 
error rates in a . dose-dependent manner i n  rhesus monkeys tra i ned on a 
compl ex mul t i p l e-schedu l e  repeated-acqu i s i ti on operant tas k .  
There have been s everal stu d i es maki ng  di rect comparisons between 
the effects of PCP a nd other pharmaco log ical agents on schedul e-con­
trol l ed behav ior .  Wenger �nd Dews ( 1 976)  reported that . both PCP and 
ketami ne produced effects s im i l ar to those of i-amphetamine  and d i s ­
s i mi l ar to  those o f . pentobarbi tal i n  m i ce tra i ned on � �ul ti pl e  F I FR 
sc hedul e o f  food · presentat ion .  Ba l ster and Ba i rd (1 979 )  a l so found that 
the effects of PCP  on  DRL respondi ng for food reinforcement in mice  were 
more s im i l ar to the effects of d-amphetami ne than they were to the 
effects o f  pentobarbital . I n  contrast ,  Brandao et a1 . ( 1 980 ) found that  
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l ow doses of ketami ne i ncreased pun i shed res pond i ng i n  pi geons , whereas 
a l l doses o f  i-amphetami ne tested produced only decreases i n  p un i s hed 
respond i ng .  Pentobarbi tal produced l arge i ncreases in puni s hed res­
pond i ng in this  parad igm .  Cha i t  and �lcMi l l an  ( 1 980) al so. found that PCP 
a nd pentobarbi ta l  both i ncreased punished res pond i ng i n  pi geons . I n  
summary , i t  appears that the effects of PCP o n  schedu l e -control l ed 
behav ior  may have two components . On food-re i nforced behav ior , the 
effects are amphetam i ne- l i ke ,  whereas the effects o f  PCP on  pun i s hed 
beha v i or s eem to c l osely resembl e the effects of the barbi turates . 
Re i nforci ng properti es . W i th most drugs of abu s e ,  an imal s can  be 
tra i ned to perform a task to sel f-admin i s ter the dru 9 .  There have been 
s ev eral reports that rhesus monkeys can be tra i ned to l ever press for 
L v .  i nfus ions of PCP ( Ba l ster et �. , 1 97 3 ;  Pi c kens et �. , 1 97 3 ;  
Ba l s ter and Woo lverto n ,  1 979 ) . Thi s i s  of spec ia l  i nterest because  PCP 
is often c l a s s i fi ed as  a hal l uc i nogen and wh i l e  ha l l uc i nogens are 
a bu s ed by humans , they are not rel ia bly se l f-admi n i stered by l aboratory 
an imal s ( Deneau et �. , 1 969) . Moreton et �. ( 1 977 ) have a l s o  demon­
s trated the ketamine  is  rel i ably sel f-admi n i stered by rhesus  monkeys . 
Th i s  s uggests that PCP and the d i ssoc iat ive  anestheti cs represent a 
u n i que  c l ass o f  hal l uc i nogens . 
Recentl y ,  Bal ster and Wool v erton ( 1 97 9 )  have s hown that rhesus 
monkeys g iven unl imi ted access to PCP· can sel f-adm i n i ster suffi c i ent 
amounts to . produce phys i cal  dependence .  Th i s  phys i ca l  dependence was 
evi denced i n  a �li thdrawal syndrome cons i st ing  of pri a pi sm , tremors , 
i rr i tabi l i ty and preconvul s i ve  act i v i ty .  McCarthy a n d  Harri gan  ( 1 976)  
us i ng a n  un l imi ted access  parad i gm with ketamine in  rhesus monkeys , 
found that ketamine produced phys i cal  dependence with  wi thdrawal symptoms 
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s i mi l ar to those descri bed for PCP ( Bal ster and Woo lverton , 1 979 ) . 
Carrol l a nd Meisch 11 980a ) 'establ i shed that oral PCP coul d serve 
as  a rei nforcer in rhesus monkeys over a range of concentrations . They 
' found that food deprivation i ncreased PCP i nta ke as i t  does other drug 
re inforcers ( Carrol l a nd Meisch 1 979 ,  1 980b ;  Mei sch  and K1 i ner , 1 979 ;  
Carrol l et  �. , 1 979 ) . 
To l erance .  There have been s everal recent studi es of to l erance 
devel opment to PCP. Pi nchas i  et �. 11 978a ) stud i ed the effects of 
chro n i c  PCP a nd PCE on rotarod performance in mice . They found that 
revers i bl e  tol erance devel oped to both drugs . ' The extent of tol erance 
d epended upon dos e ,  frequency and route of adm i n i strati on . Woolverton 
et a 1 . ( 1 980) stud ied the effect of chronic  PCP admin i stration on m i l k 
i n take by rats . A 2-fol d s h i ft to the r ight i n  the dose-response curve 
was s een a fter seventy consecut ive  days of PCP admi n i stration (4 . 0  - 8 . 0  
mg/ kg , 1 .  p . ) .  
Pryor � �. (1 977 )  reported that 1 . p .  i nj ections of 2 . 5  mg/kg PCP 
for s i x  days produced tol erance to the di sruptive effect of 2 . 5  mg/kg 
PCP in rats respond ing  on  a FR1 0 schedul e of food presentation . I n  
contra s t ,  the i ncrease  i n  l ocomotor acti v i ty caused by PCP was enhanced 
by t h i s  treatment . I n  a recent report , Ruffi ng and Dom i no (1 980 )  pro­
v i ded evi dence for first dose to l erance ,  demonstrated by a s i gn i fi cantly 
s hortened duration  of suppress i on of bar pres s i n g  in rats tra i ned on a 
FR s chedul e of food presentation a fter PCP admi ni s trat ion  ( 3 � 2  mg/kg , 
i . p . )  . 
Ba l s ter a nd Cha i t  ( 1 976 )  found that da i l y  i n ject i ons o f  gradual ly 
i ncrea s i ng doses of PCP ( 0 . 2  - 1 . 0 mg/kg , i .m . )  over a four- month per iod  
produced a s i gn i ficant s h i ft to  the r ight i n  the  dose-response curve of 
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two out  of three rhesus monkeys tra i ned on a cha i n  FI FR schedul e of food 
pres entati on . Comparisons of the gross behavi oral effects of an acute 
dose o f  PCP ( 1 . 0  mg/kg , i . m . l in these
'
three subj ects to the effect i n  
three naive  monkeys a l so i nd i cated tol erance devel opment . 
C h a i t  and Ba l s ter ( 1 978 ) stu d i ed the effect of chron i c  i . m . . PCP 
(82 - 1 26 days ) g iven u p  to four times a day in i ncreasing  doses ·to. 
s q u i rrel monkeys . Al though the regimens were i nd i v i du a l i zed to max im ize  
tol erance devel opment , a compari son  of pre- and post- chronic  dose-
effect curves for the effects of . PCP on operant behavior reveal ed only a 
2 - fo 1 d  tol erance devel opment . I n  general u s i ng chron ic  regimens 
desi gned to maximi ze tol erance devel opment , experimental ev idence i nd i cates 
on ly  a 2- to 4-fo 1 d  s h i ft i n  the PCP dose-effect curv e .  
Several . s tud ies have expl ored the mechani sm of t h e  devel opment o f  
to l erance t o  PCP.  Murray and Hor ita ( 1 979 )  reported n o  di fference i n  
max imum bra i n  l evel s o f  PCP between rats tol erant t o  the effects o f  PCP 
on s chedul e-control l ed performance and non-to l erant rats . Thi s  argues 
aga i nst a d i s posi tional mecha n i sm of tol erance to PCP . However , i n  
other stud i es behavi oral effects o f  PCP have been shown to correl ate wel l 
w ith  bra i n  l evel s of PCP (Harti n et !!l. , 1 98 0 ;  Woo l v erton et !!l. , 1 97 9 ) . 
For exampl e ,  Woo l verton et !!l. (1 979 )  found l ess  3H_PCP i n  the bra i ns of 
h i g h-wei ght rats than in  the bra i ns of l ow-weight  a n imal s whi ch correl ated 
with · d i m i n i s hed effects of PCP in the h i g h-wei ght group .  
Several studi es impl i cate a l earned component i n  t h e  devel opment o f  
tol erance t o  PCP .  Wool verton and Bal ster (1 97 9 )  admi n i stered PCP (8 
mg/kg , i . p . ) to rats tra i ned on a FI s c hedu l e  of water del i very for 36 
days ei ther before or a fter the experimental sess i o n .  I n  thi s  experi ­
mental s i tuation , the subjects recei v i ng post-sess i o n  PCP wou l d  not be 
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a bl e to l earn to res pond under the i nfl uence of PCP.  Redetermi nation of 
the dose-effect curve a fter chronic  dos i ng revea l ed a 2-fo ld  s h i ft to 
the r i ght i n  both groups . However , greater tol erance occurred to the 
effects of PCP on response patterning  and tol erance was l os t  more s l owly 
i n  the pre-ses.s ion  group demonstra t i ng a sl i ght  contribution of behavioral 
vari abl es to tol erance devel opment . Ruffi no and Domi no ( 1 980)  al so 
d emonstrated a l earned component i n  the first dose tol erance to PCP 
ment ioned earl i er in thi s section . Rats given  the first dose of PCP i n  
t hei r home cages a nd t h e  s econd dose i n  the operant s i tuation showed 
tol erance only a fter the s econd dose .  The  tol erance demonstrated i n  
t h i s  group  .a fter the  s econd dose was equal to  the  tol erance demonstrated 
a fter the first dose in the group given the drug for the fi rst time i n  
the  operant s i tuation i ndicating  a l earned behav ioral tol eranc e .  I t  
seems l i kely that both behav i oral a n d  pharmacol og ica l  vari abl es pl ay a 
part i n  the devel opment of tol erance to PCP .  
The d i scriminative  stimul us  paradigm . Because  so many of the · 
experiments i n  t h i s  d i s s ertation i nvol v e  the u s e  of the drug d i scrimi na­
t i on parad igm ,  I wi l l  d i scuss th i s  procedure in some deta i l . 
A d i s criminative  s timul us  i s  any feature of an an imal ' s  envi ronment 
wh i ch spec i fi cal ly covaries wi th the avai l a bi l i ty of a rei nforc i n g  
s t i mu l us ( Schuster a n d  Ba l ster , 1 977 ) .  When an  operant behavior  i s  
rei nforced 6nly i n  t h e  presence of a spec i fi c  stimu l us , t h e  frequency o f  
the  occurrence of that behavior  i n  t h e  presence of the  stimu l us i ncreases . 
The behav ior i s  then sa id  to be u nder the control o f  the stimu l u s . 
The first demonstration  that a drug coul d serve as a d i scrimi native 
st imu l us for a choice task was carr i ed out by Conger (1 951 } .  He  
· tra i ned rats to  respond d i fferenti a l ly i n  a T-ma ze for food rei n forcement 
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based  on the  admi ni stration of ethanol or pl acebo . Si nce th i s  d i scovery , 
many drugs have been found to serve as d i scriminative  stimul i u s i n g  a 
vari ety o f  experimental desi gns . Ba s i ca l l y ,  i n  a drug d iscrimination  
s tudy the anima l s  are tra i ned to  respond di fferently under di fferent 
drug condi tions . One response ( e . g .  l eft l ever pres s )  i s  rei nforced 
u nder one drug s tate , whi l e  a d i fferent response (e . g .  ri ght l ever 
pres s )  is  reinforced . under the second or the no drug state . 
Behav ior which  has been brought under st imu l u s  contro) may al so 
occur in the presence of d i fferent but s im i l a r  s timul f. For exampl e ,  i f  
a n  an imal i s  trai ned to respond one way when a whi te l i ght i s  on , and  
another way in  the dark ,  l i ghts of decrea s i ng i ntens ity wi l l  produce an  
i ncreas i ngly l arger percentage of dark-appropriate res pondi n g .  This  
phenomenon is  termed stimu l us general i zat ion or transfer . A genera­
l i zat ion  gradi ent is the function that rel ates res ponding  to di fferent 
val u es of a test stimul i .  The amount of respond i ng appropriate for the  
tra i n i ng s timulus  wh i c h  is  produced by a novel stimulus  i s  consi dered to  
be  an  i ndi cation of the  s i m i l a r i ty of the  two stimul i .  On the bas i s  
o f  th i s ,  i t  ·i s  poss i bl e  t o  determine  to what extent various pharma­
col ogi cal agents are s i m i l ar or di fferent u s i ng  thi s parad i gm .  
Wi th drug stimul i ,  genera l i zation can b e  tes ted a l ong the qual i ­
t i a t i v e  a s  wel l as the quant i tative  d imens i ons . A dose-effect determi nat ion  
can  be made which  i nd i cates that  as drug doses l ower than  the tra i n i n g  
dos e of a drug a r e  g i v e n ,  the animal emits  l ess  and l ess drug-appro-
pri ate res pond i ng i n  a dose-dependent manner . Thi s i s  a quanti tati ve 
genera l i zation  grad i ent .  Al ong the qual i tative  d i mens i ons , general i -
. zat ions have been s hown to occur between drugs with  a s imi l ar  spectra 
of pharmacol ogical  properti es , but not bet\�een drugs o·f d i fferent drug 
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cl asses a nd pharmacol og ical properties . For exampl e , i- amphetam ine  has ' 
been found to general i ze to methamphetami ne ,  but not to LSD  or ps i l o­
cybi n .  Th i s  finding  has been cons i stently. repl i cated by many i nvest i ­
gators u s i ng a vari ety of drug c l a sses ( Barry , 1 974 ; Schus ter a n d  Ba l ster , 
1 97 7 )  . 
I n  testing drugs for genera l i zation al ong the qual i tat ive  dimen­
s i ons , i t  is very i mportant to control for equal i ty o f  the quantitat ive  
d imens ion .  For th is  reason , i t  i s  necessary to  tes t  a compl ete dos e  
range of t h e  novel compound . 'Another major probl em wi th i nterpreti ng 
drug g eneral i zation data has been cal l ed by Overton ( 1 974)  "transfer 
test overi nc1 us ivenes s " . Often in general i zation tes ti ng the i nj ection  
o f  a drug  un l i ke the  tra i ni ng drug  wi l l  resul t i n  mostly nondrug choi ces 
in s p i te of the fact that this same compound i s  known to be d i scr im ina bl e 
from vehic l e .  Th i s  same phenomenon cou l d  be true o f  other novel compounds 
whi ch  produce predomi natel y drug-appropr i ate res pond i ng .  
The d i s criminative stimul us  parad igm i s  a powerful too l  i n  the 
s ense  that it is a method for measuring  some very spec i fi c  properti es of 
psychoacti ve compound s .  I n  add it i  on , i nformati on about behavi ora 1 
d i s ruption produced by a drug can be obta i ned from th is  same task by 
measuri ng response rate suppress ion , runway l atency or some other 
i ndi cation o f  non-spec i fi c  impa i rment .  Th i s  paradi gm i s  a l so val uabl e 
i n  trying  to determine  the mechani sms of drug acti o n ,  as wel l  as for 
screen ing compounds . The ' present stud i es use  th i s  technique i n  order to 
exp l ore some of the structural rel ati onsh i ps between pCP and drugs wh i c h  
p roduce a PCP- l i ke d i scriminative  cue .  
Speci fi c i ty of the d i scrimi native stimul us  properi tes of PCP . 
Overton ( 1 974) first establ i shed that PCP cou l d  serve as a d i s criminative  
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stimu l us  in  rats tra i ned in  s hock-escape T-ma ze ta s k . " Usi ng the same 
experi mental parad i gm ,  Overton ( 1 97 5 )  compared the d i scri m i nati ve st imu l us  
effects o f  ketami ne , PCP a nd pentobarbi tal i n  rats . Transfer tests 
showed no general i zation  between PCP or ketami ne and pentobarb i tal . 
Wh i l e  transfer tests s howed genera l i zation between PCP and ketami ne i n  
a n i mal s trai ned to d i scrimi nate ei ther drug from sal i n e ,  rats cou l d  be 
tra i ned to d i scrimi nate PCP from ketami ne i n  a drug versus drug tas k .  
Jarbe and Henr i ks�on ( 1 974 )  cou l d  not obta i n  st imul u s  control wi th 
i . p .  i nj ections of 2 . 0  mg/kg PCP v s . sal i ne i n  rats wi th a T-shaped 
water maze tas k .  In  a l ater study ( Jarbe e t  �. , 1 97 5 )  u s i ng  rats 
trai ned i n  an  el ectr i fi ed T-maze tas k ,  a dose-rel ated acqu i si t ion  of 
drug  d i scrimi nati on with PCP ( 1 . 0  - 4 . 6 mg/kg , i . p . )  vs . sal i ne was 
reported . Transfer tests conducted w ith various  dos es of morph i n e ,  
chl orpromaz i ne , d i tran , pentobarbital , �9-THC and �8-THC i nd i cated that 
none of these drugs general i zed to PCP . Dose- rel ated general i zat ion  was 
reported for ketami ne a nd PCE . The order of potency of these compounds  
for st imu l us control in  th i s  study was : PCE > PCP > ketamine . Pol i ng 
et �. , ( 1 979) tra i ned rats to d i scr imi nate PCP from sal ine in a two­
l ever food- rei nforced drug d i scrimi nati on tas k .  H e  tested for general i ­
zati on  to agon i sts and antagoni sts o f  the dopami nerg i c, chol i nerg i c , 
sertonerg i c  a nd GABA neurotransmi tter systems . The s pec i fi c i ty of the 
PCP c u e  was  aga i n  demonstrated in  that only ketam i ne  produced PCP­
appropri ate respond i ng . They concl uded that these res u l ts paral l el ed 
prev i ous  f indi ngs u s i ng other procedures whi c h  suggest that the effects 
of PCP proba bl y  refl ect a wide vari ety of" neurochemi cal actions produced 
by the dru g .  
I n  an  a bstract ,  Shannon ( 1 97 9)  reported general i zation test i ng o f  a 
�26-
number of drugs usi ng rats tra i ned i n  a two-choice d i s crete tria l  
avoi dance tas k  t o  di scrimi nate PCP from sal i ne .  Genera l i zation testi ng  
was  carri ed out wi th a s er i es of structural anal ogues of PCP  as wel l a s  
wi th other psychoactive  drugs i ncl uding  £�amphetamine , scopol ami ne , LSD 
and 1'.9-THC .  He found that only the PCP anal ogues and the psychoto"­
mimeti c benzomorphan op io i d  N-a 1 1y1 normeta zoc i ne ( SKF 1 0 ,047 ) ,  produced 
a PCP- l i ke c ue .  Th i s  f inding  of s i m i l ar stimul us properti es between PCP 
and an op io id  is v ery important i n  the context of this d issertation  
s i nce it  was at th i s  poi nt that  s tudi es of the  stereoi somers of benzomor­
phans were begun . 
Simi l ar it i es i n  the Effects of PCP and Opi o i ds 
Concurrent wi th  th.e studi es descri bed i n  th i s  d i s s ertation com­
pari ng the effects of PCP to i ts anal ogues as wel l as opioids  and non-
o p i o i d  a nal ges i cs , other i nvesti gators have been expl oring  these re) ati ons h i ps . 
Stud i es from other l a boratories  wi l l  b� revi ewed i n  th i s  background 
section  a l though most o f  what fol l ows wa s not known at  the time the present 
studies  were desi gned . Many of the studi es to be descri bed i n  th i s  
d i s s ertation have been p ubl i shed and  are  a part o f  th is  devel op i ng  
research fi el d .  T he  rel ationshi p between th i s  research and  these other 
recent s tudi es wi l l  be descri bed i n  the various cha pters · i n  whi ch  the 
data a re pres ented . 
There have been a number of recent stud i es compar ing  the d i scrimi ­
native  stimul us properti es of phencycl i d i ne wi th those of a vari ety of 
op io ids . Ho l tzman ( 1 980) tra i ned rats to di scrimi nate between PCP and 
sa l i ne in a ·two-cho ice  d i screte trial  avoi dance parad i gm .  Dose-dependent 
PCP-a ppropri ate respond i ng was produced by cycl azoc i ne ,  a psychotomimet i c  
benzomorphan· opi oi d ,  N-a1 l ynormetazoctne , ketami ne a n d  dextrorphan , the 
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d - i somer o f  l evorphanol . A vari ety of other op io ids  (ethyl ketocyc lazoci n e ,  
ketocyc l a zoc i n e ,  pentazoci ne a nd dextromethorpha n )  whi ch were tested d i d  
n o t  genera l i ze to PCP .  
Herl i ng et �. " ( 1 980 )  tra i ned d i fferent groups of pi geons to d i s ­
crimi nate dextrorphan ,  ketam i ne or cycl azoc i ne  from sal i ne i n  a two-l ever 
FR20 o perant tas k .  Al l s ubj ects showed dose-rel ated drug-appropri ate 
res pond i ng when admi n i stered any of the tra i n i ng compounds or PCP . 
Nei t her ethyl ketazoc ine  nor nal orph ine  genera l i zed to the tra i n ing  
drugs . I n  the dextrorphan" tra i ned an imal s ,  the l- isomer , l evorphanol , 
resul ted i n  sa l i ne respond i ng whereas both dextromethorphan and cycl or­
p ha n ,  a no ther psychotomimet i c  op i o i d ,  produced dose-dependent drug­
appropri ate respond ing . 
Teal a nd Hol tzman ( 1 980)  tra i ned rats to di scrimi nate between 
sa l i ne a nd h i g h  or  l ow doses of cycl azoc i ne in a t�/o-choice d i screte 
tr ia l  avoidance paradi gm .  General i zat ion  testing  determi ned that keto­
cycl a zoc i ne and N-al l yl normetazoci ne produced di scrimi native  stimul u s  
effects comparabl e t o  both tra i ni ng doses of cycl azocine . Ethyl keto­
cycl a zoc i n e ,  pentazoc i ne  and l eval l orphan produced general i zation  i n  
a n ima l s  trai ned wi th the  l ow dose but not the h i g h  dose o f  cycl a zoc i n e .  
Morp h i ne a nd nal orphi ne d id  n o t  produce drug-appropri ate responding  i n  
a n ima l s  tra i ned w ith ei ther dose o f  cycl azoci n e .  Both ketamine  and PCP 
produced drug-l ever a ppropriate respond i ng in both groups of animal s .  
Mesca l i n e ,  �-amphetam i ne and LSD d i d  not produce drug-l ever appropr i ate 
res pond i ng in ei ther grou p of an imal s .  H i g h  doses of nal trexone fa i l ed 
to compl etely b l ock  s timul us  control of behavior  by ei ther of the cyci a zo c i ne 
tra i n i ng doses . I t  was concl uded that at l ea st  part of the d i s criminati v e  
st imu l us  properties of cycl a zoc i ne a r e  attri buta bl e  to a non-narcot ic  
component o f  act ion  of the  dru g .  I n  t h i s  l i gh t ,  i t  i s  i nteres t i ng that 
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Harri s ( 1 980) cou l d  not antago n i ze the rate-decreas i ng  effects of 
N-al l yl normetazoc ine  or cycl azoc ine  on  fixed - i nterval performance i n  rats 
with h i g h  doses of nal oxone or nal trexone . 
Young � �. ( 1 980)  tra i ned rhesus monkeys to di scrimi nate ketam i n e  
from sa l i ne i n  a two-l ever operant task .  PCP , P CE  a nd  dextrorphan 
produced dose-dependent drug-appropr iate res pond i ng whereas cycl azoc i n e ,  
N-al lynormetazoc ine  a nd codei ne  d i d  not .  They suggested that s peci es 
, d i fferences may account for the d isa greement between the resul ts o f  t h i s  
s tudy and  the body of l i terature su pporti ng  the s im i l ari t i es between the 
d i scrimi native cue produced by d i ssociative anesthetics and tha t produced  
by the psychotomimetic  opi o ids . I n  any cas e ,  the drug d i scrimination 
l i terature suggests a n  o�erl a p  in  the pharmacol ogies  of PCP and the 
psychotomi meti c opi ates wh ich  has been veri fi ed in other experimental 
sys tems . 
Marti n � �. ( 1 97 6 )  have postu lated three di fferent types of 
op i ate receptors based o n  three di fferent syndromes produced by 
congeners o f  morph i ne  i n  the nondependent chron i c  spi nal dog . Mu receptor 
agon i s ts , of whi ch morph i ne is the prototype ,  produce mios i s , bradyca rd i a ,  
hypothermi a and depress ion  o f  noci ceptive  responses . � agon i sts , 
o f  whi ch ketocyc1 azoc ine  i s  the prototype ,  constri ct pupi l s ,  depress 
fl exor response and produce s edation wi thout markedly affecti ng  pul s e  
rate . N-al l yl normetozoc i n'e ( SKF 1 0 ,047 ) ,  the prototype sigma receptor 
agon i s t ,  produces mydr i a s i s , tachypnea , tachycardi a and man i a  in the 
chro n i c  s pi na l  dog .  These three receptors show marked di fferences i n  
sens i ti v i ty to na 1 trexone .  Whereas the mu  receptor agon i sts were very 
sens i tive  to a ntagonism by nal trexone , approximately ten times more 
n a 1 trexone was requ i red to antagon ize the effects of � ,agon i sts and 
even h i gher doses  were reported to be necessary to a ntagoni ze the effects 
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o f  the s igma agoni s t .  I n  a n  a bs tract , Vaupel a n d  Jasi n ski ( 1 97 9 )  reported 
.that the profi l e  of acti v i ty of  PCP in the chron ic  spi nal dog was very 
s imi l a r  to that of N-al lyl normetazoc i ne .  Both drugs produced dos e­
d ependent depress ion  of the fl exor refl ex , tachycard i a , i nc reased s ki n  
twi tch refl ex l a tency and hyperthermia . Thi s finding  was u ndoubtedly 
the bas i s  for Shannon ' s s tudy ( 1 979 )  which was di scussed earl i er i h  
w h i c h  t h e  s igma agon i s t ,  N-al l yl normetazoci ne , wa s shown to genera l i ze 
i n  rats tra i ned to d i s crimi nate PCP from sa l i n e .  
Another l i ne o f  evi dence impl i cat ing  s i m i l a r i t i es between the  
d i ssociative  a nestheti cs  and the psychotomimet i c  op io ids i s  found in  the 
rec eptor bi ndi ng l i terature.  Recently several groups of i nvesti gators 
(V i ncent � �. ,  1 978 ;  Zuki n and Zuki n ,  1 97 9 ;  Hampton et <D.. ,  1 97 9 )  have · 
reported s pec i fi c  bindi ng  s i tes for phencycl i d i ne i n  the rodent central 
nervous system .  Wh i l e  Maayan i  and Wei nstei n ( 1 980 )  argued that t h i s  
s pec i f i c  bi ndi ng i s  actual l y  a n  art i fact · of t he  rap id  fi l tration  method 
u s ed in these bi nd i ng s tud i es ,  Vi ncent et <D... ( 1 980)  reported in deta i l  
a bi n d i ng technique whi c h  makes i t  poss i bl e  to measure al l o f  t h e  PCP 
bi ndi ng  to the fi l ters and subtract this  from the total bi nd i ng  to 
obta i n  s pec if ic  b ind ing  . . 
The PCP b ind ing  s i te descri bed . by Vi ncent et �. (1 979)  ful fi l l s  
many o f  the requi rements used i n  descr ib i ng  a speci f i c  pharmaco l ogi ca l  
recepto r .  3H_ PCP i s  bound s pecifical l y  and  wi th a . h i g h  affi n i ty (Kd = 
0 . 25 �M)  to a s i ngl e ,  saturabl e and revers i bl e  s i t e .  Bound 3H_PCP can  
be  d i s pl aced by non-radi oact ive  PCP  a nd a seri es of PCP  a na l ogues . 
There i s  good correl ation between the apparent a ffi n i t i es o f  a ser ies of 
a na l ogues for thi s bi ndi ng s i te and the pharmacol ogi cal  a c t i v i t i es o f  
t h e s e  anal ogues as measured by t h e  mouse rotarod assay .  Th.e b indIng  
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acti v i ty i s  concentrated in the synaptosomal fracti ons wi th h i g hes t 
concentrations i n  the ,cerebra l cortex and corpus s tr iat um and no detecta bl e 
bi nd i n g  i n  the s p i nal  cord . Vi ncent et �. ( 1 980 ) found that wh i l e  PCP 
a nd i t s  deri vati ves bi nd s peci fica l l y  and revers i bl y  to rat peri pheral 
organs as  wel l as rat bra i n ,  only the affi n it i es for t�e bra i n  receptor 
correl ate wi th the pharmacol ogi cal act ivi t ies in the rotarod test . 
luki n a nd lu ki n' ( 1 9791 found that bound 3H_PCP coul d be d i sp l aced 
by non-radioactive PCP,  a s er i es o f  PCP ana l o gues and N-al lyl normeta­
zoc i n e  w i th rel ative  potenc i es that c losel y  paral l el ed the potency of 
these compounds i n  drug di scrimination tests in rats . I n  more recent 
s tud ies ( lu k i n  and lu k i n ,  1 980) , i t  wa s reported that speci fi C phencyc-
l i d i ne bi nding  was d i s pl aced by cycl azoc i n e  and rel a ted benzomorphans , 
but not by morph i ne or nal oxone .  
Recentl y ,  Pa l mour et �. l 1 980) i sol a ted speci fi c PCP bi nding  s i tes 
in the rat and Afr i can green monkey bra i n .  They ' found that bound PCP 
was d i s p l a ced by l ow concentrat i ons of s tructural anal ogues of PCP and 
moderate concentrati ons of cycl azoc ine  and N-al lyl normetazoci ne . A 
pos s i bl e  s igma receptor was al so i so,l ated by these i nvesti gators . 
Cross-d isp l acement experiments i nd icated that PCP d i d  not bind  th i s  
receptor . 
Su � �. ( 1 980) have reported that PCP a nd fi fteen structural 
a na l ogues d i s pl ace 3H-nal oxone in the opi ate receptor b ind ing  assay .  
The rel at ive  potencies for d i sp l acement correl ated wel l wi th potenc i es 
on the mous e  rotarod and the rat d i scriminative s timul us  tes t .  The I CSO 
for PCP was 2S  �M , a bout 1 0- fol d l ess than the I CSO for morph ine . Smi th 
et �. ( 1 980 ) reported that ketami ne d i s pl aced 3H-nal oxone in the opiate 
receptor b i nding  assay. The potency of ketam ine  in this assaY , was 
reduced by sodi um . suggest ing  that ketamine  i nteracts wi th the opi ate . 
receptor as a n  agon i s t .  I t  was a l so found that t h e  (+) i somer was a 
more potent agon i s t  than the C- l. i somer . I n  thi s s tudy , ketami n e  was 
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found to be a pproximately 3-fol d l ess potent than morphine  i n  di sp l ac i n g  
3H-nal oxone . Vaught · ( 1 980 )  reported that both PCP and ketami ne i nh i bi ted 
3H-di hydromorphi ne  bi nd i ng i n  mouse  bra i n  homogenate , but both were 
a p proximately 3000- fo ld  l ess potent than morph i ne or nal oxon e .  
I n  l i ght of these fi nd i ngs , i t  i s  i nteres t i ng tha t there h a s  been 
rel ati vely 1 1 ttl e expl oration of the ana l ges i c  properti es of PCP and 
ketami ne .  The l i terature o n  the s ubj ect up  to th i s  poi nt present a 
rather u ncl ear and  i ncons i stent pi cture.  Chen et a l . ( 1 959)  reported 
no anal ges i c  effect of PCP in m ice  u s i ng a ta i l  pi nch test for anal gesi a .  
I n  several other speci es i n  wh i ch  anal ges i a  was examined by pri ck i n g  the 
s k i n  wi th a k n ife ,  anal ges ia  wa s only  seen at  doses of PCP wh i ch produced 
catal epsy or general a nesthes i a .  Chen and Weston ( 1" 960 ) reported PCP-
i nduced impa i rment of the response to noc i cept i ve  s timul i in .rhesus  
monkeys , but on ly  at  doses whi ch a l so impai red v i sual  and audi tory 
responses . There have been s everal reports of PCP-i nduced ana l ges i a  i n  
humans , but only at doses with  grossl y obs ervabl e effects on behavior  
( Johns tone � �. ,  1 959 ;  Col l i ns et  �. , 1 96 0 ;  Mu i r  et i!l. , 1 961 ) .  Many 
and  Ki ng ( 1 979) reported PCP- i nduced anal ges i a  i n  the rat ta i l  fl i c k  
test a t  doses wh ich  l ed to n o  gross ly  observabl e behav ioral changes 
( 0 . 05 mg/kg , s . c . ) .  Thi s anal ges i a  was antagoni zed by pretrea tment �/ ith  
nal oxone .  I n  contra s t ,  Markov/i tz and  Kornets ky (1 978 ) reported a 
hypers ens i ti v i ty to foot s hock i n  rats fo l l owi n g  l ow doses of PCP (1 . 2 5  -
5 . 0  mg/kg , i . p . ) .  Because  d i fferent routes o f  admi n i s tration were used , 
i t  i s  d i ffi cul t to ma ke a d i rect comparison  between these two stud i es . 
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Sadove et �. , ( 1 971 ) reported an anal ges i c  effect of ketamine i n  
humans a t  dos es wh i c h  d i d  not produce catal epsy but did  produce d i zz i ness  
and s edat ion .  Ryder et � ( 1 978 ) reported that ketamine had  anal ges i c  
acti v i ty i n  mice u s i ng the phenl yqu i none wri th ing  tes t .  This anal ges i a  
was reversed by h i gh doses of nal oxone ( 1 0  mg/ kg , i . p . ) .  
I n  summary , there a ppear to be some i nteres ting  areas of overl a p  
i n  t h e  pharmacol o g i es o f  PCP a nd the opiates , particul arly the s igma a go­
ni sts . The drug d iscrimi nation data i ndi cates that PCP and some psycho­
tomimeti c opi ates cross-general i ze .  The receptor bi ndi ng l i tera ture 
i ndi cates that certa i n  psychotomimetic opiates di spl ace PCP in the PCP 
bi nd i ng assay and PCP and ketam i ne d i s pl ace opiates in the opiate b i nd i n g  
assay .  Wh i l e  the s i m i l ar it ies  i n  anal ges i c  act i v i ty of PCP a n d  the 
opi ates are l ess  conv i nc ing , · there are no doubt some i nteres ting  1 i nes 
to pursue in further expl oring  pharmaco log ical  s i m i l arities  between 
these groups of compounds . 
Stereospec i fi c  Effects of Opioids and Ketamine  
Another i nteresti ng area to  be  i nvesti gated i n  cl ar ifying  the 
overl a p  between the psychotomimetic opio ids , many o f  whi ch are from 
the benzomorphan seri es , and the di ssoci at ive  anesthetics l i es i n  the  
stereospec i fi c i ty of the acti ons of the benzomorphans . The  benzomorphans 
have a n  unusual s eperation  of acti v i ty between the  optical i s omers . I n  
many cases , whi l e  greater anal ges i c  activ ity l i es i n  the ( - ) i somer , th i s  
i somer wi l l  prec i pi tate wi thdrawal i n  the  morph i ne-dependent rhesus 
monkey . The (+) i somer general l y has l ess  anal ges i c  act iv ity ,  but i t  
has been found that thi s i somer wi l l  suppress wi thdrawa l  i n  the morphi n e­
dependent rhesus mon key (Vi l l arrea l , 1 970 ) . I n  wor k i ng with a 
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racem i c  mi xtu�e in  the  benzomorphan series , it  is  proba bl e that  one i s  
worki ng  wi th a mi xture o f  two active  compounds wh i ch each have thei r own 
d i sti nct spectra of pharmacol og i cal acti v i ty .  Al l of the work des­
cr i bed so far rel ati ng to the s i m i l ar it ies between PCP and the psycho­
tomimeti c opioids has been done wi th racemi c mixtures of the opi o i ds . 
I n i t ia l  s tud i es of the stereoi somers of N-a l l yl normeta zoc ine  . (Swa i n  e t  
�. , 1 973 )  revea l ed t h e  C- ) i somer t o  b e  a n a  1 orphi ne-l i ke antagoni s t 
. capabl e of prec i p i tating  wi thdraw �  i n  the morph i ne-dependent rhesus  
monkey .  On the other hand , th.e (+ )  i somer was descri  bed as a non­
narcot ic  CNS depressant whi ch  produced marked atax i a  i n  rhes us  monkeys , 
an effect we now know to be s im i l ar to that produced by PCP.  
Studi es i nvest igating  pure s tereoi somers of other benzomorphans 
have a l so i nd i cated a subs tanti a l  d i fference in their pharmacol ogica l  
profi l es .  The  ( + )  i somers of pentazoc i ne  and  cycl azoc i ne have been 
found to be i nactive in i nhi bi t ing  phenyl qui none-i nduced wr i thi ng  i n  
mi ce ( Pearl a nd Harri s ,  1 966)  and i n  i nh i bi ti ng the contraction o f  the 
gu i nea pig i l eum ( Harri s � �. ,  1 969) . In add i t ion , the (-)  i somer of 
cycl a zoc ine  is  reported to be more than 400 times more potent than the 
(+)  i somer as  a meperid ine  antagon i st  ( Pearl and Harri s ,  1 966)  and a s  an  
antago n i s t  o f  morphi ne in  the rat ta i l  fl i c k  test ( Pearl et �. , 1 968 ) . 
I n  contra s t  to i ts substanti a l l y  more promi nent antagonist  effects , the 
( _ )  i somer o f  cyc l azocine  wa s only  5 to 20 times more potent than the ( + )  
i s omer i n  t h e  mouse rotarod test a n d  i n  decreas ing  l ocomotion i n  m ice  
( Pearl et �. ,  1 968 ) .  McMi l l an  a nd Harr i s  ( 1 97 2 )  found that the ( - )  
i s omers o f  both cycl azoci ne and  pentazocine were 2 to  3 times more 
potent than the (+ )  i somers i n  decrea s i ng rates of schedul e-control l ed 
respondi ng i n  p i geons but 30 t imes more potent than the (+) i s omers i n  
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bl ocki ng the rate-decrea s i ng effects of morph i ne on schedu l e-control l ed 
respond i ng .  I n  a recent study ( Cowan et �. , 1 979 ) , ( - ) -cycl azoc i n e  was 
reported to be 1 . 6 t imes more potent than ( + ) -cyc1 azoc i ne as an ant i ­
convul sant , and ( + ) - pentazoc i ne was reported to be 5 . 6  t imes more potent 
than i ts ( - )  i somer as a pro-convu lsant .  These studies  i nd i cate that 
whi l e  the ( + )  i somers of these benzomorphans do not have op i ate-l i ke 
properti es ,  they are i ndeed active compou nds . The C- ) i s omers a ppea r to 
possess most of the o p i o i d  antagon i st  act i v i ty .  
C l i ni cal studi es have reported that the ( - )  i somer o f  pentazoc i n e  
i s  a more potent anal ges i c  ( Forrest e t  �. , 1 969 )  and resp i ratory depressant 
( Bel l v i l l e  and Forrest ,  1 968) i n  man than the (+)  i somer . Resu l ts from 
thi s s tudy a l so i nd i cated that the ( + )  and ( - )  i s omers have d i fferent 
s u bj ect ive  effects i n  man . The ( + )  i somer produced feel i ngs of a nx i ety 
wh i l e  the ( - )  i s omer p roduced a morph i ne- l i ke s edati o n .  
T h e  stereospeci fi c i ty o f  t h e  pharmacol og ical  properti es of the 
d i s soc iat ive  anestheti cs have al so recently been the . subject of i nvesti ­
gati on . Whi l e  PCP i s  not optical ly acti v e ,  ketami ne does have a c h i ral  
center . Severa l stud i es have i nd i cated d i fferences in  the pharmaco l og i cal  
properti es o f  the i nd i v i dual ketamine  enantiomers in  anima l s .  Mar i etta 
et �. ( 1 977 ) ,  us i ng rats , reported that the ( + )  i somer of ketami ne 
wou l d . e l i c i t  periods  of hypno s i s  l ast ing  twice  as l ong as the (- 1 i s omer 
a fter equ imo 1 ar doses . The C+J i somer a l so caused l ess post -hypno t i c · 
l ocomotor stimu l ation  than the ( - )  i somer at equ i hypnot i c  doses . Ryder 
et �. ,  ( 1 978) found that i n  m ice  the C+ ) i somer of ketami ne was 3 ti mes 
more potent than the ( - )  i somer as  an  anal ges i c  u s i n g  the p henyl q u i none  
wri.thi n g  tes t ,  1 . 5 t imes more potent in  hypnot i c  activ i ty a nd 1 . 8 times 
more potent i n  caus i n g  l ocomotor st imu l at ion .  A recent cl i n i cal  study 
by Wh i te et �. ( 1 980 ) i nd icated that (+ ) - ketam i ne produced more effecti v e  
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anes thes i a  than { - } - ketami ne , wi th l ess i nci dence of psychic  emergence 
reacti ons or agi tated behav ior .  Me1 i s ka et a 1 . { 1 979 }  exami ned the 
effects of ketamine enantiomers in rats trai ned on a FI schedu l e of food 
presenta t ion .  Low doses o f  { - } - ketami ne · i ncreased respons e rates i n  a 
rate-dependent manner ,  the l ow control rates were i ncreased more than 
the h i g h  control rates . The { + }  i somer d i d  not i ncrease . response rates 
a t  a ny dos e .  H i  gher doses of both drugs produce dose-dependent .decreas es 
i n  FI res pond i n g .  · Smi th et �. ( 1 980 ) have i nvesti gated the i nteraction  
o f  racem ic  ketami ne and ketamine enanti omers wi th the opiate receptor . 
They found tha t  { ± } - ketami ne d i s pl aced 3H-na 1 0xone . The {.+ }  i somer .  was 
3 to 4 times more potent than the { - }  i s omer i n  d i sp l acing na l oxone . 
Th i s  s tereose1 ecti v i ty i s  cons i stent · wi th · the studies menti oned prev ious ly  
{ Ryder � �. ,  1 978 ;  Wh ite  et '!l. , 1 980}  i nd i cat i ng that (+ ) - ketami ne 
has a greater anal ges i c  effect . than  the { - }  sal t .  Thus , there is  some 
ev idence for qual i tative  di fferences in the effects of ketami ne enan-
t iomers . 
Simi l ar i t i es i n  the  Effects of PCP,  Etoxadro1 and Dexoxadro1 
�nother g roup  of compo�nds wh i ch are s tructural ly di ss imi l a r to PCP , 
the 2 - { 2 , 2  s u bsti tuted 1 , 3 d i oxol an-4-yl ) pi peri di nes , al so seem to 
share many pharmacol ogi cal propert i es with  the d i ssociative  anestheti cs . 
Chen { 1 973}  reported that with  i ncreas i ng doses the s equence o f  observabl e 
effects of PCP and ketami ne i n  l a boratory an imal s i s  s i mi l ar for etoxadr.o l  
a n d  dexoxadrol . Thi s i s  of part icu lar  i nterest i n  l i ght of the recent 
f i nd i ngs j u st  revi ewed concern i ng the over l ap  between the psychotomimetic  
o p i a tes and  phencycl i d i n e ,  because most of the  early i nvest i gati ons o f  
d exoxadrol focused on  i ts anal ges i c  properti es . . Cl i. n i ca l  stud i es lS imo pou l os 
et  2l. , 1 97 0 ;  La sagna and Pearson , 1 96 5 ;  Wi l l  i ams et �. , 1 969 }  have 
s hown dexoxadrol to be an ana l ges i c  of effi cacy s imi l ar to a sp ir i n  i n  
man ,  a l though psychotomimetic properti es were cons i s tently seen at  
hi gher doses . 
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Etoxadrol has been i nvesti gated for cl i n i ca l  use  as an  anestheti c .  
As wi th PCP and ketamine , humans anestheti zed wi th etoxadrol ma i nta i n  
pharyngea l , l aryngeal and l i d refl exes . Tachycardia , tachypnea as  wel l 
a s  nys tagmus and emergence del ir i um  have been observed (Wi l son et �. , 
1 97 0 ,  1 973 ;  Fredrickson et �. , 1 976 ) . As a consequence of these findi ngs , 
etoxadrol has been c l a s s i f i ed al ong wi th PCP and ketami ne as a di ssoc i ­
a t i v e  a nestheti c ( Co hen , 1 965) . 
D .  Spec i fi c  Aims 
The fol l owi ng studi es were desi gned to i n�estigate the behav i oral 
pharmaco logy of the d i ssoc iat ive  a nestheti cs and rel ated compounds . I n  
Experi ment I ,  t h e  effects o f  phencycl i di ne a n d  three structural anal ogues o n  
food rei nforced fi xed-i nterval performance i n  rhesus monkeys were compared . 
I n  Exper iment I I ,  five s tfuctural anal ogues of PCP were t�sted for 
genera l i zation  to PCP i n  squi rrel monkeys tra i ned to di scrimi nate PCP 
from sal i ne in a two-l ever operant task .  
Because o f  the many s i m i l ari ti es between PCP,  etoxadrol and dexoxa­
drol reported in the l i terature,  Experiment I I I  wa s des i gned to expl ore 
the  d i scrim i nat ive s timu l u s  properti es of dexoxadrol and etoxadrol i n  
squ i rrel monkeys tra i ned to d i scrimi nate PCP from sal i ne i n  a two-l ever 
opera nt ta s k .  T h i s  shou l d  hel p t o  further defi ne t h e  l i nk between the 
aryl cyl oal kylami nes a nd these s tructural ly d i s s i m i l a r  compounds . 
Mos t  of the studi es di scussed i n  the prev i ous  pages concerning  
general i za tion  between PCP  a nd psychotomimetic opi ates used the racemi c 
m i xture of the opiates . I n  the case of N-a l l yl normetazoc i n e ,  the (+) 
and  the ( - )  i somers have been shown to have d i fferent pharmaco l ogi cal 
profi l es ( Swa i n  et a l . ,  1 97 3 ) . In Exper iment IV , the di scrimi native 
s t i mu l us propert i es o f  the pure stereo i somers of N-al lyl normetazoc i ne 
were studi ed i n  rats and s qu i rrel monkeys tra i ned to di scrimi nate PCP 
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from sa l i ne .  Because  cycl azoc i ne a l so demonstrates a seperat ion  of 
pharmaco l o g i cal acti v i ty between i ts stereo i somers , Experiment V I  was  desi gned 
to further i nvesti gate the overl ap  i n  the di scrimi native stimul us  properti es 
o f  cyc l a zoci ne and PCP- l i ke drugs in the l i ght of any poss i bl e  stereo s peci ­
fi c i ty i n  the d i scriminative  st imu l us pro perti es of cycl azoc i n e .  I n  
Experiment V ,  t h e  d i scr imi nat ive  sti mul us  propert ies  of the stereo i somers 
of ketami ne were i nvesti gated i n  rats tra i ned to di scriminate PCP from 
sa l i ne .  
The purpose o f  t h i s  work i s  to further defi ne  the behavi oral  pharma- . 
col ogy o f  PCP a nd compounds whic h  are structura l ly a nd/or pharmacol o­
g i cal l y  s i m i l a r  to PCP .  A good deal  of attention has been focused on 
the  overl ap  in the pharmacol og i es of the d i ssoc i at ive  anesthet i cs a nd 
the psychotomimetic op iates . Hopeful l y ,  i nvesti gati ons of the behav i oral 
and pharmacol ogical  s i m i l ari ti es o f  such  structural ly di verse compou nds 
cou l d  prov ide  i ns i ght i n  the general area of psychotomimeti cs a nd psycho­
ti c behav i or .  
I I .  COMPARISON OF PHENCYCLID INE  AND THREE ANALOGUES ON FIXED-INTERVAL 
PERFORMANCE I N  RHESUS MONKEYS ( EXPERIMENT I )  
A .  I ntroduction 
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The i l l i c i t  synthes i s  of phencycl i d i ne ( PCP )  and many of i ts deri ­
vati ves i s  a rel atively s impl e process and several anal ogues , mos t 
nota bly 1 - 1 - ( 2-thi enyl ) cycl ohexyl p i p er i d i ne(TCP) and N-ethyl -l-phenyl ­
cycl ohexyl ami ne ( PCE ) ,  are known to have appeared i n  · street use  ( Shul g i n  
a nd Maclea n ,  1 976 ) . For t h i s  reason , a s  wel l a s  to ascerta i n  s tructure­
act i v i ty rel ationsh i ps ,  there is a need to determine  the pharmaco l og i cal  
properti es o f  d i fferent aryl cycl oal kyl ami nes and hOl� they compare to 
those of PCP ( Chen et �. , 1 959 ) .  
McCarthy � �. ( 1 965) found that ketami ne , 2- ( 0-chl orophenyl ) -2-
methyl ami nocycl ohexanone , had  much  the  same s pectra of pharmaco l o g i ca l  
a cti v i ty a s  PCP, · but wa s l ess  potent . They reported that the durat ion  
of a nes thes i a  produced by ketami ne i n  monkeys was shorter than  that of  
PCP ,  a nd the  onset  o f  the  anti convul sant acti v i ty of ketamine  i n  mi c e  
was more rapid than �li th P C P .  Chen ( 1 965 ) found that P C P ,  TCP , P C E  and 
ketam i ne a l l  produced a s imi l a r ,  character i sti c catal epsy in p i geons . 
TCP and  PCE were found · to be rel at ively equ i potent to PCP and ketami ne 
was  a pproximately 1 / 1 0  as  potent as  PCP�  
P i nchas i  et �. ( 1 978a ) compared PCP,  PCE and TCP on forced rotarod 
performance in m ice .  They found peE to  be  sl i ghtly more potent than PCP 
or TCP.  Furthermore , PCE was found to have a rapid onset and offset . 
Pea k effects of PCE were observed 5 to 1 0  m i n  after s ubcutaneous i nj ec­
t i  on , wi th performance returni n9 to normal wi thi  n 60 mi  n ,  even at  the  
h i ghest  dose  ( 20 mg/kg ) . Kal i r  et �. ( 1 969 ,  1 978 )  a l so  found PCE to be  
s l i ghtly more potent than PCP  i n  di srupti ng mouse rotarod activ i ty .  
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Several · i nvesti 9ators (Maayani � �. ,  1 973 , 1 97 4 ;  Paster et �. � 1 974 ; 
Pi ncha s i  et �. , 1 97 7 ,  1 978a , 1 978b ; Wei nste i n  et �. , 1 97 3 )  have reported 
that PCP ,  PCE and TCP have both anti chol i nerg i c  and anticho l i nestera s e  
acti v i ty u s i ng both receptor b i nd i ng and bi oassay procedures . The 
purpos e of th is  study was to compare the effects of PCP, TCP ,  PCE , and 
ketami ne ( Fi gure 1 )  on fi xed- i nterval ( F I )  performance i n  rhesus  monkeys . 
B .  Methods 
An ima l s  
The subj ects were four adul t ma l e  rhesus monkeys whi c h  had pre­
v i ous ly  been used in a s tudy o f  the effects of cannabi noids on fixed­
i nterval respond i ng ( Brady and Bal ster , 1 980a ) .  At l east tVIO months 
dur ing  whi ch no drugs were admi n i stered i ntervened between these s tudi es . 
The same behavioral performance was used i n  both studi es . The an ima l s 
were mai ntai ned at a constant wei ght ( 6-8  kg ) by adjusted post-sess i o n  
feed i ngs a n d  had free access t o  water · i n  thei r home cages . 
Apparatus 
The experimental sessi ons were conducted in an  upri ght refr i gerator 
s h el l equi pped with an  exhaust fan and a house .1 i ght on the cei l i n g .  
The monkeys were s eated i n  a prima te chai r ,  wh i c h  restricted movement by · 
a wa i s t  stock and s houl der r i ngs , for the duration  o f  the experimental 
s ess i o n .  Immedi atel y before i ni tiation  of t h e  sessi on , t h e  cha i r  was 
p l aced i n  the chamber fac i ng the front door upon wh i c h  a response l ever , 
three colored stimu l us l i ghts and a food troUgh were mounted . Lever 
pres s i ng was mai nta i ned by the presentation of two 1 gram banana fl avored 
food pel l ets ( Noyes , Formul a  L )  by an automat ic  feeder ( BRS/ LVE  POC ) 
l oca ted outs i de on the chamber door .  The  experimental conti ngencies 
were coritrol l ed by sol i d  state programmi ng equ i pment l ocated in an 
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F IGURE 1 















adjacent room . Data were recorded automatical ly i n  the form of response 
tota l s and cumul ative response recordi ngs . 
Procedure' 
The an imal s had been tra i ned to res pond on a mu l ti p l e  FI 5 mi n 
t ime  out  1 m in  schedu l e  of food presentat ion .  At  the  beg i nn ing  of the 
s ess ion , the house l i ght  and' the l i ghts over the l ever were i l l uminated . 
The first response a fter 5 mi n resu l ted i n  food del i very .  If  t h e  a nimal 
did not respond wi thi n 1 min ( 1  imi ted hol d I ',li n )  after the 5 -m i n  i nter­
val had e l a ps ed ,  the ava i l abl e food pel l ets were forfei ted and the 
s chedu l e advanced i nto a I -m in  time out during  whi ch  the l ever l i ghts 
were turned off and respond i ng had no consequenc e .  A rei nforced response 
a u toma ti cal l y  advanced the schedu l e i nto the t ime out wh i ch occurred 
between each fixed-i nterval . The sess ion  was termi nated after the 
fi fteenth FI  component , a t  whi ch  time the house l i ght and l ever l i ghts 
were exti ngu i shed .  Experimental sessi ons were conducted s even days a 
wee k .  
W h e n  s tabl e res pond i ng was achi eved , drug i nj ections were given 
i .m .  on  the day fol l owing  three consecutive  base l i ne days when respons e 
rates vari ed by l ess  than 20 percent , usual ly every fourth day . The 
a n imal s were i nj ected whi l e  in the primate cha i r  5 min before the i n i ­
t i at i on  o f  the s ess i o n .  The animal s were then kept i n  a hol d ing  area 
u nti l i mmedi ately before the i n i t iation of the s ess ion  when the cha i r  
wa s pl aced i n  the operant chamber .  The  di fferent drugs were g iven i n  a 
ra ndom s equence wh ich  di ffered for each an imal . Each  drug was given t'o 
two s u bj ects i n  an a scend i ng dose order and to the rema i n i ng two s ubjects 
i n  a des cendi ng dose order . 
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Da ta Ana lys i s  
Non- injection response rates for t h e  three days precedi n g  each 
i nj ection  were used to ca l cu l ate basel i ne response rates . For rate­
dependency analys i s  ( Kel l eher and Mors e ,  1 958 ) ,  the FI was d i v i ded i nto 
five l -m i n  s egments and drug effects on l ocal res ponse rates were graphed 
a s  a function of the average rates of respond ing  i n  correspond ing  s eg­
ments of the FI for the basel i ne days . The duration of the l im i ted hol d  
was not used i n  the cal cul ation of respons e rates for - the termi nal bi n .  
Onl y treatment days during  whi ch overal l respond i ng exceeded 0 . 1  res­
ponse per s ec were i ncl uded i n  rate-dependency cal cul ations . Res ponses 
per s ec for each of the fi fteen i nterva l s  in the sess ion  were ca l cu l a ted 
by m easur i ng the hei ght o f  the peak for each i nterval on the cumu l at ive  
records and ca lcu l at ing  the  number of responses . 
Drugs 
Phencycl i di ne HCl was s uppl i ed by B io  Ceut i c  Laborator i es (Serny­
l a n ) . - Ketami ne HCl was suppl i ed by Parke-Da v i s  and Co . ( Ketal a r ) .  
They were d i l uted with  0 . 9 - percent _ sal i ne to a concentration that 
res u l ted i n  an  i nj ection vol ume of 0 . 2  ml /kg . PCE and TCP as the HCl 
s a l ts I-Iere s uppl i ed by the Nat ional I nst i tute on Drug Abu s e .  These 
drugs were d i s sol ved in sa l i ne  to a concentration  that resul ted i n  a n  
i nj ection  vol ume of 0 . 2 ml /kg . Veh i cl e i nj ecti ons of 0 . 2  ml / kg sal i ne 
were g i ven once d u r i ng the tes t i ng of each dru g .  Al l i njections were 
g i ven i . m .  5 m i n  pre-ses s i o n .  Dos es refer to the sal ts . 
C .  Resu l  ts 
The FI 5 m i n  schedul e of rei nforcement generated pos i tively accel er­
ated patterns of respond ing  characteri st ics  of FI performance . - The 
base l i ne rates ±1 S . E . M .  throughout the experiment for each of the 
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four  s u bjects were 1 . 36 ± . 08 ,  1 . 1  ± . 0 5 ,  . 23 ± . 01 , and 1 . 53 ± . 0 5  
responses per sec ·. Al though res ponse rates for each monkey were fa i rl y  
s tabl e ,  there were wide d i fferences between monkeys . As a consequence 
the data is presented as percent change from basel i ne rates averaged 
across a n imal s .  
Fi gure 2 shows the group dose- respons e curves for each o f  the . fou r  
compounds tes ted . Dose-rel ated decreases i n  respond ing  were seen for 
a l l four compounds . The s l ope of the dose-effect curve was a l so s i mi l ar 
for each of the drugs . Al though only decreases i n  average response  
ra tes are seen  i n  th i s  fi gure , each  of the  four compounds produced 
modest response rate i ncreases at l ower doses . These i ncreases are not 
evident in the. group avera ges because they were smal l i ncreas es and they 
occurred at d i fferent doses i n  the d i fferent· s ubj ects . At the hi gher 
doses o f  each compou nd , s im i l ar observabl e effects cou l d  be seen prior  
to or after the  ses s i ons whi l e  the  subjects were seated i n  the  restra i n i n g  
cha i r .  Sedati on , i ncoord i nation , exces s i v e  sal i vati on and nystagmus 
were o ften noted . An imal  87784 showed an unusual i ns ens i t i v i ty to TCP . 
Doses u p  to 6 times those  wh ich  compl etel y su ppressed respond i ng i n  t h e  
other an imal s were needed t o  s uppress respond i ng i n  thi s animal . The 
l arge s tandard error for the effect of 0 . 4  mglkg TCP i s  l argely due  to . 
the  l ac k  of effect of thi s  dose of TCP on a n imal  87784 . 
Tabl e 2 shows the ED50 val ues for s uppres s i on of operant respond i ng 
for each of the four  compounds tes ted as cal cu l a ted by l i near regres s i o n .  
A comparison of t h e  potency o f  t h e  three anal ogues to PCP s hows that TCP 
is s l i ghtly more potent than PCP , PCE i s  s l i ghtly l ess  potent than PCP , 
a nd ketami ne i s  approximatel y 1 / 1 0  as potent as PCP i n  suppress ing  
operant res pondi n g .  T h e  di fferences between PCP  and TCP a r e  smal l 
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FI GURE 2 
Group  dose-response curves �or PCP and three anal ogues on sup­
pres s i on of o perant respondi ng . The effect as percent of basel i ne i s  
pl otted a s  a function o f  drug dose.  Basel i ne rates were d etermi ned by 
averag i ng the non-inj ection  response rates for the three days precedi ng 
each i njecti on .  The  poi nts a bove VEH  represent the  resul ts o f  veh i cl e 
i'njecti ons . Po i nts represent means ± S . E .M .  for four subjects except 
TCP where data is from three subj ects . Only one  animal  was tested at  
0 . 8  mg/kg PCP .  
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POTENCY OF PCP AND THREE ANALOGUES ON 
FI XED-I NTERVAL PERFORMANCE IN RHESUS MONKEYS 
ED50* RATIO  TO PCP 
DOSE (mg/ kg) (mg/ kg) 
. 28 
. 25 1 . 1 2  
. 33  . 84 
2 . 89 . 097 
RAT IO  TO PCP 
(mol es/kg) 
1 . 1 4  
. 7 2 5  
. 095 
*Do s e  resul ti ng i n  a 50% decrease  in response rates as  determi ned by 
l i near regress ion .  
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suggesti ng that these drugs are rou ghly equ i poten t .  
Fi gure 3 shows t h e  t i m e  course of the effects of two doses of each 
drug tes ted in a l l  an imal s except TCP where the data i s  from only three 
a n ima l s .  Each data poi nt represents the mean percent of basel i ne res­
pond i ng for three consecut ive  5 -m i n  i nterval s p l u s  the time outs . pCP 
a nd O . S  mg/kg PCE sho�/ed pea k acti v i ty 24-41 min after drug i njection . 
The 1 0�/er dose o f  PCE ( 0 . 4  mg/kg ) showed maximum acti v i ty 42-59 m i n  
a fter i njection .  T h e  onset of acti v i ty for ketami ne was apparent during  
the f i rs t  lS  m i n  of the  s es s i o n .  Recovery from t h e  l ow dose ( 4 . 0  mg/k g )  
o f  ketami ne began wi thi n 30 m i n  o f  drug adm i n i strati on .  At both dos es 
of PCE and the h i g h  dose of TCP , the an imal s d i d  not recover during the 
ly, hour sess ion .  
Fi gures 4 -7  are  rate-dependency pl ots for the  two hi ghest doses of 
a l l  drugs  tes ted in  each subj ec t .  The rate-dependency pl ot for the drug 
doses ' whi ch  resu l ted in  overal l response rates l ess than 0 . 1  response 
per sec are not s hown . Each poi nt i s  the ratio  of the drug rate of 
respondi ng to control rate of respond ing  pl otted agai nst the control 
rate of res pond i ng during  each of the five l -� in  portions of the Fl . 
The heavy dashed hori zontal l i ne represents the no-effect l i ne , where 
the drug rate i s  equal to the control rate during  each portion  of the 
i nterva l . A typi cal  rate-dependent effect i s  evi denced by a shi ft from 
the no-effect l i ne towards a l i ne  wi th a negative sl ope . Al l four drugs 
produce th i s  effect in al l an ima l s  at  l east a t  one dose and genera l l y  
a t  both h i g h  doses . I n  a number of ca ses thi s was a dose-dependent 
effect wi th a greater negative · s l ope at the hi ghest dos e .  
D .  Di scussion  
Our fi ndi ngs show marked s im i l ar it ies  between the acti ons o f  P CP ,  
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F IGURE 3 
Time course of the effects of PCP a nd three anal ogues on operant  
respond i ng duri ng a 1 �  hour operant sessi o n .  O n  the ordi nate i s  p ercent 
basel i ne respond i n g .  The basel i ne rates were determi ned by avera g i n g  
t h e  non-i njection  response rates for the three days precedi n g  the 
i nj ect ion .  The a bsci ssa  represents the 1 5  6-m i n  i nterval s  of the 1 �  
hour  s ess ion  graphed i n  groups of three ,  such  that each  po i nt represents 
18 min o f  respond i n g .  
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FIGURE 4 
Rate-dependency pl ots for PCP and a �a l ogues i n  animal B002 . The 
two h i ghest doses not produc i ng compl ete suppress ion  were plotted , 
except i n  the case of TCP where the h igh  dose ( 0 . 4  mg/kg ) resul ted i n  
overa l l  response rates l ess  than 0 . 1  respons e per s ec . O n  the ord i nate 
is  drug rate/contro l '  rate . On the abs.c i ssa i s  control rate i n  response  
p er s ec . Control ra te was determi ned by averaging  the  non- i njection 
response rates for the three days preced i ng the drug injection day . 
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FI GURE 5 
Ra te-dependency pl ots for PCP a nd anal ogues i n  a n imal B41 1 5 .  
The two hi g hest doses not producing  compl ete su ppress ion  were p lotted . 
On the ordi nate i s  drug rate/control rate . On the absc i ssa i s  control 
rate i n  res ponses per s ec ·  Control rate wa s determi ned by averag i ng 
the non-i njection response rates for the three days precedi n g  the drug 
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F IGURE 6 
Rate �ependency pl ots for PCP ind ana l ogues i n  anima l  87784 . The 
two h i g hest doses not produc ing  compl ete su ppression were pl otted . On 
the  ordi nate is drug rate/control rate .  On the a bscissa  i s  control rate 
i n  responses per sec . Control rate wa s determi ned by avera g i n g  the 
non- i nject ion response rates for the three days prec e d i n g  the drug 
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F IGURE 7 
Rate-dependency pl ots for PCP a nd ana logu es i n  an imal 847 2 .  The 
two h i ghest doses not producing compl ete suppress i o n  were pl otted , 
except i n  the case of TCP whi ch wa s not tested i n  th i s  an imal . On the 
6rdi nate is drug rate/co ntrol rate . On the absci ssa is control rate i n  
. responses per sec . Control rate was determi ned by averag ing  the non-
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PCE ,  TCP a nd ketam i ne .  Al though not quanti tated in thi s · experiment , 
h i g h  doses of a l l  four drugs produced a s imi l ar set of obs ervabl e a l tera ­
t i ons i n  the a nima l s  whi c h  i ncl uded i ncoordi nati on , excess ive  sa l i vat ion  
and  nys tagmu s .  These effects a r e  s imi l ar to those reported by Bal ster 
a nd Cha i t  ( 1 978) for moderate doses of PCP in subhuman primates . Some 
evi dence of response rate i ncreases at l ow doses of each drug were seen , 
but these i ncreases were not sUbstanti al  enough to be evi dent i n  the 
group dose- effect curv e .  Response rate decreases were seen at the 
hi gher doses of a l l  drugs . Cha i t  and Ba l ster ( 1 977 ; 1 978 ; 1 97 9 )  have  
reported a s imi l a r  effect i n  squi rrel monkeys us i ng  schedul e-contro l l ed 
perfor ces . Low doses of PCP produced smal l i ncreases in rates of 
respondi ng ,  whi l e  hi gher doses produced a dose-dependent decrease i n  
response rate . 
I n  addi tion , a l l  four drugs had a s i m i l ar rate-dependent effec t .  
The rate-dependency hypothes i s  states that the effect o f  a drug o n  a 
performance wi l l  depend on the basel i ne rate of that performance ( Kel l eher  
a nd Mo rs e ,  1 968 ) .  The  FI  schedu l e  i s  particu l arly .wel l su i ted to  s tudy 
rate-dependent effects because i t  generates a typi ca l  posi tively accel e­
rati n g  pattern of respond i ng characteri zed by l ow rates of  respondi ng 
at the begi nn i ng o f  the . fi xed-i nterval and h i g h  rates of respondi n g  near 
the end  o f  the fixed- i nterval . A typi cal rate-dependent effect of drug 
i s  to i ncrease the l ow rates o f  responding  at the beg i n n i n g  of the 
fi xed- i nterval , and  decrease the h i g h  rates of respondi ng in the l ater 
part o f  the i nterval ( Kel l eher and Morse ,  1 968 ) .  Thi s  woul d be rep­
resented graph ical ly by a l i ne wi th a negative s l o pe ,  i nd i cating  an 
i ncrease  in respond ing  in the i n i ti a l  bi ns , where the control rates were 
l ower and a decrease  i n  the l ater b i ns where the control rates were 
h i gh . I n  the case of the h i g her doses of the drugs wh ich  decreased 
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respond ing  in al l b i ns , the negatively sl oped l i ne wh i c h  fal l s  bel O\� the 
no-effect l i ne i nd i cates a greater decrease in the l ater bi ns than i n  
the i n i ti a l  bi ns . Thi s type o f  rate-dependent effect i s  s im i l ar to that 
descri bed for a· vari ety of behavioral ly active compounds ( Kel l eher a nd 
Mors e ,  1 968) . Several other i nvesti gators have reported s imi l a r  effects 
of PCP on  l oca l rates of respond i ng i n  operant performance i n  squ i rrel 
monkeys ( Cha it  and Bal ster , 1 978 ) , m ice (Wenger and Dews , 1 97 6 )  and 
p i g eons (Wenger , 1 976) . In the present study , thi s  rate-dependent 
effect was dose-dependent . The negative s l ope o f  the regres s i on l i ne 
was g eneral ly more marked at h i g her doses than at the l ower dos es . 
The potency d i fferences between the four compou nds were s im i l ar to 
those found by Chen (1 965) where PCP wa s roughly equ i potent to TCP , 
s l i ghtly more potent than peE ,  and more than 1 0-fo l d  more potent than 
ketam i ne in produc i ng cata l epsy in pi geons . Thi s  comparison o f  PCP and 
PCE  is  in  d i sagreement wi th the fi ndi ngs o f  Kal i r  et !l. ( 1 978 ) and 
P i nchasi  !!.. !l. ( 1 978a ) who · found PCE to be s l i ghtly more potent than 
PCP i n  d i s ru pti ng mouse rotarod performance .  
The time course resul ts i nd icate that the effects of ketami ne o n  
o�erant performance are ev i dent 5-23 m i n  a fter i .m .  i njecti o n ,  and 
recovery beg i ns withi n � hour o f  the i njecti o n .  The onset o f  P C E  and 
PCP were s im i l a r ,  requ i r i ng at l east 24-41  min to pea k effect .  Kal i r  
et �. ( 1 978)  measured bra i n  l evel s of peE and PCP and correl ated these 
wi th acti v i ty in di srupting rotarod performance in mi c e .  They found 
a max i mum accumul ation at  20 m i n  a fter s ubcutaneous a dmi n i strat ion  a nd 
a s l ow time course of el im i natio n .  They found that whi l e  peak behav ioral 
acti v i ty corre lated wi th peak bra i n  l evel s ,  the o ffs et of behavi ora l  
acti v i ty wa s faster than the el i mi nation o f  t h e  compound from mous e bra i n .  
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The marked i nsens i t i v i ty of an imal B7784 to TCP. warrants further 
comment.  After the experiment was over , thi s anima l  and subj ect B4l 1 5  
were i nj ected with  1 . 0 mg/kg PCP . Thi s dose produced dramat{c  observ­
a bl e  behavi oral effects in anima l  B4l l 5 , but had no observabl e effects 
on a n imal  B7784. It  is d i fficu l t to attr i bute the i nsens i t i v i ty of 
an imal B7784 to his h i s tory of PCP dos i n g ,  s i nce  th i s  degree of tol er­
a nce  was not s een i n  the other subj ects who had s i mi l ar hi s tory of PCP 
i njecti ons . In a dd i t ion , a study by Cha i t  and Ba l ster ( 1 978 ) using 
s qu i rrel monkeys g i ven chronic PCP progres s i ng to four daily i njecti ons 
found only a 2 - fol d s h i ft in the dose-respons e curves . It i s  more 
l i kely that this  i s  an i d i osyncrat i c  response .  
I n  concl us ion , these  four drugs have  been found to  have  qual i ­
tati vely s imi l ar effects o n  operant respond i ng i n  the rhesus monkey . 
Thi s i s  cons i s tent w{th other s tudi es s howi ng thes e compbunds to have 
s im i l a r  pharmaco log ica l  effects ( Chen , 1 965 ;  Ka l i r rt �. ,  1 969 , 
1 978 ; McCarthy et �. , 1 965 ;  Paster et �. , 1 974 ; Hei nstein et �. , 
1 973 ) and research demonstrati ng · that the stimu l us  properties o f  the 
These anal ogues genera l i ze to PCP in a drug d i s cr im ination parad i gm 
( Overto n ,  1 975 ; Shannon , 1 97 9 ) . I t  i s  cl ear tha t PCP i s  only representa­
tive o f  a class o f  ary lcycl oal kyl ami nes wi th s i mi l ar behavioral effects 
and pos s i bl y  s imi l ar potenti al  for a buse . 
I I I .  D I SCRIMINATIVE STIMULUS PROPERT I ES OF PHENCYCLI DINE  AND FIVE  
ANALOGUES I N  THE SQU I RREL MONKEY ( EXPERIMENT I I )  
A .  Introduction 
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In  Experiment I ,  we found that PCP ,  PCE and TCP and ketami ne had 
qual i tati vely s imi l ar effects on fixed-i nterval performance in rhesus  
monkeys ( Brady et �. , 1 980 ) . I t  i s  becoming  a pparent that a wide 
vari ety of s tructural modi f ications can ' be made in the PCP mol ecu l e  with­
out markedly a l teri ng its  pharmaco logi cal profi l e .  
As d i scussed i n  the general i ntroducti o n ,  drug d i scrimination s tudi es 
i ndi cate that PCP and some of its anal ogues have s i mi l ar di scrimi native 
st imu l us propert i es . Several i nvestigations ( Jarbe et �. , 1 97 5 ;  
Overto n ,  1 97 5 ;  Shannon , 1 979 ;  Pol i ng e t  �. , 1 979 )  i ndi cate that ra ts 
trai ned to di scrimi nate PCP from sa l i ne general i ze to structural anal ogues 
o f  PCP but not to a va ri ety of s tructura l l y  u nrel a ted psychoactive  drugs . 
Whi l e  most stud i es suggest pharmacol ogical  s i m i l ar it ies between PCP  
and many of i ts structural anal ogues , Gehrmann and Ki l l am ( 1 979 )  found 
that l - ( l - phenyl cycl ohexyl ) pyrrol i d i ne ( PHP)  produced a qual i tatively 
di fferent EEG profi l e  from other anal ogues . In add i ti o n ,  they reported 
that l - ( l -phencyc lohexyl ) morphol i ne ( PCM)  was i nactive  in the dose 
ra nge they tes ted . PHP has been d i scovered i n  i l l i c i t  street use  ( Shul g i n 
and Maclea n ,  1 976 ) .  
The present study waS desi gned to compare the d i scriminat i ve 
st imu l u s  properties  o f  PCP to those of PCE , TCP , PHP , PCM and ketamine  
( Fi gure 8 )  in  the  squi rrel monkey . There have  been rel at ivel y  few 
reports u s i ng the squi rrel monkey as a s u bject i n  drug d i scrimi nation  
stud i es . I t  s eems espec i a l l y  important to expl ore the di scriminative 
st imu l us properties o f  PCP in  primates becau s e  of the apparent spec i es-
-63- . 
FIGURE 8 
Chem i cal  structures o f  PCP a nd anal ogues u sed i n  Experiment I I .  
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s pec i fi c i ty of some of the pharmacol ogical  act ivi ti es of th i s  compou nd . 
The gross behavioral effects o f  PCP i n  man i ncl ude atax ia , nystagmus· 
and  rhythmi c  movements ( Burns et �. , 1 97 5 ;  Grei fenstei n et �. , 1 958 ) . 
These effects more c losely  resembl e the effects of PCP i n  subhuman 
primates than i ts effects in rodent spec i es ( Bal ster and Chai t ,  1 97 6 , 
1 978 ;  Chen � �. ,  1 959) . I n  order to ascerta i n  the s peci fi c i ty o f  the 
PCP cue in  the squi rrel monkeys , g eneral i zation  testing  was  a l so con­
ducted with mescal i ne ,  morp h i ne and ketocyc1 azoc i n e .  
B .  Methods 
Subj ects 
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The s ubj ects were four experimental ly na ive  adul t mal e  s qu i rrel 
monkeys ( Sa im ir i  sc i ureus , Santa Cru z ,  Bol i v i a ,  Primate Imports , Port 
Was h i ngto n ,  Ne�1 York ) . The animal s were ma i nta i ned at 80% of free­
feed i n g  wei g hts ( 0 . 8  to 1 . 0 kg)  throughout the  experiment by adj usted 
post-sess ion  feedi ngs . They had un 1  imi ted access to water i n  thei r home 
cages . 
Appa ratus 
The subj ects were restrai ned a bout the wa i s t  i n  a p lastic  primate 
cha i r  for the duration of the experimental sess i o n �  I n  the l ower 
center of the panel fac ing  the subj ect s eated in the cha i r  was a brass 
food trough i nto which  97 mg Noyes banana- fl avored food pel l ets cou l d  be  
del i v ered via  a Gerbrands model 0- 1 automatic  feeder . There were two . 
res ponse l evers fac i ng the subject equ i di s tant to the ri ght and l eft 
a bove the food trough.  A cl ear Pl ex i gl as d i v i der wi th two arm hol es was 
i nsta l l ed between the subj ect and the response l evers . To rea c h  a l ever  
or the food trough the  subj ect had  to  reach through the armhol e .  The 
p lacement o f  the Pl exi g l a s  d i v ider was such that the animal cou l d  press 
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only one  l ever at  a time . The purpose of th is  dev ice  was to prevent 
u nwanted res ponse topograph i es and to force the an ima l  to make a cho ice  
between the l evers . Above the  response panel were four sti mul u s  l i ghts . 
The anima l  was i nj ected whi l e  i n  the primate cha i r  and the cha i r  
i mmediately p l a ced i n  a sound and l i ght attenuating  i so l ation  cubi c l e 
for the pretreatment time and the duration of the experimental sess i o n .  
The on ly  source of l i ght was the four stimul us  l i ghts a bove the l ev ers 
wh ich  were i l l umi nated at  the i n it i ation of the sess ion  . . Sol i d  state 
programmi ng equ i pment and recording  dev i ces were l ocated in a n  adjacent 
room . 
Procedure 
The subj ects were tra i ned to respond on a fi xed-ratio 32  ( FR32 ) 
s chedu l e of food presentation .  Thi rty-min  s es s i ons  were conducted 
s even days a week .  I n i ti a l l y ,  the subj ects were tra i ned to respond on  
ei ther l ever on  a n  FR1 schedu l e .  Once l ever press i ng  was establ i shed , 
drug i nj ecti ons were begun .  E ach  an ima l  received either sa l i ne or  0 . 16 
mg/kg PCP 5 m i n  pre-sess ion  on a doubl e a l ternation  schedul e .  i . e .  two 
days of PCP i njections fol l owed by two days of sa l i n e  i njections . From 
t h i s  poi nt o n ,  respond ing  on only one l ever was rei nforced during  the  
s e s s io n .  For two an imal s ,  responses o n  t h e  l eft l ever produced re in­
forcement on  PCP  days a nd responses on the  ri ght l ever produced re i nforce­
ment o n  sa l i ne days . The l ever cond i ti ons were reversed for the other 
s u bjects . Res ponses on the i ncorrect l ever reset the FR conti ngency for 
rei nforced respond i ng on the correct l ever . Res ponse requ i rements were 
gradua l l y  i ncreased unti l a l l an imal s rel i ab ly  responded under a FR32 
schedu l e . 
When rel i abl e FR32 res pond i ng was establ i s hed , exti ncti on probes 
were i ni ti ated . Every th ird sess ion  was begun wi th a 2-mi n period 
duri ng whi ch respond i ng was not rei n forced, a fter wh i c h  the sess ion  
was  continued as u sua l  on  the  FR32 schedul e .  Di s crim i nation tra i n i n g  
was conti nued unti l the subj ect h a d  ten consecutive  exti nction probes 
wi th  80 percent or more respond i n g  on  ·the appropriate l ever .  
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Fo l l owi ng d i scrimination tra i ni ng ,  the effects of substi tuti ng  
0 . 02 ,  0 . 04 ,  0 . 08 ,  0 . 24 ,  0 . 32 and 0 .4  mg/kg doses of PCP  for the 0 . 1 6  
mg/kg tra i ni ng dose were determ i ned . Two anima l s received the doses i n  
ascend i ng order , and two an imal s recei v ed the doses i n  descend ing  order . 
The four m i ddl e doses were tested twice  i n  each anima l ; one determ i ­
nati on was preceded by a P C P  tra i ni ng day a n d  t h e  s econd determination  
was preceded by a sa l i ne tra i n i ng day. Test s es s i ons were· conducted 
on ly  i f  the animal compl eted the first fixed-ratio  on the appropriate 
l ever on  the control day precedi ng the test day . The test sess ion  
cons i sted o f  a 2 -m i n  exti nction period after which  the animal s were 
returned to thei r cages . The doubl e al ternat i on conti nued on control 
days wi th  the test s es s i ons i nterspersed such that one PCP and one  
. s a 1 i ne tra i n i ng day preceded each  succes s i v e  tes t day . 
Fo l l owing the PCP dose-response determi nati on , s timul us genera l i ­
zation  tes t i ng was conducted i n  a s im i l ar manner wi th  s ix  doses of 
ketam ine  ( 0 . 2  - 4 . 0  mg/kg ) , PHP ( 0 . 02 - 0.4  mg/kg ) , peE  ( 0 . 02 - 0 . 4  
mg/kg ) , TCP ( 0 . 02 - 0 . 4  mg/kg)  and PCM ( 0 . 2  - 4 . 0  mg/kg ) .  These doses 
were chosen to cover a rCinge from no effect to marked suppress i on of 
response rates duri ng the 2 �i n  test sess i ons . For each  an imal , two 
determ i nations were made of the four mi ddl e doses of each drug . I n  one  
a n i ma l , a s ev enth dos e  of PCE ( 0 . 48 mg/kg ) was  tested i n  order to  deter­
m ine  a dose whi ch compl etely suppressed respond i n g .  
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The order in  whi ch the di fferent drugs were given to each a nimal 
was randomi zed . Al l doses of a given drug . were adm in i stered to a g iven  
s ubj ect before testi ng  the next drug . For PCE and ketami ne , two an imal s 
recei ved each drug i n  ascend i ng dose order , and two an ima l s  received 
each drug i n  a descendi n g  dose order . Onl y three subj ects were tested 
wi th TCP,  PHP a nd PCM. For PCM and TCP , two an imal s recei ved the drugs 
i n  a d escend i ng dose order and one a nimal received the drug i n  an  ascen d i ng  
dose order . For PHP,  two anima l s  received the drug i n  an ascendi ng  dos e  
o rder , a nd one animal received the drug i n  a descend i ng  dose order . 
Fo l l owi ng general i zation  testi ng wi th the structural ana l ogues o f  
PCP ,  s ti mu 10s  general i zation test ing  wa s conducted i n  these four subjects 
pl us  two add it ional monkeys ,tra i ned a s  descri bed ear1 i er , i n  a s im i l a r  
manner with three doses o f  morph i ne ( 0 . 64 - 2 . 56 mg/kg ) ,  ketocycl azoc i n e  
( 0 . 01 - 0 . 04 mg/kg ) a nd mescal i ne ( 3 . 0  - 30 . 0  mg/kg ) .  The order i n  
wh i c h  these three drugs were g iven to each an ima l  was randomized .  Al l 
doses of a given drug were admin i s tered to a g iven subject before 
tes ti ng the next drug . Al l an imal s recei ved the drugs i n  ascendi ng  dos e  
orde r .  Each  dose was tested twi ce  i n  each subject .  
Drugs 
PCP was suppl i ed by B io  Ceutic  Laborator ies ( Sernyl a n ) . Ketami ne 
HC1 was suppl i ed by Parke- Dav i s  a nd Co . ( Keta 1 a r ) . PCE , TCP , PHP  and 
PCM were suppl i ed by the National  I nst itute on Drug Abu s e .  T h e  mes­
cal i ne was suppl i ed by Mann Research Laboratori es . For these drugs , 
doses refer .to the hydrochl oride sal ts . Morphi n e  sul fate was s uppl i ed 
by the Nati ona l I nsti tute on Drug Abuse .  The  drugs were d i l uted with  o r  
d i ssol ved i n  steri l e  sal i ne t o  a concentration that resul ted i n  a n  
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.i nj ection  vol ume of 0 . 2  ml /kg . Ketocycl a zoc ine  sul fonate , a generous 
g i ft of Dr . J . H .  Woods from the Uni vers i ty of Mi c h i gan , was d i s so l ved i n  
2 - 3  drops o f  l actic aci d .  The pH o f  the sol ution  was then adjusted to 
7 . 4  w ith  2-3 drops of NaOH . The so l ution  was then d i l uted with steri l e  
s a l i ne to a concentration that resul ted { n  a n  i nj ection vol ume o f  0 . 2  
m l / kg .  Al l i nj ecti ons were given i .m .  5 mi n pre-ses s i o n .  For al l drugs 
except ketocyc lazoc i ne ,  vehi cl e i nj ections were 0 . 2  ml /kg . of 0 . 9  percent 
sa l i ne .  For ketocycl a zoc: i n e ,  veh i cl e i njectio ns were 0 . 2  ml / kg o f  
s a l i ne mi xed with the amount o f  l acti c ac id  and NaOH necessary to keep 
the h i ghest dose o f  ketocyc l a zoc i ne in sol uti on . Al l doses refer to the 
sa I ts .  
Data Ana lys i s  
T h e  overal l response rates for tota l responses on both l evers as  
wel l a s  the proporti on of responses on the  PCP-appropriate l ever were 
ca lcu l ated from responding  on test days . For each dru g ,  a sal i ne test 
s e s s i on conducted at the end of the drug dose-response determi nation  was 
u s ed to cal cul ate vehicl e response rates and percent PCP-l ever respond i ng 
a fter vehi cl e adm i n i strat ion for that dru g .  Percent drug-l ever res­
pond i ng was determi ned by d i v i d i ng the number of PCP-l ever appropri ate 
responses made duri ng the test peri od by the total  number of responses 
made dur ing that time a nd mul ti plyi ng  by 1 00 .  The effective dose 50 
percent ( E D50 ) for each anal ogue was determi ned by l east squares l i n ear  
regres s i on a nalys i s  u s i ng the  l i near portion  o f  the  dose-response data 
for percent drug-l ever respond i ng and the descend i n g  l imb of the dose­
response data for percent of veh i ci e response rates , For the doses 
wh i c h  were tes ted twi c e ,  the average of the two val ues was used i n  the 
ca l cu l at ion  of the E D50 . . 
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One samp l e  i-tests (a � 0 . 05 )  were carr ied out compari ng the perc ent 
o f  bas el i ne response rate fol l owing  the admi n i stration of the t hree 
l owest doses o f  each anal ogue tested wi th a hypothes i zed mean of 1 00 
percent o f  basel i ne .  Compari sons were made for each drug i nd i v i dua l l y  
a t  a l l  three doses i n  al l animal s as  wel l  as test i ng the effect o f  t h e  
l owes t  doses o f  a l l  drugs i n  a l l a nimal s grouped together . A two sam p l e 
pa i red i-test (a � 0 . 05 )  was carri ed out comparing  the percent drug­
l ever a ppropri ate respond i ng fol l owing  a sal i ne tra i ni n g  day to the 
p ercent drug-l ever a ppropri ate res pondi ng fol l owi ng  a PCP tra i n i n g  day' 
for t he  doses of each drug whi ch were tested twi ce i n  each an imal . 
C .  Resul ts 
The number of s ess i ons to reach the cri teria for beg i nn i ng the PCP  
dose-response curve ranged from 38  to  60  (x  = 47 . 3  ± 2 . 33)  i n  d i fferent  
s u bj ects . The  tra i n i ng dos e  o f  PCP ( 0 . 1 6 mg/kg )  produced approximate ly  
85  percent drug-l ever a ppropriate respond i ng ( Fi gure 9 ,  u pper l eft 
panel ) .  Hi g her doses of PCP produced an even hi gher percentage o f  drug­
l ev er a ppropriate choices .  At  the 0 . 08 mg/kg dose  of PCP , the a n ima l s  
made a pproxima tely 7 8  percent drug-l ever appropri ate cho i ces wi thout 
a ny s i gn if icant decrease  in response rate . Al l five anal ogues produ ced  
a dose- rel a ted i ncrease  , i n  the percent o f  responses made  on the  PCP­
a p propriate l ever ( F i gure g ) . At some doses , each of the analogues pro - , 
duced s t imul us control of respond i ng oomparabl e to or greater than t h a t  
o f  the  P CP tra i n i ng dose .  For a l l  s i x  compounds , the s l opes o f  the 
l i nes for percent drug-l ever appropriate res pond ing  were s im i l a r  ( Tab l e 
3 ) .  For those drug doses that were tested twi ce , there was no s ig n i f i ­
cant d i fference ( p  � . 05 )  between t h e  percent drug-l ever appro priate  
F IGURE 9 
Group dose-response curves for PCP and fi ve  anal ogues for sup­
pres s i on of operant respond ing  and for percent drug-l ever a ppropriate 
respond i ng .  T he  percent o f  veh ic l e response rate ± S . E . M .  averaged 
across a nimal s (da shed l i nes ) and the percent drug l ever res pond i ng ± 
S . E . M .  averaged across a ni mal s (sol i d  l i nes ) are on the ordi nate wi th 
the corres pond i ng drug dose on the abc i ssa . Veh ic l e rates were averaged 
for the 2-mi n test session with sal i ne pretreatment a t  the end of each 
drug dose-response determination for al l anima l s  tested wi th  that day . 
The number o f  animal s tested wi th each drug i s  i nd i cated i n  each panel . 
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I TABLE 3 
POTENCY OF PCP AND FIVE ANALOGUES FOR STIMULUS GENERALI ZATION AND SUPPRESSION OF 
OVERALL RESPONSE RATE I N  SQU IRREL MONKEYS 
[050* Rat io  ED50*** Ratio  
Drug-Lever to Res ponse Rate to 
ED50s for Response 
Rate Su ppress lon / 
Drug Res20nd l ng PCP · S1 02e** SU22ression PCP S1 ope** Drug-Lever Respond ing 
PCP . 05 78 . 4  . 1 7  1 . 0  -1 1 5  3 . 4  
( . 04- . 07 )  ( . 1 3 - . 2 5 )  
rcp . 03 0 . 61 80 . 4  . 24 1 . 4 -280 7 . 7 
( . 02 - . 05 )  ( . 1 6- . 36 )  
PHP . 06 1 . 2 59 . 7  . 28 1 . 6 -254 3 . 7 
( . 05- . 08 )  ( . 24- . 34 )  
PCE . 07 1 . 4 73  . 33 1 . 9 -222 4 . 6  
( . 05- . 1  ) ( . 28 - . 4  ) 
PC�1 . 35 6 .8 5 5 . 1 · 2 . 3 1 3 . 3 - 1 47 6 . 6  
( . 24- . 5 )  ( 1 . 7 -3 . 4 )  
KET . 58 1 1  . 3  90 . 2  2 . 3  1 3  . 2  -246 3 . 9  
( . 4 - . 7 6 )  ( 1  . 9-2 . 7 )  
* Dose (mg/kg o f  base )  resul t i ng i n  50% drug-l ever appropr iate respond i ng as  determi ned by l i near regression and 
95% confidence l imits i n  parenthes i s .  
. 
** I n  l og dose (�g/ kg ) - percent effect u n i ts . 
***Dose (mg/kg of ba se)  resu l t i ng I n  a 50% decrease I n  response rates as determined by l i near regression a nd 
95% confidence l im its I n  parenthes i s .  
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respond i ng for the test days fol l owing  sal i ne tra i ni ng days and the test 
days fol l owi ng PCP tra i ni ng days . 
Overa l l response rates for each animal  remai ned fa irly s tabl e 
throughout the experiment . Average val ues ± S . E . M .  i n  responses per 
sec for the response rates on vehi cl e test days for each anima l  wer e : 
. 64 ± . 03 ,  1 . 9 ± . 22 ,  1 . 87 ± . 1 3  and 2 . 1  ± . 31 . The effect o f  PCP and 
the ana l ogues o n  overa l l response rate was o ften bi pha s i c .  Mean response 
rate i ncreases over vehi cl e control rates ,were frequently s een wi th  l ow 
doses o f  each drug ( Fi gure 9 ) . I-tests mak ing  i nd iv idual compar i sons  
between the percent o f  v ehi cl e respond ing  produced by the three l owes t 
doses o f  each compound a nd a nul l hypothes i s  mean of 1 00 percent fa i l ed 
to i nd i cate that these response rate i ncreases were s i gn ificant  (p � 
0 . 05 ) .  I-tests comparing  the percent of vehi c l e  responding  for the 
l owes t doses o f  a l l  drugs tested grouped together to the 1 00 percent 
n u l l hypothes i s  a l so  showed no s i gn i ficant d i fference ( p  � 0' . 05 ) . 
H i gher doses o f  a l l  s i x  compounds produced, a dose-dependent d ecr eas e  i n  
response rate . At , the h i g her drug doses some anima l s  d id  not respond a t  
a l l .  Test days for which  the an ima l s  response rates were l es s  than 
0 . 05 response per sec were not i ncl uded in the percent drug-l ever 
appropri ate respondi ng tabul ati o n .  Tabl e 3 shows the ED50 va l ues for 
s u ppress i on of operant respond ing  and for percent drug-l ever respond i ng 
for each o f  the six compounds tested . The rel ative  potency for produc i ng 
drug-l ever a ppropriate respond i ng wa s :  TCP > PCP > PHP > PCE > PCM 
> ketam i n e .  The rel ative potency for suppres s i on of operant respond i n g  
was : PCP > TCP ' >  PHP > P C E  > PCM = ketami ne . I n  a l l  cases , the dose 
necessary to s uppress operant respondi ng to 50 percent o f  veh i cl e  rates 
was 3 to 8 times l arger than ED50 dose for drug-l ever appropri ate respond i n g .  
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For a l l  six anal ogues , s im i l ar observ'ab1 e effects after adm i n i ­
s tration of h igh  doses · were noted when the an ima l s  were removed from t h e  
experimental chamber a t  t h e  end of t h e  test sess i o n .  These i ncl ude 
exces s i v e  sa l i vat ion ,  nystagmus and ataxi a .  
Fi gure 1 0 ,  shows the dose-response determinati ons for morph i ne , 
ketocyc 1 a zoci ne and mescal i ne for percent PCP-appropri ate respond i n g  and 
for  percent of control response rates . None of these drugs produced 
dose-dependent drug-l ev er appropri ate respond i n g .  Each drug was tested 
up to doses which  produced marked suppression  of response rates . 
D .  D iscussion  
The res u l ts of thi s experiment i nd i cate that  a l l five anal ogues . 
tested have d i scrimi native .st imu1 us  propert i es s imi l ar to those o f  PCP . 
Al l f ive  anal ogues produced PCP-appropri ate respond ing  i n  a dos e-dependent 
fa s h i o n .  At  l ea st  one  dose and usual l y  two or th�ee doses o f  each o f  
t h e s e  drugs produced stimul us  control of respond i n g  comparabl e t o  t h e  
P C P  tra i ni ng dose .  Furthermore,  for a 1 1  s i x  compounds , the hi  ghes t 
. doses g i ven produced st imul us  control of respondi ng greater than PCP 
tra i ni ng dose .  
T h e  data for t h e  general i zation  test ing  wi th morph i n e ,  ketocyc 1 a ­
zoc i ne a nd mesca l i ne emphas i ze the spec i f.i c i ty o f  the phencycl i di ne . 
d i scrimi native cue and val i date the procedure used i n  thi s experiment . 
Ketocyc l a zoc i ne i s  a benzomorphan opio i d  and mescal i ne i s  a hal l uc i ­
nogen . Li ke resu l ts reported by Shannon (,1 979 )  and Pol i ng et �. 
( 1 979 ) , . our data i ndi cate that the ary1 cyc 1 oa 1 ky1 ami nes may represent a 
u n i que  cl ass of psychoactive drugs . 
Al l of the ana l ogues tested had compara bl e effects on rate of respo nd i ng . 
For each compound , there was a rel atively l ow dose wh ich  produced a 
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F IGURE 1 0  
Group dose-res ponse curves for morph i n e ,  ketocycl azoc i ne a nd 
mesca l i ne for . suppres s i on of operant respond i ng for percent drug-l ever 
a ppropri ate respond i ng in the squi rrel monkey .  The percent o f  veh ic l e 
response rate ± S . E . M .  averaged for 6 an imal s (dashed l i ne s )  and the 
percent drug-l ever a ppropriate res·ponding  ± S. E . r-1 . averaged for 6 
an ima l s  ( sol i d  l i nes ) are  on the ordi nate wi th  the correspondi ng drug 
dose bn the a bsci ssa . Two determi nati ons were made for the effects each 
dose of each drug . Vehi cl e rates were cal cul ated over the 2-mi n test 
sess ion  wi th vehi cl e pretreatment at  the end of each drug dose-response 
d etermi nati on .  
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cons i stent but stati s tical l y  i ns i gn i fi cant i ncrease i n  overal l response 
rates . These fi ndi ngs are cons i s tent wi th other reports of i ncreases 
i n  l ow rates o f  schedul e-control l ed respond i ng wi th  l ow doses of PCP i n  
s q u i rrel monkeys (Cha i t  and Ba l ster , 1 977 , 1 978 ,  1 979 ) . For the mos t  
part , these response rate i nc reas i ng doses produced l ess than 50 percent  
drug- l ever ·a p propri ate res pond ing . I t  i s  pos s i bl e  that thi s i s  due  to 
some behav ioral acti v i ty of these compounds at doses even l ower than  
those p roducing  the d i scrimi nati ve  stimu l u s . I t  a l so poss i bl e  that 
u s i ng a l ower tra i n i ng dose of PCP; genera l i zation  wou l d  be  seen a t  
t h e s e  res ponse rate i ncreas i ng  doses . Hi gher doses of al l compounds 
s uppressed operant res pond ing  in a dose-dependent fash ion . The s l opes 
for . the descendi ng l imb of the dose-response curves were simi l a r  for a l l 
s i x  drugs . 
For a l l  o f  the PCP anal ogues , the ED50 val ue  for response rat e  
s uppression  was 3 to 8 t imes l a rg er than the , ED50  val ue  for drug-l ever 
a ppropri .ate res pondi n g .  Doses coul d b e  found for al l compounds whi c h  
produced 70  t �  1 00 percent drug-l �ver appropri ate respondi ng wi thout 
d e.crea s i ng res ponse rates to bel ow sal i ne control l evel s .  Thi s  i n­
di cates that the drug d i scrimination parad i gm i s  a very sens i t i v e  method 
to assay the behav ioral acti v i ty . of  PCP-l i ke compounds . 
The gross observabl e effects of h i g h  doses of a l l  s i x  drugs were 
al so s im i l a r . · Excess i ve  sal i vati o n ,  nystagmus and an i nabi l i ty to 
ma inta i n  bal a nce on  a perch when returned to the home cage were the 
most notabl e features . Bal ster and Cha i t  ( 1 976 , 1 978)  have reported 
compara bl e effects in primates a fter PCP a dm i n i stra t i o n .  
O u r  data s upport mos t  of t h e  previous  work i n  both i n  v i vo and  
� v itro systems i n  s howi ng pharmaco log ica l  s i m i 1 ari.t i. es between the  
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five anal ogues tested here and PCP .  I n  agreement wi th  Experiment I 
( Brady et �. , 1 980 ) , we found that these ana l ogues had si m i l ar o b­
s ervabl e effects on primates , as wel l as s im i l ar effects on schedu l e­
control l ed performa nce . The pres ent study al so su pports the prev ious  
drug  d i scrimination work done  wi th PCP  in  a drug  vs . sal i ne  ta s k .  I n  
a dd i t ion , PCP ,  P C E  and TCE have been shown i n  s everal stu d i es ( Kl oog e t  
�. , 1 97 7 ;  Maayan i  e t  �. , 1 974 , 1 973 ; Pa ster e t  �. , 1 974 ; P i nchas i  e t  
�. , 1 978a , 1 978b ,  1 977 ; Wei nstei n � �: ,  1 973 ) t o  have bo t h  ant icho l i -
nergic and anticho l i nesterase activ ity u s i ng receptor bi nd i n g  and bioassay 
procedures . 
One i nterest ing descrepancy between our fi nd i ngs  and those reported 
i n  the  l i terature l i es  with  the study by Gehrmann and Ki l l am ( 1 97 9 ) 
where they report a qual i tat ive  d i fferences between the EEG c hanges· 
produced by PHP a nd those produced by the rest of the anal ogues which  
they tested . Neither our study nor any in  the 1 i terature i nd i cates  that  
the  spectra of action of PHP d i ffers from that of PCP i n  a vari ety o f  
pharmacol ogical a ssays . 
There i s  some d i sagreement i n  the l i terature concern ing the  potency 
of the anal ogues rel at ive  to PCP .  Most stud ies  f ind  PCM and ketamine to 
be a pprox imatel y 1 15 to 1 /1 0  as potent as PCP .  There a l so seems to be 
g en eral agreement that PCP ,  PHP and TC P are roughl y equ i potent . Howeyer , 
confl ict ing  resu l ts have been o bta i ned concer n i ng the potency o f  PCE  
rel at ive  to  PCP . Several i nvesti gators u s i ng motor effects of m ice  
(Bal s ter , 1 98 0 ;  Ka l i r et �. , 1 978 ; P incha s i  et �. , 1 978a ) have  reported 
that PCE is 2 to 3 times more potent than PCP .  Jarbe et �. ( 1 97S ) 
reported that PCE was somewhat more potent than PCP a nd Shannon 0 97 9 } 
found PCE to be nearl y 6 times more· potent than PCP i n  the d i scriminat i v e  
-80-
s ti mulus  paradigm u s i ng rats . On the other hand , i n  the pres ent stu dy 
PCE  a nd PCP were found to be roughly equi potent i n  producing  drug-l ever  
appropri ate respond i ng ,  and in  Experiment I u s i ng rhesus monkeys ( Brady 
� �. ,  1 980)  PCE was s l i ghtly l ess  potent than PCP in suppress i ng 
response rates mai nta i ned u nder a fixed- i nterval schedu l e .  Chen ( 1 96 5 )  
found PCE and PCP to b e  equ i potent i n  produc ing  cat�p�y i n  pi geons . 
Thus , PCE a ppears i n  general to be more potent tha n PCP i n  r�derfts- ,� 
i s  ei ther equi potent or somewhat l ess potent than PCP i n  monkeys and  
pi g eons . Wh i l e  the reason for these  d i s crepanc i es i s  not cl ear , 
i t  coul d refl ect a d i fference , i n  the biodi s pos i tion  of PCE i n  rodents 
Kal i r  et �. ( 1 978 ) found that a hi gher percentage, of the i nj ected 
amount o f  drug was found i n  the bra i ns o f ' mi ce a fter peE admi n i stra t i o n  
t h a n  a fter P C P  adm i n i stration . S im i l a r  stud i es have not yet been done 
wi th primates . 
----�----
One l a s t  poi nt concerns the use  of pr imates i n  drug d i scriminati o n  
procedures . There have been rel atively few reports us ing  squi rrel 
monkeys i n  drug d i s crimi nation stu d i es ( Hol tzman et �. , 1 976 ; Wool verton 
and Tro s t ,  1 978 ; Teal and Hol tzma n ,  1 980b ) . Wool verton and Trost  ( 1 978 ) 
fou nd that s qu i rrel monkeys coul d d i scrimi nate doses of coca i ne l aO-fo l d 
l ess  than those used i n  many rat d i scrimi nation stud i es wi th coca i ne .  
The tra i ni ng dose o f  PCP used i n  thi s study was 2 0  times l ess  than that 
u s ed in  our rat studi es and those reported by others ( Jarbe et �. , 
1 975 ;  Overto n ,  1 97 5 ;  Shannon , 1 979 ) �  Th i s  sens i t iv ity coupl ed with the 
d i fferences in  the behavi oral acti v ity of the di ssociative  a nesthet ics  
between primates and  rodents makes i t  espec i a l l y  important to  a ssay the  
acti v i ty of PCP  and  i ts , a nal ogues i n  primates . 
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I n  concl u s i o n ,  PCP was found to produce stimu l us control  over 
respond i ng i n  squi rrel monkeys in a dose-dependent manner . The drug 
d i scri m i nation paradi gm prov i des a very sens i ti v e . measure of PCP ' s  
behav i oral acti v i ty i n  s o  far a s  drug-l ever appropriate res pond i ng was 
mai ntai ned a t  doses whi ch  produced no observabl e effects . The  f ive  
s tructural anal ogues of PCP  whi c h  were tested a l l  produced dose-depen­
dent PCP-a ppropriate respondi ng and were s im i l ar to PCP in thei r obser­
vabl e effects as  wel l a s  thei r effects on overal l  response rates . 
Severa l psychoacti ve compounds from d i fferent pharmacolog ica l  c l asses 
d i d  not produce PCP-appropriate respond ing . 
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I V .  COMPARI SON O F  THE DISCRIMI NATIVE STIMULUS PROPERTIES O F  PHENCYCL I D I N E  
DEXOXADROL AND ETOXADROL (EXPERIMENT I I I )  
A .  I ntroduct ion  
I n  spi te of structural d i s s imi l ar it ies , ev i dence i ndi cates that  
etoxadrol and dexoxadrol ( Fi gure l l ) ,  both 2- ( 2 , 2-subst i tuted 1 , 3 d i oxo l an-
4-yl } p i peri d i nes , s hare many pharmaco l og i ca l  properti es wi th phen­
cycl i d i ne ( PCP ) and ketam ine .  With i ncreas i ng doses , the sequence of 
observabl e effects i n  l a boratory animal s is s im i l ar for. a l l  fou r  compounds 
( Chen , 1 973) . Genera l l y ,  there is a progress ion  from hyperact i v i ty to 
atax i a ,  catal epsy , general anesthes i a  and convul s i ons . The promi nence 
of these s tages var i es greatly among d i fferent speci es . For exampl e ,  
hyperact i v i ty after l ow doses i s  q u i te promi nent i n  rodents , but on ly  
occa s i onal l y  reported i n  non-human primates and  man ( Chen et �. , 1 95 9 ;  
H i l dago et �. , 1 971 ; Bal ster and Cha i t  1 97 6 ,  1 978 ) . 
As was the case wi th PCP a nd ketam i n e ,  etoxadrol has been i nv es ­
ti gated for u s e  as  an  anesthet i c .  Ini t i al stud i es wi th s everal l a bora­
tory s pec i es i nd i cate str i ki ng s i m i l arities  i n  the effects of ketami ne 
and  etoxadro l  on the cardiovascul ar  and respi ratory systems ( H i l dago et 
�. , 1 971 ; Traber et �. , 1 970 ;  Kel l y  et �. , 1 971 ) and i n  the el ectro­
phys i ol og ica l  effects o f  these two drugs ( Tang and Schroeder , 1 97 3 ;  
Ju l i en a n d  Kaven , 1 975 ) .  Cl i n i ca l  tri a l s  i nd i cated that humans anes­
thes i zed w i th etoxadrol ma i nta i n  pharyngea l , l a ryngeal and l id refl exes . 
Tachyeard i a  and tachypnea as wel l as nystagmus and emergence del i r i um 
have been obs erved (Wi l son et �. , 1 97 0 ,  1 973 ; Frederi ckson et �. , 
1 976 ) . As a consequence of these fi ndi ngs , etoxadrol has been c l a s s l ­
fi ed a l ong wi th P C P  a n d  ketami ne as  a d i ssoc iat ive  a n esthet i c .  
Mos t  o f  the early i nvesti gati ons o f  dexoxadrol focused on  i ts 
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FIGURE · 1 1  
Chemical  structures of PCP ,  dexoxadrol and etoxadrol . 
PCP 
1- (  I - phenylcyc lohexyl ) 
piperidine 
DEXOXADROL 
0- 2-( 2 ,2- diphenyl-I ,3 d ioxolo n-4-yi l 
. p iperidine 
ETOXADROL 




ana l g es i c  propert i es . , H i l dago and Thompson ( 1 963 ) reported that dexoxa­
drol  produced hypera l ges ia  and antagoni zed morphi ne-i nduced anti no­
c i ception on  the hot pl ate in mice . Col l i ns and �leeks ( 1 967 ) found 
that constant i nfus ion  of dexoxadrol in se l f-ma i ntai ned morph i ne-dependent 
rats did not decrease the rate of  morphi ne se l f-admi n i s tration as  mos t 
d ependence-produci ng  op iates do . On the bas i s  of thi s find i ng ,  they 
concl uded that dexoxadrol wou l d  probably not have op io id- l i ke add ict ion  
l i a bi l i ty i n  man . Cl i n ical  studies  ( S imopou l os et  !l.. , 1 970 ;  Lasagna 
a nd Pearso n ,  1 965 ;  Wi l l i ams et �. , 1 969) have shown dexoxadrol to be a n  
a na l ges i c  o f  effi cacy s im i l ar to asp ir in  i n  man with  psychotomimet i c  
properti es a t  h i g her doses . 
The di scrimi nati ve  st imu l us properti es o f  PCP seem to be rel at i ve ly  
s pec i f i c  i n  that on ly  s tructural a nal ogues of P CP  and  several psycho­
tomimetic  op io id  der ivati ves N-a l l yl normetazoc i n e  � cycl azoci ne and 
dextrorphan genera l i ze to PCP in rodents (Shannon , 1 979 ;  Hol tzman , 
1 980) , p i georis ( Herl i ng � �. ,  1 980)  and squi rrel monkeys ( Experiment 
I I ,  Bra dy and Bal s ter ,  1 981 ) tra i ned to d i scriminate PCP from s a l i n e .  
T h  i s s tudy was des i gned t o  determi n e  i f  dexoxadro 1 and etoxadro 1 wou l  d 
genera l i ze to PCP i n  squ irrel monkeys trai ned to di scrimi nate PCP from 
s a l i ne . , 
B .  Methods 
Subj ects 
The s ubj ects were three adul t mal e squi rrel monkeys (Sa imiri  
sc i ureus , Santa Cruz ,  Bol v i a , Primate Imports , Port Wash i ngton , New ' 
York )  which  had previous ly  been used i n  the study o f  the  di scrim i ­
nati v e  st imu lus  properti es of  structural ana l o gues o f  PCP ( Experiment 
I I ,  Brady and Ba l ster ,  1 981 ) .  The an imal s were 'ma i nta i ned at  80% o f  
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the i r  free-feeding  wei ghts ( 0 . 8  to 1 . 0  kg ) throughout the experiment by 
adjusted post-sess ion  feed i ngs . '  They had unl im ited access to water i n  
thei r home cages where they were i nd i v i dual ly housed i n  standard primate 
cagi ng . 
Apparatus 
The apparatus u s ed in thi s  study i s  i dentical to the one descri bed 
i n  Experiment I I .  
Procedure 
The procedure for tra i n ing  the subj ects to di scrimi nate PCP from 
sa l i ne has been descri bed i n  Exper iment I I . The subjects had been , 
trai ned to respond on a fixed-rat io  32 ( FR32 ) schedul e of food pre­
s entati o n .  Thi rty -mi n  sess ions were conducted s even days a wee k .  Each 
a n imal' recei ved an  i nj ection o f  ei ther phys io l ogical  sal i ne or 0 . 1 6  
mg/kg PCP on  a doubl e al ternation schedu l e ,  i . e .  two days o f  PCP i njecti o n  
fol l owed by two days of  sa l i ne i njections , etc . The an imal was i nj ected 
whi l e  i n  the primate cha i r ,  20  min pre-s es s i on . The cha i r  was immed i ­
ately pl aced i n  a sound a n d  l i ght attenuating  i sol ation cubi cl e ( Cou l bourn 
Model E1 0-20)  for the pretreatment time and the duration  of the exper i ­
mental s e s s i o n .  T h e  o n l y  source of l i ght i n  t h e  cubicl e was t h e  fou r  
s t i mu l us  l i ghts above t h e  l evers wh ich  were i l l um i nated at the  i n i t i a ­
t ion  o f  t h e  sess i on .  For two animal s ,  t he  l eft l ever was rei nforced o n  
P C P  tra i n i ng days a n d  t h e  ri ght l ever was rei nforced on  sal i ne tra i ni ng 
days . The l ever cond i ti ons were reversed for the other subj ect . 
Responses on the i ncorrect 1 ever reset the FR conti ngency for rei n-
forced respond ing  on  the correct l ever . 
I n i ti a l l y ,  every third sess ion  began wi th  a 2 -m i n  per iod  during  
whi c h  responding  was not  rei nforced , after whi ch the  an imal  was cont i nued 
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as usua l  on the FR32 schedu l e  for the rem ai n i ng 28 mi n .  Tes t s ess ions  
were not i n i ti ated u nt i l  an  an imal had  performed 85 percent or more 
responses on  the a ppropri ate l ever during  four consecutive ext i nction  
probes . The  effects o f  s u bst ituting  various  doses o f  PCP , etoxadrol and 
dexoxadrol for the 0 . 1 6  mg/kg dose of PCP were determi ned on  test days . 
Tes t s es s i ons were conducted every thi rd day i f  the animal compl eted the 
f i rs t  fixed-ratio  on  the a ppropriate l ever on the tra i n i ng day preced i ng 
the test day . Tes t session cons i s ted of a 2 -m i n  exti nction per i od a fter 
wh i c h  the an imal s were returned to the ir  ho�e cages . The doubl e a l ter­
nation  conti nued on  tra i ni ng days w i th the test sess ions i nt erspersed 
such that a PCP a nd a sal i ne tra i n ing  day preceded each succes s i ve test 
day. 
The three drugs were tested in a di fferent order in each  s u bj ect . 
For each  drug , two anima l s  received the doses i n  ascend ing  orde r ,  a nd 
one  a n i mal received the doses i n  descend i ng order . Tests were conducted 
w ith  s even doses of PCP ( 0 . 02 - 0 . 4  mg/kg ) ,  and ei ght doses of dexoxa­
drol ( 0 . 06 - 1 . 92 mg/kg) a nd etoxadrol ( 0 . 04 - 0 . 8  mg/kg ) . The fou r  
m i ddl e doses of each compound were tested twi ce  i n  each an imal ; o n e  
d eterm i nation  was preceded by a PCP tra i ni ng day a n d  t h e  second deter­
mi nati on was preceded by a sal i ne tra i n i ng day . 
Data Ana lys i s  
Overa l l  res ponse rates on  both l evers and proportion  o f  responses  
o f  the drug-appropri ate l ever were a nalyzed for test days . A vehi cl e 
test sess ion  conducted at the end of each i nd i v idual drug dose-response  
determ i nation  was used to  ca l cul ate veh i cl e response rates a nd percent 
drug-l ever responding  a fter vehi cl e admi n i stration  for that dru g . 
Drug-l ever respond ing  was determined by d i v i d i ng the number of drug-l ever 
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appropri ate responses made during the test period by the total number o f  
responses made during  that time.  Effects of test drug doses o n  overa l l  
response rates o n  both l evers were ca l cul ated a s  the percent o f  the 
response rate on  the vehi cl e test days conducted for each drug . The 
effective  dose 50  percent ( EDSO ) for each drug was determi ned by l ea s t  
squares l i near regress ion  analys i s  us i ng t h e  dose-response data for 
p ercent drug-l ever respond ing  and for percent of vehi cl e response rates 
for the  1 i near port ions o f  the dose-response curves . For the doses wh i c h  
were tested twic e ,  the average of the two val ues was used i n  t h e  cal cu ­
l a ti on of the EDSO . 
One sampl e i-tests (a � 0 . 05 )  were carri ed out compari ng the over-
al l res ponse rates fol l owing  the adm i n i s tration of the rate- i ncrea s i n g  
doses o f  PCP a nd dexoxadrol wi th a hypothes i zed mean of 1 00 percent o f  
basel i ne .  A two sampl e pai red i-test ( a  � 0 . 05 )  was carri ed out comparing  
the  percent drug-l ever a ppropriate respondi n g  fol l owi n g  a sal i n e  tra i ni n g  
day to the  percent drug-l ever a ppropriate respondi ng  fol l owi ng  PCP 
tra i n i ng day for the doses of each drug whi c h  were tested twice  i n  each 
a n imal . 
C .  Resul  ts 
Fi gure 1 2  s hows the dose-response rel at ions h i p  for mean percent 
vehi cl e response rate and mean percent drug-l ever responding for PCP , 
dexoxadrol a nd etoxadrol . The tra i n i n g  dose o f  PCP ( 0 . 1 6  mg/kg )  
produced 92  percent drug- l ever a ppropriate res pondi n g  o n  test  sess ion s . 
Hi g her doses o f  PCP produced a n  even hi gher percentage o f  drug-l ever 
appropri ate choi ces . At the  0 . 08 mg/kg dose o f  PCP , the  an ima l s made 
approximatel y 82 percent drug-l ever appropriate choi ces without any 
decreas e  in response rate . Both  dexoxadrol and etoxadrol produced a 
dose-related i ncrease i n  the percent of responses made on the  PCP-
· -89-
FI GURE 1 2  
Group dose-response curves for PCP,  dexoxadrol and. etoxadrol for 
s u ppress ion of operant respondi ng for percent drug-l ever appropriate 
respond ing  i n  the squi rrel monkey . The percent of vehicl e response rate 
± S . E . M .  average for 3 an imal s (das hed l i nes ) and the percent drug- l ever 
a ppropri a te respondi ng ± S . E .M .  averaged for 3 animal s ( sol id  · l i nes ) are 
on . the  ordi nate wi th the correspondi ng drug dose on the a bs c i s s a . Two 
determi nations were made for the effects of the middl e 4 doses of each 
dru g .  · Veh i cl e rates were ca l cu l a ted over the 2 mi n test se ss i on wi th  
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a ppropriate l ever . At l east  three doses of both compounds produced 
s timul us  control of respond ing  comparabl e to or greater than that of the  
PCP  tra i n i ng dose .  For a l l  three compounds the  s l opes of the  l i nes for 
percent drug-l ever appropriate respond i ng  were s i m i l ar  ( Ta bl e 4 ) .  
Res ponse  rates for the � hour s ession  for each animal  rema i ned 
fa i rly ' s ta bl e throughout the experiment . Average val ues ± S . E . M .  i n  
responses per s econd for the response rates o n  the 4 vehi cl e tes t days 
for each animal  were : 2 . 4  ± 0 . 3 2 ,  1 . 83 ± 0 . 20 and 1 . 21  ± 0 . 25 .  The 
effect of PCP and dexoxadrol on  overal l response rate was often bi pha­
s i c .  Res ponse rate i ncreases were frequently s een wi th a t  l east one  l ow 
dose o f  both drugs , however , these were not stati sti cal ly s i gni ficant 
(p � 0 . 05 ) . Hi g her doses o f  a l l three compounds produced a dose-dependent 
decreas e  i n  operant respond i ng .  Test days for wh ich  the animal s respo n s e  
rates were l ess  than 0 . 05 response per sec were not i ncl uded i n  the 
percent drug-l ever a ppropri ate responding tabu l ation . For a 1 1  three 
compounds , the s l opes o f  the descending  l imb of the l i ne for percent of 
vehi cl e respond i ng were s imi l ar ( Tabl e 4 ) . 
Ta bl e 4 s hows the E050  val ues for suppress i on of operant respon d i n g  
a nd for percent drug-l ever respondi ng for each o f  t h e  three compounds 
tes ted . For both s uppress i on o f  overal l response rate and for produci ng 
drug-l ever a ppropriate respond i ng ,  PCp was 4to ! t imes more potent than 
dexoxadrol and 2 to 3 times more potent than etoxadrol '. For a l l  three 
compounds , the dose necessary to suppress operant respond ing  to 50 
percent o f  vehi cl e rates was 4 to 7 ti mes l arger than the E050 dose for 
drug-l ever a ppropri ate respond i n g .  
S imi l a r  gross behavioral effects were noted a fter adm in i stration o f  
h i g h  doses of al l three compounds . These i nc l uded excess ive  sal i vat ion , 









POTENCY. OF PCP ,  ETOXADROL AND DEXOXADROL FOR STIMULUS GENERAL IZATION AND SUPPRESSION OF 
OVERALL RESPONSE RATES IN  SQUIRREL MONKEYS 
ED50* Rat io  ED50*** Ratio ED50s for Res ponse 
Drug-Lever to Res ponse Rate to Rate Su ppress ion/  
ResEond i ng PCP SloEe** SUEEression PCP Sl oEe** Drug-Lever Respond i ng 
. 04 1 . 0  67 . 9  . 23 1 . 0  -1 21 5 . 3 
( 0 . 3- . 07 )  ( . 1 9- . 39)  
. 1 2  2 .8 8 5 . 8  .46  2 . 0  -1 58 3 . B 
( . 1 0- . 1 5 ) ( . 32- . 81 ) 
. 1 9 4 . 3  63 . 2  1 . 23 5 .3 -96 6 . 5  
( . 1 3 - . 26 )  ( . 96-3 . 4 )  
*Dose  (mg/ kg o f  ba se)  resul t i ng i n  50% drug-l ever appropri ate respond i ng as determined by l i near regress ion and 
95% confi dence l im its i n  parenthes i s .  
**In l og dose (�g/kg ) - percent effect u n i ts .  
***Do s e  (mg/kg of ba se)  resul t i ng i n  a 50% decrea se i n  response rates a s  determi ned by l i near regression and 
95% confidence l im i ts i n  parenthes i s .  
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cons i s tently wi th etoxadrol and dexoxadrol than wi th PCP . 
D .  D iscussion  
Etoxadrol and dexoxadrol have PCP-l i ke d i scrimi native stimul u s  
properti es and a l l  three s uppress operant respond i ng i n  a dose-dependent 
manner . I n  a l l  cases , the EDSO dose for suppress ion  of operant res pond i ng 
wa s 4 to 7 t imes l arger than the ED50 dose for PCP-a ppropriate respond i n g .  
Th i s  "i s  consi stent wi th Experiment I I  (Brady and Ba l ster , 1 981 ) i n  
fi nding  that i n  PCp-tra i ned squ i rrel monkeys , a ser ies of structural 
anal ogues of PCP p roduced PCP-appropriate respond ing  in doses 3 to 8 
t imes l ess than the doses neces sary to s uppress operant respond i ng . I n  
addi tion  to suggesti ng a s i m i l ar  profi l e  of behav ioral  activ i ty ,  thi s  i s  
a l so  a n  i ndi cation that the d rug-di scrimination parad i gm i s  a very 
sens i t i v e  method for measur ing  the central nervous system activ i ty o f  
a l l o f  these compounds . 
There have been a number of early reports (lu k i n  and luki n ,  1 979 ; 
Vi ncent � �. ,  1 979 ;  Hampton et �. , 1 980)  of a s pec i fi c  bi nd i ng s i te 
for PCP i n  the rodent nervous system , suggest ing  the poss i bi l i ty of a 
receptor medi ati ng the effects of PCP.  Th� bi ndi ng  of the psychotomimet i c 
op io ids  and dexoxadrol to these s i ies is of consi derabl e i nterest 
( lu k i n  a nd lu k i n ,  1 979 ;  Hampton et �, 1 980 ) . The demonstration  that 
etoxadro l and dexoxadrol poss ess di scriminative stimu l us properties  
s im i l a r  to  PCP p rovides a rationa l e  for the  use  of these drugs  whi ch are  
chem i ca l l y  u nrel ated to PCP  to  characteri ze a putat ive  PCP  recepto r .  
I n  concl us ion , the resul ts o f  this experiment support the l i tera­
ture i n  fi ndi ng many s i m i l arities  i n  the pharmacol og ical  properti es o f  
PCP,  dexoxadrol a nd etoxadrol ( Chen , 1 973 ) . Both etoxa drol and dexoxa-
drol g eneral i ze to PCP i n  the drug di scrimination task and al l three 
compounds have s im i l a r  effects on grossly obs ervabl e beha v i or .  Further  
expl orati on of the  l i nk  between these  compounds wi l l  hel p to el u c i date  
the nature of the  overl ap  between the  d i ssociative  anes theti cs and the  
psychotomimetic  op io ids . 
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V .  D ISCRIMINATIVE  STIMULUS PROPERT I ES OF STEREOISOMERS OF N-ALLYL­
NORMETAZOCINE  IN PHENCYCL ID I NE-TRAINED  SQUIRREL MONKEYS .AND RATS 
AND THE EFFECTS OF NALOXONE ( EXPERIMENT I V )  
A .  I ntroduction 
-95-
On the bas i s  of the s pectra of effects produced by vari ous  o p i o i ds 
i n  the chronic  s p i na l  dog , Marti n et �. ( 1 976 )  have postu l a ted three 
d i s ti nc t  op iate receptors : the mu receptor wi th morphi ne as the proto­
typ i c  a goni s t ,  the � receptor wi th ketocycl azoc i ne  as  the prototypi c 
a gon i s t ,  a nd the s igma receptor wi th N-a l l yl normetazoc ine  ( SKF 1 0 , 047 ; 
Fi gure 1 3 ) as the prototypic  a gon i st .  N-a l l yl normetazoci ne i s  an  o p i o id  
derivative  o f  the  benzomorphan s eries whi ch produces ha l l u c i nat i ons . i n  
man ( Keats a nd Tel ford , 1 964) . 
I n  a recent s tudy expl oring  the d i scriminative· st imul u s  properti es 
of phencycl i di ne ,  Shannon ( 1 97 9)  found that N-al ly l normetazoc i n e  produced · 
PCP-appropriate respond i ng i n  rats tra i ned to d i s crimi nate PCP from 
s al i ne i n  a two-l ever drug d i scrimi nation tas k .  The rats were a l so  
tested for genera l i zation to  a s eries  of . structural ana l ogues o f  PCP  as  
wel l a s  a vari ety of other psychoacti ve subs ta nces · i nc 1 udi ng  ketocyc­
l azoc i ne ,  LSD;  THC a nd morphi ne .  Only N-a l ly 1 normetazocine  and the 
s tructural a na l ogues of PCP general i zed to PCP .  The s peci fi c i ty of the 
PCP cue was a l so demonstrated by Pol i ng et �. ( 1 97 9 ) . I n  PCP tra i ned 
rats tested for g enera l i zation to ketamine  and to a ser ies of c l ass ica l  
a gon i s ts a nd a ntagonists o f  various neurotransmi tter systems , on ly  
ketami ne produced drug-l ever a ppropriate respondi ng . I n  Experiment I I  
we found  that only  PCP anal ogues and not morphi n e ,  mesca l i ne or keto­
cycl azoc i ne genera l i ze to PCP . Thus , the fi nding  of genera l i zation  
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FIGURE 1 3  
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s uggests s im i l arities  between the effects of PCP and s igma agon i sts . 
I t  has al so been demonstrated that rats and pi geons gen�ral i ze 
between cycl azoci ne , another op io id  derivative  of the benzomorphan 
s e r i es and PCP,  ketam i ne and dextrorphan , the (+) i somer of l evorphanol  
( Tea l and Hol tzman , 1 980a ; Herl i n g  � �. ,  1 980 ; Hol tzman , 1 980 ) . I n  
Marti n ' s  (Ma rti n et �. , 1 976 )  cl ass i fication o f  opioid  receptors , 
cycl azoci ne a l so i s  consi dered to have a hi gh  affi n i ty for the s igma 
recepto r .  
I n  t h e  i ntroduction ,  t h e  unusual separation of activ i ty between the  
opti cal  i somers of benzomorphans was descri bed . I n  working with  a 
racem i c  mi xture i n  the benzomorphan series i t  i s  probabl e that one i s  
worki ng  wi th a mixture o f  two active compounds wh i c h  each have thei r own 
d i s ti nct spectra of pharmacol ogical  activ i ties . Stud i es wi th the 
s tereoi somers of N-al l yl normetazoc ine  ( Swa i n  et �. , 1 973 ) reveal ed that  
the ( - )  i s omer i s  a nal orphi ne- l i ke antagoni s t  wh i c h  wi l l  preci p i ta te 
wi thdra�/al i n  the morphi ne-dependent rhesus monkey , whereas the (+)  
i somer i s  a non-narcotic  CNS  depressant whi ch produces .icarked atax i a  i n  
rhesus monkeys , effects we now know to be S i mi l ar to those produced by 
PCP .  I n  al l o f  the other stud i es descri bed so far with  N-al l yl norm eta­
zoc i ne ,  the racemic  mi xture was used . 
Ma rti n et �. (1 976)  reported that the effects of a l l  three pro­
to type a go n i s ts 'cou l d  be antagoni zed by nal trexone , but there were 
marked d ifferences i n  sens i t i v i ty to antagon i sm . Ketocycl azoc i ne antagoni sm 
requ i red 1 0  times more nal trexone than morphi n e  antagon ism and even 
hi gher dose of nal trexone were requ i red to antagon ize  the effects of ' 
N-a l ly l normetazoci ne .  Iwamoto ( 1 979 )  reported that the  effects of N-al l yl ­
normetazoc i ne  on l ocomotor act i v i ty i n  mice  were antagoni zed by l arge  
doses o f  na l oxone ( > 20 mg/kg) whereas only 0 . 1  mg/kg na l o xone a nta­
goni zed the effects of morph i n e .  
Other i nvesti gations have i ndicated that t h e  effects of N-a1 1y 1 -
normetazoci ne cannot be bl ocked by narcoti c antagon i s ts .  Cowan et 
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El. ( 1 979) found t hat low doses of nal oxone ( 0 . 01 to 1 0 . 0  mg/kg ) coul d 
a ttenuate the · anti convu 1 sant effects of three mu receptor agoni s ts i n  
m i c e ,  whi l e  the anticonvu l sant act iv ity o f  N-a 1 1 yl normetazoc i ne was not 
a ntagoni zed by moderate to l arge doses of na l oxone . I n  a s tudy o f  the 
effects o f . narcoti cs on  schedu1 e-control l ed performance in rats , Harri s 
( 1 980)  found that nal trexone markedl y antagon i zed the rate-decreas i ng 
effects o f  morph i ne but had no effect on the rate-decreas i ng  effects of 
N-a l 1 ynormetazoc i n e .  Teal and Hol tzman ( 1 980c ) found that na1 trexone d id  
not compl etely block  the  cycl azoc i ne- l i ke stimu l u s  effects of N-a1 1 y1 -
normetazocine i n  rats tra i ned to d i scriminate cycl azoci ne from sa l i ne .  
The present study was desi gned to explore the d i scrimi native  st imu ­
l us properti es o f  N-al 1y1 normetazoc i ne ,  both t h e  racem i c  m i xture and the 
pure stereoi somers , i n  rats and squi rrel monkeys tra i ned to d i scr im inate  
PCP from sa l i ne .  Rats were studied i n  add it ion  t o  monkeys becau s e  
o f  the extens i ve u s e  o f  rat central nervous system t i ssues for receptor 
bi nd i ng studies of opio ids . The effect of nal oxone pretreatment on the 
d i scrimi native  stimu l u s  and response-rate d i srupti ng  a cti v i ty o f  the 
stereoisomers was ·a 1 so exami ned . 
B .  Methods 
S ubj ects 
For the squi rrel monkey study ,  the subj ects were s i x  adul t ma l e  
squi rrel monkeys ( Sa i m i ri sci ureu s , Santa Cru z ,  �ol i v i a , Primate Imports , 
Port Was h i ngto n ,  New York) which had prev ious ly  been u sed i n  a s tudy. of 
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the d i scrim i nati ve  s timu l u s  propert i es of structural anal ogues of PCP 
( Exper iment I I ;  Brady and Ba l s ter , 1 981 ) or dexoxadrol , etoxadrol a nd 
PCP ( Experiment I I I ;  Brady a nd Bal ster , 1 980b) . Th� animal s were ma i n­
ta i ned a t  constant wei ghts ( 0 . 8  to 1 . 0 kg ) throughout the experiment by 
adjusted pos t-sess i on feed i ngs . They were i nd i v idua l ly housed i n  stan-
' dard pr imate cagi ng where they had unl im i ted access to water . 
For the rat study , the subj ects were ten experimenta l ly  na ive  ma l e  
Sprague-Dawl ey rats ( Fl ow Laboratories , Dubl i n ,  VA) . The an imal s were 
mai nta i ned at 80% of their free- feed i ngs wei ghts ( 280-340 grams ) throughout 
the experiment by adj usted post-session  feed ings . They were i nd i v i -
dual ly housed i n  wi re mesh cages where they had u n l  im i ted access to 
water . 
Apparatus 
For the squi rrel monkey study ,  the apparatus is the same as  des­
cri bed in  the methods section of Experiment I I . 
For the rat study ,  a standard two-l ever operant rat chamber ( Model 
E1 0- 1 0 ,  Coul bourn I nstruments , I nc . ,  L!!h igh  Val l ey ,  Pennsyl van i a )  
housed i ns i de a l i ght and sound attenuating  cubi c l e  (Model E1 0-20 , 
Coul bourn I nstruments , I nc . )  was used .  The l evers were 10  cm from the 
fl oor o f  the  chamber a nd 13 cm from each other . A fOQd cup i nto wh i c h  
4 5  mg  Noyes food pel l ets ( Formul a  A)  cou l d  b e  del ivered v i a  a Gerbrands 
model 01 a utomat ic  feeder was i n  the center of the wal l  equ id i s tant from 
and 2 cm bel ow the two response l evers . A hous e  l i ght was l ocated 20 cm 
d i rectly a bove the food cup .  Sol i d  state programming  equ i pment and 
record i ng devi ces were l ocated in an  adjacent room . 
Procedure 
The procedure for tra i n i n g  the squi rrel monkeys to 'di scrimi nate PCP 
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from s a l i ne has been descri bed i n  more deta i l  i n  the methods s ecti on , o f  
Experiment I I .  The subjects were tra i ned t o  respond on a fi xed-rat io  3 2  
( FR 32 ) s chedul e of food presentation . Thirty-m i n  sessi ons were conducted 
s even days a week . Each anima l  recei ved an  i nj ection of ei ther phys io­
l og ica l  sal i ne or 0 . 1 6  mg/kg PCP on a doubl e a l terna tion schedu l e ,  i . e .  
two days o f  PCP i nj ecti ons fol l owed by two days o f  sal i ne i nj ections , 
etc . The animal was i nj ected whi l e  i n  the primate chai r ,  5 m i n  pre­
ses s ion .  The cha i r  was immedi ately pl aced in the cubi cl e .  The on ly  
source  of l i ght was the four stimu l u s  l i ghts a bove the  l evers wh i ch were  
i l l umi nated a t  the i ni tiation  of the ses s i o n .  For three anima l s ,  t h e  
1 eft 1 ever was r e i  nforced on PCP  days a n d  t h e  ri  g h t  1 ever �Ias r e i  nforced 
o n  sa l i ne days . The 1 ever ' cond i ti ons were reversed for the other three 
s u bj ects . Responses on the i ncorrect l ever reset the FR conti ngency for 
rei nforced respond i ng the 'correct 1 ever . 
The effects o f  s u bsti tuti ng various doses of PCP , ( ± } - N-al l y1 -
normetazoc i n e ,  ( +} -N-a l lyl normetazocine  a nd ( - ) -N-a l l y1 normetazoc i ne  for 
the 0 . 1 6  mg/kg dose of PCP were determi ned on test days . Tes t  s es s i ons 
were conducted every th ird day if the anima l  compl eted the fi rst FR on  
the  a ppropr iate l ever on the control day preced i ng the  test day . Tes t 
sess i ons cons i sted of a 2-min exti nction peri od a fter wh i ch the an ima l s  
,were returned to thei r home cages . The doubl e a l ternation ' continued o n  
control days wi th the test sess ions i nterspersed such that a PCP and a 
s a l i ne tra i n i ng day preceded each success i ve  test day . 
For each drug three an imal s recei ved doses i n  ascend ing  order a nd 
three anima l s  recei ved the doses ' i n  descending  order . The PCP dose­
response determi nation was conducted first in a l l subjects . The other 
drugs were a dm i n i stered in random order . Tests were conducted wi th fi v e  
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doses  of PCP  ( 0 . 04-0 . 64 mg/kg ) ,  ( ± ) -N-al ly1 normetazoci ne ( 0 . 04- . 64 
mg/kg ) ,  and ( - ) -N-a1 1 y1 normetazoc i ne ( 0 . 02- . 32 mg/kg ) ,  and seven doses 
of ( + ) - N-a1 1y1 normetazoc i ne ( 0 . 04-2 . 56 mg/kg ) .  The doses were chosen to 
cover a range from no effect to nearly compl ete suppress ion  of "response 
rates duri ng the 2-min test sessi ons . The thre� m iddl e doses of eac h  
compou nd were tested twi ce i n  each an imal ; o n e  determi nation was pre­
ceded by a PCP tra i ni ng day and the second determi nation  was preceded by 
a s a l i ne tra i n i ng day . 
Fo l l owi ng the dose- response determination for al l four compounds , 
t he  effect of nal oxone on the response rate d i srupti ng and d i scrim i ­
native  s timul us  properti es of (+) a n d  ( - ) -N-a 1 1 y1 normetazo c i ne was 
d etermi ned i n  �ach a n imal . Test sessi ons were conducted i n  the manner 
descri bed above wi th two doses of nal oxone ( 1 . 0  and 3 . 0  mg/kg ) ,  0 . 64 
mg/kg ( + )- N-a1 1y1 normetazoci ne a l one and i n  combi nat ion wi th 1 . 0 and 3 . 0  
mg/kg naloxone ,  and 0 . 32 mg/kg ( - ) N-a1 1y1 normetazoc i ne al one and i n  
comb i nation  with 1 . 0  and 3 . 0  mg/kg na l oxone .  Al l i nj ections were g i ven 
i ;m .  5 min pre-ses s i o n .  
For t h e  r a t  s tudy ,  t h e  subj ects were shaped t o  respond on  a fi xed­
ratio  32  ( FR32 ) schedu l e  of food presentat ion . Th i rty-m i n  s ess i ons were 
conducted s even days a wee k .  I n i tia l ly ,  the s u bjects were tra i ned to 
res pond on ei ther l ever on a FR 1 s chedul e .  Once l ever pres s i n g  on  
both  l evers was  establ i s hed ( two to  ten  ses s i ons ) drug i nj ections were 
beg u n .  Each  an imal  recei ved ei ther sal i ne or 3 . 0  mg/kg P C P  1 0  m in  pre­
sess ion  on a doubl e "al ternation  schedu l e .  From th i s  poi nt o n , respond i ng  
on  on ly  one  l ever was rei nforced during t he  s es s i o n .  The a n imal was 
pl aced i n  the chamber immed iately after the i nj ecti on and the  house 
l i ght was i l l umi nated a t  the s tart of the s es s i o n .  For fi v e  an imal s ,  
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responses on the l eft l ever resul ted i n  re i n forcement on PCP days and  
responses on the r i ght l ever resul ted i n  rei n forcement on sal i n e  days . 
The l ever cond iti ons were reversed fo r the other five subjects . Res­
ponses on  the i ncorrect l ever reset the FR cont i ngency for rei nforced 
r es pond i ng on the correct 1 ev·er .  Res ponse requ i rements were gradua 1 1  y 
i ncreased unti l a l l an imal s rel i ably responded under a FR 32 schedu l e  
( 28 to 58 sess i ons ) .  
When rel i abl e FR 32 respond i ng wa s establ i s h ed ,  test probes were 
i n i t i ated.  Every thi rd s ess ion  began wi th a 2 -m i n  period during wh i c h  
respondi ng on  ei ther l ever was rei nforced , a fter wh ich  the ses s i on was 
conti nued as usual  on the FR 32 schedu l e .  Di scrimination tra i n i ng was 
conti nued u nti l the s u bject had four  consecutive  test periods wi th  85  
percent or more respond i ng on the  appropri ate l ever .  
Fo l l owing  d i scrimi nation  tra i n i n g ,  the  effects of subst i tuti ng  0 . 3 ,  
1 . 0 a nd 1 0 . 0  mg/kg doses o f  PCP for the 3 . 0  mg/kg tra i ni ng dos e  were 
determi ned . Five  anima l s  received the dos es i n  ascending order and f ive  
a n ima l s  recei ved the  doses i n  descend ing  order .  Al l drug doses were 
tes ted twi ce in each an imal ; one determination  was preceded by a PCP 
tra i n i ng day. and the s econd determi nation was preceded by a sal i ne 
tra i ni ng day .  Tes t sessi ons were conducted only i f  the animal compl eted  
the fi rst FR  on  the  a ppropriate l ever on the control day precedi ng the . 
test day . Test s es s i ons cons i sted of a 2 -mi n period duri ng  whi ch res­
pond i ng on  ei ther l ever was rei n forced , after whi ch the animal s were 
returned to thei r cages . The doubl e a l ternation conti nued on control 
days with  the test sessi ons i nterspersed such that one PCP and one 
s al i ne tra i ni ng day preceded each s uccess i ve  test day . 
Fo l l owing  the PCP dose- response determ i nati on , stimu l us general i za t i on 
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testi ng was conduc'ted i n  a s im i l ar manner with five doses o f  (± ) - N­
a l lyl normetazoci ne ( 0 . 3- 30 . 0  mg/kg ) , ( + ) -N-al lyl normetazoc i ne ( .0 . 3-30 . 0  
mg/kg)  a nd ( - I N-a l l yl normetazoci ne ( 0 . 3-30 . 0  mg/kg ) .  These doses were 
chosen to cover a range from no effect to nearly compl ete s uppression  o f  
response rates during  the 2-m i n  test sess i o n .  Eac h  dose was tested 
twi ce  in each an imal ; one determi nation was preceded by a PCP  tra i n i ng 
day a nd the s econd determi nation was preceded by a sal i ne  tra i n i n g  day . 
The order i n  whi ch  the di fferent drugs were given to ' each a n imal  
was  random i zed . Al l doses  of a g iven drug were admi nistered to a g iv en 
s u bj ect  before testi ng the next dru g .  Fi ve  an imal s rece i v ed each drug 
in  ascendi ng dose order and five anima l s  recei v ed each drug in  descen­
di ng  dose order . 
Fo l l owi ng the dose-response determination  for a l l  fou r  compounds , 
t he  effect of nal oxone on the response rate disrupting  and d i scr i m i ­
n a t i v e  stimul us  propert i es of ( + ) . a n d  ( - ) -N-a1 1y1 normetazoci ne was 
determi ned i n  each animal . Test sessions  were conducted i n  the manner 
descri bed a bove wi th 30 . 0 mg/kg nal oxone , 1 0 . 0  mg/kg {+ ) -N-a l l yl nor..: 
meta zoci ne a l one and in combi nation wi th 30 . 0  mg/kg nal oxone 1 0 . 0  mg/kg 
{ - ) - N-a1 1y1 normetazocine  a l one and in combi nation wi th 30 mg/kg nal oxone • . 
Nal oxone wa s admi n i stered subcutaneously 20 m i n  pre-sess i on ; N-al l yl nor­
metazoci ne was admini stered i . p .  1 0  mi n pre-ses s i o n .  
Da ta Ana lys i s  
Both overal l response rates o n  both l evers and proportion  of res­
ponses on  the drug-appropr iate l ever were analyzed for test days . A 
s a l i ne test s es s i on conducted a t  the end of each i nd i v i du a l  drug .dose� 
response determi nation was u sed to cal cul ate vehi cl e response rate a nd 
percent drug-l ever respond ing  after vehi cl e admin i stration  for that 
dru g . Drug- l ever respond i ng was determi ned by d i v i d i ng t he  number o f  
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drug-l ever appropriate responses made during  the peri od by the tota l 
number o f  responses made duri ng that t ime .  Effects of tes t drug doses  
on overa l l  response rates on both l evers were cal cu l ated as the percent 
of the response rate on  the vehi c l e  test days conducted for each dru g .  
For the doses that were tested twi c e ,  the average o f  the two val ues was 
used  i n  the EDSO determ i nat i o n .  The effect ive  dose 50 percent ( ED50 ) 
for each drug was determi ned by l east squares l i near regress i on 'analys i s  
u s i ng the dose-response data for percent drug-l ever respond i ng and for 
percent of veh i c l e response rates for the l i near porti ons of the dose� 
response curves . These cal cul ations ,/ere made a fter a l og 1 0  transformation 
o f  the  dose expressed as  �g/ kg o f  the bas e .  A two sampl e pai red l-test 
(a � 0 . 05 )  was  carr i ed out compar ing the percent drug�l ever appropriate  
res pond i ng fol l owi ng a sal i ne tra i n ing  day to  the percent drug-l ever 
a ppropri ate respond i ng fol l owi ng a PCP tra i n i ng day for eac h  drug dos e  
t h a t  was tested twi c e .  A two sampl e pa ired l-test was carri ed out  
compar ing  the  percent drug-l ever a ppropriate respondi ng  and  percent 
vehi cl e response rate fol l owi ng the admi n i s tration  o f  the N-al l yl ­
normetazoci ne i s omers al one to the percent vehi c l e  response rate fol l owi ng  
the  adm i n i stration  o f  N-al lyl normetazoc i ne i n  combi nat ion with  nal oxone . 
Drugs 
The pure stereoi somers o f  a-N-al l yl normetazoci ne as wel l 'a s  the 
racem i c  mi xture were synthes i zed by Dr . E . L .  May for this s tudy . 
The racemic  mi xture wa s i n  the form of the hydrochl o ri de sa l t .  The 
stereo i somers were i n  the form of the hydrobromi de sal ts .  The 
compos it i on of al l three was confi rmed by C ,  H,  N a na l  ys is and  hi  gh­
reso l ution  mass s pectrometry . Pur i ty was assured by thi n-l ayer 
chromatography on s i l i ca -gel . 
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PCP was obta i ned from B io  Ceut ic  La borator ies ( Sernyl a n )  in  a 
s teri l e  s tock sol ution o f  1 00 mg/ml . Na 1 oxone HCl �/a s su pp 1 i ed by Endo 
Labora tori es . Al l drugs were d i l uted wi th or d i sso l ved i n . s teri l e  
sa l i ne to a concentration  that res u l ted i n  a n  i nj ection  vol ume o f  0 . 2  
ml /kg  for the squi rrel monkeys a nd 1 . 0 ml / kg for the rats . Al l squi rrel 
monkey i nj ections were i . m . ; rat i njections were i . p .  except for the 
na l oxone i nj ections , which were s . c .  Veh ic l e i nj ecti ons were 0 . 2  ml / kg 
(mon keys ) or 1 . 0 ml /kg ( rats ) of 0 . 9  percent sal i n e .  For PCP a n d  na loxone , 
doses refer to the hydrochl oride  s a l t .  For t h e  N-a l l yl normetazoc i ne  
compounds , doses were adm in i stered ba sed on t he  above descri bed hydro­
c h l o ride  or hydro bromide  hemi hydrates sal ts ; however potency estimates 
for a l l  compounds were cal cu l ated on the bas e .  
C .  Resul ts 
Squ i rrel Monkey Study 
The tra i n i ng dos e  of PCP ( 0 . 1 6  mg/kg ) produced a pproximately 90 
percent drug-l ever a ppropri ate respond ing  (F igure  1 4 ,  upper l eft panel ) .  
A hi gher tes t dos e  of  PCP ( 0 . 32 mg/kg ) produced an even hi gher p ercentag e  
o f  drug-l ever appropri ate choi ces whereas 0 . 64 mg/kg a lmost compl etely 
e l imi nated res ponding  on ei ther l ever .  Both ( t ) -N-al lyl normetazoc i ne  
a nd ( + ) - N-al lyl normetazocine  produced a dose-rel a ted i ncrease i n  the 
p ercent of  res ponses made on  the PCP-appropri ate l ever  (Figure  1 4 ) .  At 
some d os e ,  both compounds produced s timul us  control of respond i ng com­
para b l e  to or greater than that of the PCP tra i n i ng dos e .  For these 
three compounds , the s l opes o f  .the l i nes for percent drug-l ever a ppro­
pri ate res pond i ng were s im i l ar (Ta bl e 5 1 . Unl i ke the  racem ic  m i xture 
and the (+ ) i somer of N-a l l yl normetazoc ine  the ( - J  i somer did not 
resul t i n  over 40 percent PCP-appropriate respond i ng at any of  t he  
-1 07-
FIGURE 1 4  
Grou p  dose-response curves for PCP ; (± ) -N-a l l ynormetazoci ne , ( + ) ­
N-a  l lyl normetazoci ne and (� ) -N-a l lyl normetazoc i  ne for t he  s uppress ion  o f  
operant respondi ng a n d  for percent drug-l ever a ppropriate respond i ng i n  
the squi rrel - monkey . The mean percent drug-l ever a ppropriate respond i n g  
± S . E . M .  averaged across animal s ( dashed l i nes ) a nd t h e  mean percent 
control response rate ± S . E . M .  a veraged across an imal s ( so l i d  l i ne s ) a re 
on the ordi nate with  the corresponding  drug dos e  on the absci ssa . 
Veh ic l e rates were ca l cu l ated over the 2-mi n tes t s es s ion  wi th  vehi cl e 
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POTENCY OF PCP AND N-ALLYLNORMETAZOCINE FOR STIMULUS GENERAL IZATION AND SUPPRESSION OF 
OVERALL RESPONSE RATES IN SQUIRREL MONKEYS 
ED50* Rat i o  ED50*** Ratio  ED50s for Response 
Drug-Lever to Response Rate to Rate Su ppress ion 
Drug Res Eond i ng PCP Sl oEe** SUEEression PCP Sl oEe** Drug-Lever Respond i ng 
PCP . 07 1 . 0  83 . 1 9  1 . 0  -1 05 2 . 9  
( . 01 - . 09) ( . 1 5- . 28 )  
( ± ) -N -Al l y1 - . 1 4  2 . 1  80  .23  1 . 2 -1 01 1 . 7 
normetazoc ine ( . 1 2 - . 1 7 )  ( . 97 - . 36 )  
( + ) -N-Al l y1 - . 1 9  .2 . 9 1 06 1 . 1 5 . 7 -1 43 5 . 7 
normeta zoc i n e ( . 1 6- . 25 )  ( . 97 -1 . 3 )  
( - ) -N -Al l y1 - . 07 . 34 -86 
( . 04 - . 1  ) 
*Dose (mg/kg of ba s e )  - resul t ing  i n  50% drug-l ever appropriate respond i ng as determi ned by l i near regression and 95% confidence l imits  i n  parenthes i s .  
** In  l og dose (�g/kg ) - percent effect u nits . 
***Dos e  (mg/kg of ba se )  resul t i ng i n  a 50 decrea se i n  response rates as determi ned by 1 i near regression and 
95% confidence l imtis  in parenthes i s .  
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doses  tested ( Fi gure 1 4., 1 0�ler r i ght panel ) .  For the drug doses  tha t 
were tested twice , there was no s i gn i ficant d i fference ( p  � . O S )  between 
the perc ent drug-l ever appropriate respond i ng for test days fol l owi ng  
sal i ne tra i n i ng days and test days fol l owing  PCP tra i n i ng days for 
PCP ,  racemic  and ( + ) -N-Al l yl normetazoc i ne .  
Overal l response rates for each  an imal rema i n ed fa irly  stabl e 
throug hout the experiment . Averag e  va lues  ± S . E . M .  for response  rates 
o n  the four vehicl es test days for each  a nimal wer e :  1 . 8 ± . 1 6 ,  1 . 03 ± 
. 2 S ,  1 . 2 ± . 2 5 ,  . 93 ± . 07 ,  2 . 2 S  ± . 2 2 , 1 . 2 ± . 24 responses per sec . Al l 
fou r  compounds produced a dose-dependent decrea s e  i n  response rates . At 
the h i gher drug doses , some a nima l s  did not respond at a l l . Test days 
for wh ich  the an imal s '  response rates were l es s  than 0 . 05 respons e  
per s ec for t h e  2 -m i n  ext i nction period were n o t  i ncl uded i n  t h e  percent 
drug-l ever a ppropr iate respond i n g  tabu l ation . The sl o pes of the l i nes · 
for response rate su ppress ion  are s i m i l a r  for al l four compounds ( Ta bl e 5 ) . 
A dose of 0 . 1 6  mg/kg PCP a nd 0 . 64 mg/kg ( + ) -N-al l yl normetazoc i ne 
resul ted i n  greater than 90 percent PCP-l ever a pprorpriate responses 
with only m i n imal effects on re�ponse rates ; whereas· for (± J -N-al l yl ­
normetazoc i n e ,  a h i g h  · percentage of PCP l ever responses  onl y occurred at 
0 . 32 mg /kg or greater ; doses wh i c h  decreas ed response rates over 50 
percent . For ( - ) -N -a l l yl normetazoc i n e ,  doses of 0 . 08 mg/kg or greater 
decrea s ed response rates dur i ng the test sess ions  with  no evidence o f  
genera l i zation t o  t h e  PC P cue .  
Ta bl e 5 s hol1s the  EDSO va l  ues  for percent drug-l ever  responding and 
for suppress ion  of o perant respond i ng for al l four compounds , PCP 11as 
a pprox imatel y 3 t imes more potent than the ( + )  i somer and twice a s  
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potent a s  the racemic  m ixture of N-al lyl normetazoci n e  i n  producing  drug­
l ever a ppropriate respond i n g .  r:n so far as  the (+)  i somer i s  not more 
potent tha n  the racemic  mi xture i n  produci ng PCP-a ppropriate respond i ng  
and  the  ( - )  i somer does not  produce PCP-appropri a te r espondi ng , the data 
are i nconsi stent with  the i dea of an add i ti v e' effect of the i s omers i n  
the  racemi c mixture for the production o f  the phencycl i d i ne c u e .  The 
rel at i v e  potency for s u ppres s i on of operant res pond i n g  was : , ( - )  i somer 
> PCP > racemic  mixture > (+) i s omer . For response rate suppres s i o n ,  
t h e  rel ative  potenc i es o f  t h e  optical i somers of N-al l yl normetazoc i n e  
compared t o  the racem ic  mixture a r e  cons i s tent wi th a n  add i t i v e  effect 
of the i somers . For PCP a nd ( + ) -N-al lyl normetazoci n e ,  the dose  neces­
sary to , s uppress operant respond i ng to 50 percent o f  vehi c l e  rates was 
3 to 6 ti mes l a rger than  the E050 dose for drug-l ever a ppropriate  res­
pond i ng . I n  the case of ( ± ) -N-al lyl normetazoc ine ,  the E050 dose for 
s u p press ion  of operant respond i ng was only 1 . 7 times l arger than the  
E050 dose for drug-l ever a ppropri a te respond i n g .  
Al though n o  systemati c measure of observabl e effects was made , 
s i mi l ar observabl e effects a fter admi n i stration of h i g h  doses o f  al l 
four compounds were noted . Thes e i ncl uded exces s i ve sal ivat ion , nys­
tagmus and a taxia .  
The effects o f  1 . 0 and 3 . 0  mg/kg nal oxone a l one and i n  combi nati on  
wi th  0 . 64 mg/kg ( + )-N-al lyl normetazoci ne on drug-l ever appropri ate 
respond i ng and overa l l  rate of res pond ing  are presented in Fi gure 1 5 .  
The doses o f  nal oxone tested d i d  not produce over 1 0  percent PCP-appro­
pri a te respond i ng a nd d i d  not antagoni ze the PCP-appropriate respond i n g  
produced by 0 . 64 mg/kg ( +) -N-a l l yl normetazoc ine .  Dcses:of 1 . 0 mg/kg a n d  
3 . 0 ,mg/kg nal oxone s uppressed overa l l  response rates t o  approximately 7 5  
and 55  p ercent o f  control l evel respectivel y .  There was n o  s i g ni fi ca n t  
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FIGURE 1 5  
Group  dose-response data for percent dru g - l ever appropriate res­
pond i n g  and percent control response rate for nal oxone and ( + ) - N-a l l yl ­
normetazoc i ne a l one and i n  combi nation i n  squi rrel monkeys . The percent 
of vehi c l e  response rate ± S . E . M .  (open bars ) averaged for 6 subjects 
and �he percent drug-l ever a ppropriate respond i ng ± S . E . M .  ( s haded bars ) 
a veraged for 6 subjects are on the ordi nate wi th the correspond i ng 
dose on the a bsci ssa . 
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d i fferenc e ( p  � 0 . C5 ) t h e  �ercent o f  control responding  after ei ther dose 
of nal oxone when g iven a l one and the percent of ba sel ine  respond i ng for 
the nal oxone - ( + ) - N-a1 1 y1 normetazoc i ne comb ination . Fi gure 1 6  s hows the 
effects of 1 . 0 and 3 . 0  mg/kg nal oxone al one and in combination  with  0 . 32  
mg/kg  ( - ) -N-a 1 1ynormetazoc i ne on  drug-l ever a ppropr i ate res pond i ng and  
overa l l rate o f  respond i ng . The  data for nal oxone al one a r e  the same as  those 
presented iri Figure 1 5 . Th i s  dose of ( - ) -N-a 1 1 y1 normeta zocine  suppres s ed 
overa l l  res ponse rates to approximatel y 5 percent of control and d i d  not 
p roduce  over 5 percent drug-l ever a ppropr i ate respond i ng .  The ( - ) -N­
a l 1 y1 normetazocine  combi nation with  both  doses  of na l oxone s ti l l  produced 
l ess  t ha n  1 5  percent drug-l ev er a ppropr iate respond i ng .  Whi l e  ne ither 
dos e  o f· nal oxone reversed the response-ra te di sruption produced by 0 . 3 2  
mg/kg ( - ) -N-a1 1y1 normeta zoci ne ,  the effect of the ·combi nat i o n  of t h e  two 
drugs  on overa l l  response rates i n  both cases is l ess than one  m ight  
expec·t by adding  the effect of eac h  drug  g iven al one . However , there i s  
no s i gni ficant d i fference ( p  � 0 . 05 )  between the effect o f  0 . 32 mg/kg ( - ) ­
N-al l y1 normeta zoci ne a l one  a nd i n  combination  wi th ei ther dose o f  nal o -
xone on  percent. o f  control res ponse rate . 
Ra t Study 
The average sess ions to cri teria ( ±  S . E:M . )  for acqu i s it ion  o f  t he  
PCP c u e  was 49 . 2  ± 1 0 . 7 .  Fi gure 1 7  s hows percent o f  correct choi ces on  
sa l i ne a nd PCP test  probes whi c h  started as  soon  as · the s u bj ects were 
respond i ng consi stentl y on  a FR32 schedul e .  By the tenth test  probe 
(5  sa l i ne ,  5 PCP) the average percent o f  correct responses was  appro x i ­
mately 70  percent for eac h  l ever .  By t h e  twel fth test probe (36  sess ions ) ,  
one  a nimal had reached cri teri a .  After 28 test probes (84 sess ions ) a l l 
s u bj ects has reached the cr i ter ia  for acqu i s i t ion of the PCP  d i scrimi na­
tion cue . PCP dose-response determ i nations were started i n  eac h  s u bj ec t  
FI GURE 1 6  
Group dos e-response data for percent drug-l ever appropriate 
respond i ng and percent control res pons e rate for na l oxone and ( - ) -N­
a l lyl normetazoci ne a l one and in combi nation in squi rrel monkeys . The 
percent of vehicl e response rate ± S . E .M .  ( open bars ) averaged for 6 
s u bj ects a nd the percent drug-l ever appropr i ate respond ing  ± S . E . M .  
( s haded bars ) averaged for . 6 subjects are o n  the ordi nate wi th the 
corres pond i ng drug dose on  the a bsc i s sa .  
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FI GURE 1 7  
Group  dose-response data for acqu i s i tion  o f  PCP d i scrimi nation i n  
rats . The percent sal i ne o r  drug-l ever responding  ± S . E . M .  averaged for 
a l l  s u bj ects tested i s  on the ordi nate and the number o f  the test i s  on  
the  a bsci s sa .  S i x  da i l y  s ess ions compr i s e  each  test number , two tra i n i n g  
days fol l owed by a s a l i ne test day and two tra i n i ng days fo l l owed by a 
PCP  test day . Tra i n i ng began wi th 1 0  subj ects . The numbers a bove the 
poi nts o f  the PCP graph  represent the number of an ima l s tested a t  the  
poi nt and the sal i ne poi nt bel ow it .  Anima l s  were no l onger tested 
after reachi ng cri teria .  
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as soon as the acqu i s i ti on cri ter i a  wa s reached . 
The tra i ni ng dose o f  PCP ( 3 . 0  mg/kg) produced a pproximately 95 
percent drug-l ever a ppropriate  respond i ng ( Fi gure 1 8 ,  u pper l eft panel ) .  
A h i g her dos e of PCP ( 1 0 mg/ kg)  produced an  even h i g her percentag e  o f  
drug-l ever a ppro�riate choi ces , a l though rates of respond i ng were mar­
ked ly  decreased and some anima l s  did not res pond at a l l .  Both ( ± ) -N­
a l l yl normetazoc i ne a nd ( + ) -N-al l yl normetazoci ne produced a dose-rel ated 
i ncrease  in the percent o f  res ponses made on  the PCP- a ppropriate l ever 
( Fi gure 1 8 ) .  The h i g hest percentage of res ponses on  the PCP l ever 
wa s l ess  than 85 percent for the racemate , whereas the (+) i somer 
reached l evel s greater than 95 percent , comparabl e to the PCP tra i ni ng 
dos e .  For these three compounds , the sl opes of the l i nes for percent 
drug-l ever a ppropr iate r espond i ng were s im i 1 ar " ( Ta b1 e 6) . Unl i ke the 
racemi c m i xture and the (+) i somer of N-a1 1 ynormetazoc i ne , the ( - )  
i s omer d i d  not produce " greater than 2 0  percent " PCP-appropriate 
respond i ng at  any of the doses tested ( Fi gure 1 8 ,  l ower r i ght panel ) ,  
a l though doses were tested which  markedly decreased response rates . 
For the compounds whic h  genera l i zed to PCP , there was no s i gni f i ca nt 
d i fference ( p  � 0 . 05 )  between the percent drug-l ever appropr i ate res­
pond i ng for test days fol l owing  sal i ne tra i n i n g  days and test days 
fol l owi ng  PCP tra i ni ng days . 
Overa l l  response rates for each  a nima l remai ned fa i r l y  stabl e 
throughout the experiment .  Average  val ues ± S . E . M  fo;- response rates on " 
the  four  v eh i cl e test days for each anima l  were : " . 8  ± . 0 9 ,  1 . 8 ± . 1 1 , 
. 97 ± . 0 9 , 1 . 5 ± . 1 9 , 2 . 53 ± . 57 ,  1 . 2 ± . 1 2  , 1 . 4 ± . 24 ,  . 7 1  ± . 0 2 , . 68 
± . 08 a nd 1 . 1 2  ± . 27  responses per s ec . Al l four  compounds produced 
a dose-dependent decrease i n  response rates . At the h i gher drug doses , 
" some an ima l s d id  not respond at a l l .  Test days for which  a n imal s ' " respo n s e  
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F IGURE 1 8  
Group dose-response curves for PCP ,  ( ± ) - N-al lyl normetazoc i ne ,  (+ ) _  
N-a l lyl normetazoci ne and ( - ) -N-a l l yl normetazoci ne for suppress i o n  of 
·operant responding  and for percent drug-l ever appropri ate respond i ng i n  
the  rat.  The mean percent drug-l ever appropri ate respond ing  ± S . E .M 
averaged a cross a nimal s (sol i d  l i nes ) and the mean percent control 
response rate ± S . E . M .  averaged across an imal s (dashed l i nes ) are on  the 
ardi nate wi th the corresponding  drug dose on the a bsc i ssa : Veh i cl e 
rates were ca l cu l ated over the 2-min test session  wi t h  vehi cl e pre­
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rates were l ess than 0 . 05 response per s ec for the  2-min tes t period 
were not i ncl uded in the percent drug-l ever appropriate respond i ng 
tabu l a  ti o n .  
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The tra i n ing dose of PCP ( 3 . 0  mg/ kg ) and the 1 0 . 0  mg/kg test dose 
o f  ( + ) -N-a1 1y1 normeta zoc i ne resul ted in  greater than 80 percent PCP­
l ev er a ppropriate r espond i ng wi th no . effect on overa l l  response rates . 
On the  o ther hand , 80 percent or greater PCP-l ever appropriate  r esponses 
were on ly  seen a t  doses ( ± ) -N-a1 1y1 normetazoc i ne that reduced response  
rates  by 25  percent o r  mor e .  
Ta bl e 6 shows the  E050 val ues for percent drug-l ever respond i ng 
and for suppress ion  of operant res pond ing  for a l l  four compound s . PCP 
was a pproximately 4 times more potent than the (+) i somer or the racemi c 
m i xture of N-al 1y1 normetazoci ne i n  produc i ng PCP-l ever appropr i ate  
res pondi ng . The fact that the ( + ) i somer a nd racem i c  m ixture are equ i ­
potent i n  producing  PCP-appropr iate respondi ng whereas the ( - ) i somer 
does not produce PCP-appropri ate respond i ng is i nconsi s tent wi th  the  
i d ea o f  an  a dd i ti v e  effect of the i somers i n  the racem ic  mixture  for  the  
production o f  the PCP-cue.  
The rel ative potency for su ppression  of o perant respond i n g  was :  
PCP > ( - ) i somer > racem ic  mi xture > (+ )  i somer . For response  rate 
. suppres s i o n ,  the relative potenci es of the opt i cal  i somers of N-a1 1 y1 -
normetazoci ne  compared to the racemic mixture i s  rough ly  cons i stent · w ith  
a n  add i ti v e  effect of the i somers . For PCP ,  (+ ) - N-al l y1 normetazoc i ne 
a nd ( ± ) -N-al l y1 normetazoc i ne ,  the  dose necessary to suppress o pera.nt  
respond i ng to 50 percent of vehi cl e rates was  2.8 times l arger than the 







POTENCY OF PCP AND N-ALLYLNORMETAZOCINE FOR STIMULUS GENERALI ZATION AND SUPPRESSION OF 
OVERALL RESPONSE RATES IN  RATS 
ED5D* Ratio  ED50*** Rat io  ED50s for Response 
Drug-Lever to Res ponse Rate to Rate Suppress ion / 
. Drug Resl:!ond i ng PCP Sl ope** Suppress ion PCP  Sl ope** Drug-Lever RespoDd i ng 
PCP . 98 1 . 0  74 2 . 7  1 . 0 -64 2 .8 
( . 8-1 . 2 )  ( 2 . 0-3 . 9 ) 
( ± ) -N -Al l yl - 3 . 95 4 . 0  62 1 1 . 1  4 . 1  -97 2 .8 
normeta zoc i ne  ( 3 . 0-6 . 2 )  ( 7 .8-1 7 . 4 )  
(+ ) -N-Al l yl - 4 .4 5  4 . 5  71 1 2 . 6  4 . 7  -96 2 .8 
normetazoc ine  ( 3 . 0-7 . 6 )  ( 9 . 7 -1 9 . 1 ) 
( - ) -N-Al l yl - 6 . 7 2 . 5  -61 
normetazoc i ne ( 4 . 6-1 2 . 9 )  
*Dose  (mg/kg of base )  resul tfng i n  50% drug-l ever a ppropri ate respond i ng as  determi ned by l i near regression and 
95% confidence l imits  i n  parenthes i s ,  
** I n  l og dose (�g/ kg ) - percent effect u n i ts .  
***Dose (mg/ kg o f  ba se)  resul t i ng i n  a 50% decrease  i n  response rates a s  determi ned by l i near regress ion and 
95% confidence l imits  i n  parenthes i s .  
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The effects of 30 . 0  mg/ kg nal oxone al one and in  combi nat i o n  wi th  
1 0 . 0  mg/kg of ( + )  and  ( - ) -N-al l yl normetazoc i ne on drug-l ever a ppropriate  
respond i ng a nd overal l response rates i s  presented in  Figure 1 9 .  The 
dose  of nal oxone tested d i d  not produce PCP-appropriate respond i ng above 
sa l i ne l evel s and did not decreas e  overal l response rates . Nal oxone 
pretreatment did not a ntagonize  the PCP-l ever appropriate respond i ng 
produced by 1 0  mg/kg ( + )-N-al l yl normetazoc i ne and the combi nat i on had no 
grea ter effect on overa l l  response rates . ( - ) -N-al l yl normetazoc i ne d i d  
not produce PCP-appropriate respond i ng al one o r  i n  combi nation  w ith  
nal oxone .  A dos e  of 1 0 . 0  mg/kg ( - ) -N-al l yl normetazoci ne suppress ed 
overal l response rates to a pproximatel y 40 percent o f  control . There 
wa s no s i gn ifi cant d i fference (p � 0 . 05 )  between the percent of control 
response rat� a fter 1 0 . 0  mg/kg ( - ) -N-al lyl normetazoc i ne al one  ·a nd the 
percent o f  control r es ponse rate a fter the admi n i stration o f  ( - ) -N­
a l lyl normetazoc i ne i n  combi nation wi th 30 . 0  mg/kg ·na l oxone .  
D .  Di scussion  
The  resul ts in  both  squi rrel monkeys and rats  are cons i stent i n  
s howi ng that t he PCP- l i ke s timul us  properi tes of . racem ic  N-a l l y l  nor-
m etazoci ne ( S KF- 1 0 , 047) in rats reported by S ha nnon ( 1 97 9 )  and Hol tzman 
( 1 980) reside  in the ( + )  i somer . Our stud ies  al so show that the l evo 
i somer is not wi thout behav ioral acti v i ty ,  but that th i s  activ i ty i s  not 
PCP- l i ke .  Therefore , ( ± ) -N-a l l yl normetazo c i n e ,  l i ke many racem i c  benzomorphans 
(V i l l arreal , 1 970 ) , is a mi xture of drugs with  di fferi ng profi l es of 
acti v i ty and is a poor candi date for a putat ive  receptor agon i s t  in the 
three receptor s cheme proposed by Mart i n  et �. ( 1 97 6 ) . S i nce PCP a nd 
( ± ) - N-al l ynormetazoc i ne have s im i l ar profi l es of acti v i ty i n · the  spi na l  
dog ( Vau pel and Jas i ns ky ,  1 979 ) , our find i ng that  PCP and ( + ) -N -al l yl nor­
meta zoc i ne  but not ( - ) -N-a l l yl normetazoc ine  share st imul us  prop ert i e s  
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FIGURE 1 9  
Group  dose-response data for percent drug-l ever appropriate 
respond i ng a nd percent control response rate for nal oxone , ( - ) - N-a1 1y 1 -
normetazoc ine  and (+ )-N-a 1 1 y1 normetazoci ne al one and i n  combi nation i n  
rats . The percent o f  vehi cl e response rate ± S . E .M .  (open bars ) a veraged 
for 1 0  s u bj ects a nd the percent drug-l ever a ppropriate respond ing  ± 
S . E . M .  ( hatched bars ) averaged for 1 0  subj ects are on the ord i nate wi th 
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ma kes i t  l i kely that the ( + )  i some� is res pon s i bl e for the s igma 
agon i st  profi l e  of the racemate i n  the s p i na l  dog . I ndi rectl y ,  thi s  
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al so s uggests that the ( + )  i somer wou l d  be the drug o f  c hoi ce to c haracteri ze 
putat i v e  s igma receptors i n  future research ,  a nd that stereospec i f i c  
bi nding  s tudi es of the (+) a n d  ( - ) i somers �Iou l d  b e  a fru i tful approach . 
The three receptor model o f  Marti n et �. ( 1 976 ) has proven to be  
v ery u seful to  c haracterize  the d i scriminative stimul us  properti es o f  
o p i o i ds i n  l aboratory an imal s ( Tea l and Hol zma n ,  1 98 0 ;  Hoods e t  �. , 
1 97 9 ) . A number of stu d i es have converged to su ggest that a d i vers i ty 
o f  c hemi cal  c l asses may s hare stimul us  properti es wh i ch can be rel ated 
to the s igma receptor .  The d i scriminative stimul us  effects of the 
benzomorphans �-al l ynormetazoc i ne and cyc l azoc ine  have been shown to 
be s im i l ar to each  other and PCP a nd/or ketamine  ( Shannon , 1 97 9 ;  Tea l 
a nd Ho l tzma n ,  1 97 9  1 980a ; Herl i n g  et �. , 1 98 0 ;  Hol tzma n ,  1 980 ) . 
Dextrophan has a l so been reported to general i ze to PCP and/or ketamine  
( Hol tzma n ,  1 980 ;  Herl i ng et �. , 1 980 ) . The aryl cycl oal kyl ami ne d i ssoc i a t i v e  
a nesthetics have been �ons i s tentl y s hown t o  s hare d i scriminati v e  st imul u� 
propert i es ( Shanno n ,  1 97 9 ;  Experiment I I ,  Brady and Bal ster , 1 981 ) . 
Fi nal l y ,  etoxadrol and dexoxadrol , two s i m i l ar compounds whi c h  represent ­
another d i s t i nct chemi cal  c l ass , a l so have been reported to general i ze 
to PCP  ( Experiment I I I ,  Brady and Bal ster , 1 980b ) . It has yet to be 
d eterm i ned _ the exact extent of the overl ap  i n  the pharmaco log ical  pro­
perti es in these d iverse drugs , nor whether they may be acting through  a 
common r eceptor mechanism .  I t  i s  c l ear that  a number of potentia l l y  
u sefu l  tool s are ava i l a bl e  to expl ore the pharmacolo gy o f  PCP-l i ke 
d i ssoc iative  a nesthetics  as wel l as op io id  s igma agonists . 
- 1 28 -
Recentl y ,  there have been a number ' .of reperts ( lu k i n  and luk i n , 
1 97 9 ;  Vi ncent � �. ,  1 979 ;  Hampten et al . ,  1 980)  .of a spec if ic  bi nd i ng 
s i te fer PCP i n  the redent nerveus system , suggesting  the pess i bi l i ty .of 
a recepter med iat ing  the effects .of PCP.  A, series .of structura l  a na l egues 
.o f  PCP a nd ( ± ) - N-al l yl nermetazecine  ( lu k i n  and luki n ,  1 9i9 )  have  been 
feu nd te b i nd th i s  recepter a nd the rel ative  affi n i t ies fer bi nd i ng 
cerrel ate wel l w ith  their  rel at ive  petenc ies  i n  cress- general i zat ien  te 
PCP i n  the drug-d i scriminatien parad i gm .  Us i ng the pure .optica l  i semers 
.of N-al l yl nermetazec i ne in thi s bi nd i ng assay weul d be of cens i derabl e , 
va l u e  i n  further c haracter i z i ng this  putat ive  PCP recepter .  I n  the 
l i ght .of .our find i ngs , it seems l i kely that the (+) i semer .of N-al l y l ­
nermetaz.oci ne may bi nd with  a hi gher affi n i ty than the ( - )  i s.omer . The 
data s hew a greater s imil ar ity between the effects .of (+ ) -N-al l yi n.or­
metaz.ocine  and  PCP  than  between PCP  and the  racem ic  mixture . 
Fer PCP a nd ( + ) - N-al lyl nermetaz.oci n e ,  the E050 val u e  fer respense  
rate s uppressi.on  was a pprexima tel y 3 .or mere times l arger than  the E050  
va l u e  fer PCP-l ever a ppr.opriate respend i ng i n  the rat  and the squ i rrel 
menkey . Thi s i s  censi s tent with  .our .other stud i es u s i ng squi rrel 
m.o nkeys trai ned t.o d i s criminate PCP fr.om sal i ne in which s everal  s truc­
tural  a na l egues .of PCP  ( Experiment I I ,  Brady and Ra l ster , 1 981 ) a s  wel l 
a s  s tructura l l y  d i ss imi l ar cemp.ounds ( Experiment I I I , Brady and Bal s ter . 
1 980b) produced drug- l ever apprepriate respend i ng at deses 3 te 8 f.ol d  l es s  
t h a n  t he deses which  suppressed .overal l res pense rates . There was l es s  
d i fference between , the ED50 va l u e  fer PCP-appr.opriate respend i ng and the '  
E050 v a l u e  fer respense-rate suppress ien  wi th ( ± ) -N-al lyl nermetazec i ne 
i n  s q u i rrel m.onkeys , but net i n  rats . Hewever , i n  beth rats and 
menkeys nearly c.ompl ete general i zati.on to PCP .occurred with  the (+)  
i s omer at deses which  did net d i srupt respend i n g ,  whereas  res pense rate  
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d ecrea s i ng doses, of the racemate were needed to reach 80 percent or 
greater PCP- l ever· a ppropri ate respond i ng .  The poor s eparation o f  the 
st imu l us  propert i es and response-rate di srupting properti es i n  the 
racemate is  proba bl y  due to the potent response ra te d i sr u pting  effects of the 
( - )  i s omer conta i ned in  the m ixture . I n  both the rat and monkey , the  
potency for d i srupti ng respond i ng by the  racemate fel l between the 
potenc ies of the ( + )  a nd (- )  i somers i nd i cati ng  that the effects on  
operant behavior of the  racemate may be expl i ca bl e by add i n g  the effects 
of the i s omers . 
A somewhat d i fferent picture emerges for pred icting  the potency o f  
( ± ) - N-a l lyl normetazoc ine i n  general i z i ng to P C P  based u p o n  t h e  potenc i es 
of the i somers . S i nce  the ( - )  i somer wa s wi thout PCP-l i ke stimu l u s  
effects i t  m i g ht b e  expected tha t the potency of the racemate shou l d  be 
Yz that o f  the (+ )  i somer . I n  both the rat and the monkey , the (+) · i somer 
and the racemic  m ixture were roughly equ i poten t .  Thi s ra i s es the poss i ­
bi l i ty that the ( - )  i somer may i nteract wi th ( + )  i somer to enhance i ts 
PCP- l i ke stimul us propert i es . The general rel i a bi l i ty of potency 
estimates from drug general i zation gradi ents ha s not been wel l establ i shed . 
Neverthel es s ,  the consi stency o f  this  f ind i ng  i n  both rats and monkeys 
l ends strength to the poss i bi l i ty that the ( - ) i somer may enhance the 
PCP- l i ke stimu l us properi tes of the (+ )  i somer , or conversely that the 
(+ )  i s omer may a l l ow the express ion  of PCP-l i ke stimu l us propert i es of 
the (- )  i somer perhaps by ·antagon iz i ng some non PCP- l i ke acti v i ty .  
Our data i nd i cate that the di scrimi native  stimul us  and response 
rate d i srupti ng effects of (+)  a nd ( - ) -N-a l l yl normeta zoc i n e  are not 
a ntagoni zed by nal oxone in rats or squ i rrel monkeys . The doses of 
nal oxone that we used were 30 to l Oa-fo l d  hi gher than tho s e  necessary to 
a ntagonize  the di scrimi native stimul us  properties of morph i ne i n  rats 
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(�ha nnon and Hol tzman ,  1 97 6 )  and squ irrel monkeys ( Sc haefer and Hol tzma n , 
1 977 ; Teal and Hol tzma n ,  1 979 ) . It has been reported (Mart i n  et �. , 
1 97 6 )  that na1 trexone may antagon i z e  ( ± ) -N-a1 1 y1 normetazoc i ne - i nduced 
can i n e  ma n i a  and that na l oxone antagon i zes the effects of ( ± ) -N-a 1 1 y1 -
normetazoc i ne on l ocomotor activity i n  mice ( Iwamoto , 1 979 ) . Our data 
i s  more consi stent with  those stud i es report i n g  a fa i l u re of naloxone to 
bl oc k the effects of (± ) -N -a 1 1 y1 normetazoc ine  as a n  anticonvu l sant i n  
m i c e  ( Cowan � �. , 1 97 9 ) , on  schedul e-control l ed performa nce i n  rats 
(Harris , 1 980)  and its d i scr iminative stimul u s  properties  in cycl a ­
zoc i ne-tra i ned s qu i rrel monkeys (Teal and Hol tzma n ,  1 980c ) .  One pos s i l be 
expl anation for t h i s  d i sagreement in the 1 i tera ture i s  that (± J -N-al l yl ­
normetazoc ine  has some op iate a nd some nonop i ate act i v i ty .  Perha ps the 
effects of ( ± )  -N-a l l y1 normetazocine on schedu1 e-contro 1 1  ed  performance 
and its  d i scrimi native st imul u s  cue i"ng properties  are not medi ated by 
o p iate receptors and therefore are not antago n i zed by na loxone .  A more 
comp1 ete study of nal oxone . i nterac t i'ons with N-a 11 y1 normetazoc ine woul d 
be n eces sary to expl ore t h i s  poss ibi l i ty .  
I n  concl us i on , both the racemic m ixture of N-a l l yl normetazoc ine a nd 
the pure ( + J  i somer general i zed to PCP i n  a dose-dependent fa s hion i. n  
squ irrel mon keys and rats . None o f  the doses o f  the (-1 i somer o f  N­
a l 1 y1 normetazoc i ne gen�ra1 i zed to PCP in  e ither s pec i e s .  The potency of 
the racem ic  m ixture for generalizatfon to PCP rel at ive  to the potency of 
the (+) isomer i s  not cons i stent with add i t i v i ty of the d i scr im i nativ e  
stimu l us effects o f  the (+ ) and C- )  i somer i n  the racem ic  mixture.  Al l 
fou r  compounds produced a dose-dependent decrea s e  i n  overa l l  response  
rates , and a l l  four compounds produced sf:lnil ar o bserv a bl e  effects in  
squ i rrel monkeys at h igh doses . The  potency of  racemic m ixtu r e  for 
response rate suppress ion  wa s consi'stent wfth addition of the effects  
-1 31 -
of �he ( - )  and ( +) i somers on overal l response ra te . I n  both s pec i es , 
nei ther the PCP-l i ke di scrimi native stimul u s  effects of { + ) -N-Al l ynormeta­
zoc i n e  nor the response-rate d i srupting effects of { - ) -N-al lyl normetazo c i ne 
were a ntagoni zed by h i g h  doses of nal oxone . Thi s study suggests two 
v ery d i st i nct pharmaco log ica l  profi l es for the stereoi somers of · N­
a l lyl normetazoc i ne .  Further work with pure opti cal i somers of  th i s  
compound wi l l  b e  i nval uabl e i n  further character i z ing  the s igma op i ate 
receptor and the putative  PCP receptor and in further expl or i ng the 
s i mi l ari t i es between the psychotomimetic  op iates and the d i ssociative  
a nes thetics . 
VI . D I SCRIMINATIVE  STIMULUS PROPERT I ES OF KETAMINE  ENANTIOMERS I N  
PCP-TREATED RATS ( EXPERIMENT V )  
A .  I ntroduction  
Ketam i n e ,  2- ( o-chl orophenyl ) - 2-methyl ami nocyc lohexanone ,  is  a 
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d i ssoci ative  anesthet ic  wh ich  i s  very s imi l ar to  PCP  i n  its spectra o f  
p harmaco log ica l  effects ( McCarthy � �. , 1 965 ) . I t  i s  a chi ral com-
pound which  i s  u sed c l i ni ca l l y  as the racem ic  mixture of two o pt i ca l  
i somers . Whi l e  most stud i es of the pharmacol ogica l  activ i ty o f  ketami n e  
have i nvol ved the u s e  o f  the racemic  mixture ,  sev eral recent reports 
i ndi cate d i fferences i n  the acti v i ty of the enantiomers . 
I n  rodents , the ( + )  i so'mer has been reported to be more potent than 
the ( - ) , i somer in hypnotic  acti v i ty (Mari etta et �. , 1 97 7 )  a nd a s  an 
a na l ges i c  ( Ryder � �. ,  1 978) . Mel i s ka et �. ( 1 97 9 )  reported that 
whi l e  h i g h  doses o f  both the ( - )  and the (+)  i somer decreased rates o f  
schedul e-control l ed respondi ng i n  rats , l ow doses of the ( - )  i somer , 
but not the (+)  i somer i ncreased response rates . They concl uded that 
there was a qual i tative  d i fference i n  the effects of tbe  ena'nti.omers on 
schedu l e-control l ed behav ior .  I n  a recent cl i n i ca l  study , Whi te et �.  
( 1 980)' reported that ( +) - ketam ine  produced more effective anesthei i a  
wi th  l ess  i nc idence o f  emergence reactions than ( - ) - ketamine . Opiate 
bi nding  stud ies ( Sm i th et �. , 1 980)  i ndi cate that ( + ) -ketami n e  i s  
3 to 4 times more potent than ( - ) - ketami ne i n  d i s p l a c i ng 3H-nal oxone 
bi nd i ng . 
Studi es of the d i scrimi native stimul u s  properties of racem i c  keta ­
mi ne a nd PCP hav e  s hown that these two drugs cross-g eneral i ze i n  rats 
( Ov erto n ,  1 974 ;  Jarbe et �. , 1 975 ;  Shannon , 1 979 ;  Pol i ng ,  et' �. , 
1 979 ;  Hol tzman ,  1 980 ) , p i geons ( Herl i ng et �. , 1 980 ) ,  squi rrel 
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monkeys ( Experiment I I ;  Brady and Ba l s ter , 1 981 ) and rhesus monkeys 
( Young  !! �. ,  1 980) . Al l of these stud ies  have been done wi th a race­
m i c  m i xture of ketamine .  The  pres ent study wa s des i gned to i nvest i ga t e  
the  d i scrimi nati ve stimul us  properti es o f  the stereoi somers of ketam i n e  
i n  rats tra i ned t o  di scriminate  PCP from sal i n e .  
B .  Methods 
S ubj ects 
The subj ects were ten experimenta l l y  na ive  mal e Sprague- Dawl ey rats 
( Fl ow La borator ies , Du bl i n ,  VA) . The animal s were ma i ntai ned at 80% o f  
thei r free- feed i ng wei ghts ( 280- 340 grams ) throughout the experiment by 
adjus ted post-session feed i ngs . They were i ndiv idual l y  housed i n  wire  
mesh cages where they had  unl imi ted access to  water . 
Appara tus 
The a pparatus for th i s  study is identi cal to the one descri bed i n  
deta i l  i n  the methods section o f  Experiment IV . A sta ndard two- l ever 
operant rat chamber ( Model E1 0-1 0 ,  Cou1 bourn I nstruments , Inc . ,  Leh i g h  
Va l l ey ,  Pennsyl vani a )  housed i ns i de a l i ght and sound attenuating  cubi ­
c l e ( Model E1 0-20,  Coul bourn Instruments , I nc . )  wa s u s ed .  
Procedure 
The procedure for tra i n ing  the rats to d i s cr im ina te PCP from sa l i ne 
i s  descri bed i n  deta i l  i n  the methods section of Exper iment IV . The 
s u bj ects were tra i ned to respond on a fi xed-ratio 32 ( FR32 ) schedu l e o f  
food pres entat ion .  Thi rty-mi n  sessi ons were conducted s even days a 
week . Eac h  an imal  received an i nj ection of ei ther phys i ol ogical  s a l i ne 
or 3 . 0  mg/kg PCP on a doubl e a l ternation  schedul e ,  i . e . ,  two days o f  P C P  
i nj ecti ons fol l owed by two days o f  sal i ne i njections , etc . T h e  an imal  
wa s pl a ced in  the chamber immed iately fol l ow i ng the drug i nj ectio n ,  
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1 0  m i n pre-ses s i on .  The house  l i ght \'la s i l l umi nated at the i n i t i at ion  
o f  the  s es s i on . For five an imal s ,  the l eft l ever was rei n forced on PCP 
days a nd the r i ght l ever was rei nforced on sal i ne days . The l ev er 
cond i ti ons were reversed for the other five subj ects . 
I n i ti a l l y ,  every third session  began wi th a 2-mi n per iod duri ng 
which respond ing o n  e ither l ev er was rei nforced a fter whi c h  the an ima l  
was conti nued as usual  on t h e  FR32 schedu l e  for t h e  rema i n i ng 28 mi n .  
When a n  an imal had performed 80 percent or more res ponses o n  the appropri ate 
1 ev er duri ng four consecutive  2 -mi n probes , test sessi ons �Iere beg un .  
The effects o f  subst ituting  various doses o f  PCP,  ( ± ) - ketam i ne , 
( + ) - ketam i ne a nd ( - ) - ketami ne for the 3 . 0  mg/kg dos e  of PCP were d eter­
m i ned on  test days . Test sess ions were conducted every th i rd day if the  
a nimal  compl eted the  fi rst FR  on the appropr i ate l ev er on  the contro l 
day preced i ng the test day . Test sessi ons con s i sted of a 2-min  period 
duri ng whi ch  respond i n g  on ei ther l ever was rei nforced after whi c h  the 
a n ima l s  were returned to the ir  home cages . The doubl e al ternati on 
conti nu ed on control days with test sess ions i nterspersed such  that a 
PCP and  a sal i ne day preceded each success i v e  test day . 
For each drug ,  five anima l s  received doses i n  ascendi ng order and 
five a nimal s received doses  in  descending  order . The PCP dose-response 
determi nati on was conducted fi rst i n  a l l  s ubj ects . The other drugs were 
tested in random order . Tests were conducted wi th  four doses o f  PCP 
( 0 . 3- 1 0 . 0  mg/kg ) ,  ( t ) - ketam i ne ( 1 . 0-30 . 0  mg/kg ) ,  ( + ) - ketami ne ( 1 . 0-30 . 0  
mg/kg )  and ( - ) - ketamine ( 1 . 0- 30 . 0  mg/kg ) . The doses were c hosen to 
cover a range from no effect to nearly compl ete suppress i o n  of response 
rates dur i ng the 2-m i n  test sessions . Eac h dos e  was tested twi ce  i n  
each a n 'imal ;  o ne determi nation was preceded by a PCP tra i n i n g  day and 
the ·s econd determi nation wa s preceded by a sal i ne tra i n i ng day . 
Da ta Ana 1 ys i s 
The data was anal yzed i n  an identical manner to that descri bed i n  
the methods section o f  Experiment I I . 
Drug� 
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PCP was suppl i ed by B io-Ceu tic Laboratori es ( Serny1 an ) .  Racem ic  
ketarni ne H C1 was supp1 i ed by Parke- Dav i s  a nd  Co . ( Keta 1 ar ) . T he  ( - )  a nd  
(+ )  i s omers of ketam i ne were suppl i ed by Bristol  Laborator ies . The 
drugs were d i l u ted with or d i ssol ved in ster i l e  sal i ne to a concentra ­
t ion  that resul ted i n  an i nj ection vol ume of 1 . 0 m1 /kg . Al l i nj ections  
were g i ven i . p .  10  min  pre-ses s i o n .  Dos es refer to the hydrochl oride  
s a l ts . Vehi cl e i nj ections were 1 . 0  m1 /kg of 0 . 9  p�rc ent sal i ne . . 
C .  Resu1 ts 
Overa l l respons e rates for each an imal rema i n ed fa irlY sta bl e 
throughout the experimen t .  Av erage val u es ± S . E . M .  i n  responses 
per s ec for the response rates on  vehi cl e test days for each an ima l  
were : 1 . 91 ± 31 , 1 . 03 ± . 21 , 1 . 4 5  ± . 4 , 1 . 1 ± . 3 , 1 . 01 ± . 2 5 ,  
1 . 56 ± . 31 , . 98 ± . 1 2 ,  . 86 ± . 1 , 1 . 33 ± . 2 ,  1 . 28 ± . 3 1 . The tra i n i ng 
doie o f  PCP ( 3 . 0  mg/kg) produced a pproximately 85 percent drug-l ever 
a p propriate respond i ng ( Fi gure 20,  u pper l eft panel ) .  Thi s dos e  had no 
effect on response rate . Al l three forms of ketamine produced a dose­
rel ated i ncrease  in the percent of responses made on  the PCP-appropri ate 
l ever ( Fi gure 20 ) . Whi l e  each o f  the three compounds produced over 80 
percent drug-l ever a ppropriate respond i ng at  some dos e , only the racem i c  
m i xture produced th i s  l evel  of drug-l ever appropriate respondi ng a t  
doses �Ih i c h  d i d  not decrease response rates . For both stereo i somers , 
doses �Ihi c h  produced greater than 50 percent drug-l ever appropriate 
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F I GURE 20 
Group  dose-response curves for PCP , { ± ) - ketami n e ,  { + ) -ketami ne and 
( - ) - ketami ne for s uppress ion  of  operant respond ing  and for percent drug­
l ever a ppropri ate respond i ng in rats . The mean percent drug�l ever 
appropriite responding  ± S , E .M .  averaged across an ima l s  ( �d l i d  l i nes ) 
and the mean percent control response rate ± S . E . M .  averaged across 
an imal s (das hed l i nes ) are on the ordi nate with the correspond i ng 
dose o n  the abscissa . . Veh ic l e rates were cal cul ated over the 2 -mi n test 
s ess i on . wi th v ehi cl e pretreatment at  the end of each drug dose-response  
determ i nation . 
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respond i ng ( 1 0 . 0  mg/kg) a l so decreased response rates to approximately 
50 p ercent of control . Test days for whi ch the response rates were 
l es s  than 0 . 05 response per s ec were not i ncl uded i n  the percent drug­
l ev er a ppropr iate respond i ng tabul ation . 
Ta bl e 7 s hows the E050 val u es for suppress ion  of operant respond i ng 
a nd for percent drug-l ever respond i ng for each of the four compounds 
tested . The rel ative potency for produc ing  drug-l ever appropriate 
responding  was :" PC� > ( ± ) - ketami ne > ( - ) -ketami ne > (+ )-ketam i ne .  
The r el ative  potency for response rate s uppress i on  wa s :  PCP > ( ± ) ­
ketami ne = ( + ) -ketamine  > C- )-ketam i ne .  Whi l e  the dose o f  PCP necessary 
to s uppress operant respond i ng to 50 percent o f  vehic l e rates was 4 
t imes l arger than the E050 dose for drug-l ever appropr iate respond i n g ,  
for the other three compounds there was approximatel y a 2-fo1 d d i ffer­
ence between the E050 for response rate su ppress i on and the E050 for 
drug- 'I ev er a ppropriate respond ing . The s l o pes o f  the l i nes for drug­
l ev er a ppropri ate respond i ng a nd for response rate suppress ion  are 
s i m i l a r  for a l l  four compounds ( Ta bl e  7 ) .  
D .  Di scuss ion  
The resul ts of th i s  experiment i nd i cate that  both stereo i somers of  
ketam i ne have  d i scrimi nati ve  stimu l us properties  s imi l ar to  those  o f  
PCP .  Al l three compou nds produced PCP-appropriate respondi ng ;n  a dose­
d ependent fash ion . The s l opes of a l l  of the dose-respons e curves were 
s i�i 1 a r ,  a l so suggestiv� of qual itatively s im i l ar effects . 
Whi l e  the h i gher doses of a l l  four compounds suppressed operant 
respond i ng in a dose-dependent fash ion ,  there was a greater d i fference 
between dos es whi ch  produced drug-l ever appropriate respond ing  and dose s  






POTENCY OF PCP AND KETAMINE  I SOMERS FOR STIMULUS GENERALIZATION AND SUPPRESSION OF 
OVERALL RESPONSE RATES I N  RATS 
ED50* Rat io  ED50*** Ratio  E050s  for Response 
Drug-Lever to Res ponse Rate to Rate Su ppression/ 
Drug Res �ond i ng PCP Sl o�e** Su��ression PCP Sl ope** Drug-Lever ResponclJng 
PCP 1 . 1 1 . 0 58 4 . 1 1 . 0  -99 3 . 9  
( . 1 2-1 . 5 )  ( 3 .3-5 . 4 )  
( ± } KET 5 . 1  4 . 9  61 11 . 2  2 . 7 -86 2 . 2 
(4 . 0-7 . 1  ) ( 8 . 6-1 5 . 5 ) 
(+ } KET 7 . 1 6 . 8 71 1 1 . 3  2 . 8 -1 02 1 . 6 
( 4 . 3 - 9 . 0 )  (7 . 3-21 . 1  ) 
( - )  KET 6 . 6  6 . 3  54 1 2 . 5  3 . 1 -95 2 . 0  
(4 . B-8 . 3 )  (7 . 9-25 . 1 ) 
*Dose  (mg/kg of ba se)  resu l t ing  i n  50% dru g -l ever appropriate res pond i ng as determi ned by l i near regression and 
95% confi dence l imits  i n  parenthes i s .  
**In  l o g  dose (�g/kg )  - percent effect u n i ts . 
" ***Oose  (mg/kg of base )  resul t i ng i n  a 50% decrease  i n  response rates as determined by l i near regression and 
95% confidence l im its i n  parenthes i s .  " 
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ketam i n e .  I n  contra s t ,  in Exper iment II u s i ng squi rrel monkeys tra i ned 
to d i scrimi nate PCP from sal i ne ,  for both PCP and (± ) -ketamine  the ED50 
dose for response rate suppress ion  was a pproximatel y 3 times l arger 
than the E050 dose for drug-l ever a ppropr iate respond i ng .  
s pec i es di fferences p l ay a rol e i n  thi s  d i screpancy . 
Perhaps 
There is some i nconsi stency in the l i terature concern i ng the rel at ive  
potenc ies  o f  racemic  ketami ne and the ( + )  a nd ( - )  i s omers . I n  both rats 
(Mari etta � �. ,  1 97 7 )  a nd mice ( Ryder et �. , 1 978 ) ,  ( + ) -ketami ne .i s 3 
t imes more potent than ( - ) - ketam ine  i n  produc i ng a na l ges ia  and the 
racem i c  mi xture fa l l s · a pproximatel y ha l f-way between these two in  poten­
cy . Thi s i s  cons i s�ent with the fi ndi ng by Smi th et �. ( 1 980)  that 
( + ) - ketami ne i s 3 t0 4 times more potent tha n ( - ) ketam i ne in d i s pl a c i ng 3H_ 
nal oxone b i nding  at  the opiate receptor and ·the report of Whi te et a1 . 
( 1 980} i nd i cati ng that ( +) - ketami ne i s  approximate ly  3 times more potent 
than ( - ) - ketam ine  as  an  anesthet ic  in humans . I n  contrast , studi es 
i nd i cate that the stereoi somers and racem ic  mixture of ketamine are  
a pprox imatel y equi potent i n  i ncrea s i ng non-spec i fi c  l ocomotor acti v i ty 
i n  rodents (Mari etta � �. ,  1 97 7 ;  Ryder et �. , 1 97 8 ;  Me1 i s ka et �. , 
1 978 )  a nd i n  cau s i ng l oss o f  r i ghting  refl ex and l etha l i ty i n  rats 
( Mar i etta et �. , 1 977 ) .  Our data i ndicate no l arge potency d i fference  
between racemic  ketam ine  and the  ( + )  and ( - )  i somers for production  o f  
PCP-appropri ate respondi n g  or for suppress ion  of operant respondi ng . 
These data do not su pport the study of Hel i ska e( �. ( 1 980)  reporting  
a qua l i tat ive  d i fference i n  the effects of ketamine  enantiomers on 
schedul e-control l ed performance in rats . They report that a t  doses u p  
t o  60 . mg/kg i . p . , ( - } -ketami ne produced o n l y  i ncreases  i n  response rates 
whi l e  at  doses of 30 mg/kg and a bov e ,  ( + } - �etamine  decreased response 
rates i n  a dose-dependeni fa s h ion  i n  rats tra i ned on a FI schedu l e o f  
food presentation . 
Several i nvestigations have i ndi cated that l ow doses of racem ic  
ketam ine  produce res pons e  rate i ncrea ses i n  p i geons  ( Wenger , 1 976 ) , m i ce  
( Wenger a nd  Dews , 1 976 ) and  rats (Mel i ska a nd  Trevor , 1 978 ) tra i ned 
u nder FI schedu l e of food presentation . As mentioned earl i er ,  Mel i s ka 
et �l. ( 1 979 ) recentl y reported i ncrea ses in response rates to as h i g h  
a s  3 times control rates a fter t h e  adm i n i stration  of ( - ) -ketami ne 
to rats  tra i ned under a FI schedul e .  I n  the same study , onl y response 
rate decreases were s een a fter ( � ) -ketam ine  adm i n i strat ion . I n  the 
present study ,  l ow doses  of al l three compounds produced sma l l  response  
rate i ncreases i n  i nd i v idual a n imal s ,  but when  the  data �Ias averaged 
acro s s  a n imal s no response rate i ncrea s i ng doses were found for a ny of 
the compounds . Thi s  poss i bl e  d i screpancy between th i s  study and those 
reported i n  the l i terature coul d be due to a d i fference i n  bas el i n e  
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rates of perfromance between these stud i es . The effects of (± ) -ketam i ne 
o n  opera nt performances have been s ho�m to be _ dependent on the basel i ne 
rate of the performance (Wenger , 1 97 6 ;  Wenger - and Dews , 1 976 ) such  that ­
l ow rate performance i s  i ncrea sed and h igh  rate performance i s  decrea s ed . _  
Res ponse  rates a fter veh icl e adm i n i stratidn  averaged 1 . 32 ± . 1 6  responses 
per sec in this  study . These rel at ivel y  h i g h  rates may not be sens it ive  
t o  rat e - i ncrea s i ng effects . 
The l i tera ture i nd icates that (± ) -ketam i ne i s  a pprox imatel y 1 /5 
to 1 /1 0  a s  potent as PCP i n  a var i ety of pharmacol og ical a s says . I n  
Exper iment I I  ( Brady a nd Bal ster , 1 981 ) we found rough ly  a 9-fol  d d i ffer 
ence in potency between PCP a nd ketamine as a d i scr iminative  stimu l u s  
a nd i n  response rate d i sru pt ion  i n  t h e  squ irrel monkey . T h i s  study 
i n  rats  i s  i n  agreement with prev ious  study i n  fi nd i ng (± ) -ketami ne to 
be cons i stently  l ess potent than PCP as a d i scrimi native stimu l u s  and 
in d i srupt i ng operant performance , but we found a somewhat smal l er {3 
to 7 - fol d }  potency d i fference between these compound s . 
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In  concl us ion , racemic  ketam i n e ,  { + } - ketamine  and { - } -ketam i ne 
produce dose-dependent drug-l ever a p�ro priate  respond i ng i n  rats tra i ned 
to d i scrim i nate PCP from sal i ne .  The s l o pes · of the dose-effect curves 
for el l l  four drugs were simi l a r .  There was no s i gn i ficant potency 
d i fference between { ± } - ketam ine  and e ither of the s tereo i somers for 
produc i ng drug-l ever a ppropriate  respond i ng or for response rate sup­
press ion . Thu s ,  there i s  no ev i dence for a qual i tat ive d i fference i n  
the  PCP-l i ke effects o f  s tereoi somers of ketam i n e .  T h i s  i someri c  pa i r  
wou l d  b e  a poor candidate for studies  of t h e  s tereos pec if i c i ty o f  the 
effects of arylcycl oal kl am i nes . 
V I I .  STEREOSELECTIV ITY OF THE STIMULUS EFFECTS OF CYCLAZOCI NE I N  PCP­
TRAINED  SQUIRREL MONKEYS ( EXPERIMENT V I )  
A .  I ntroduction  
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Several recent reports have  i nd i cated an  ov erl a p  between the  
d i scrimi native stimu l u s  properti es of phencycl i d i ne ( PCP)  a nd those o f  
cycl a zoc i n e ,  ( ± ) - ( 2-cycl opropylmethyl - 2 ' -hydroxy- S , 9-dimethyl - 6 , 7-
benzomorphan ,  Figure 2 1 ) .  Tea l a nd Hol tzman ( 1 980a ) found that i n  rats 
tra i ned to d i scrimi nate between sal i ne and high or l ow doses  o f  cyc l a -
zoc i ne PCP produced dos e-dependent drug-appropriate respondi ng i n  both 
groups · o f  an imal s .  Herl i ng et �. ( 1 980) reported that PCP produced 
drug-appropria te respond ing  i n  three grou ps o f  p igeons tra i ned to d i scrimi nate . 
d extrorpha n ,  ketamine  or cyc l azoc i ne from sa l i n e .  I n  rats tra i ned to 
. d i scrimi nate PCP from sal i n e ,  cyc l a zocine  has been fou nd to. genera l i ze 
to PCP ( Hol tzma n ,  1 980) . 
S imi l a r  to other opio i ds , cycl azoc i ne has a h igh  degree o f  stereo­
s el ecti v i ty in i ts pharmacol og ical  acti v i ty .  The ( - )  i somer o f  cycl a ­
zoc i ne a nd many other benzomorphans have been found t o  b e  more potent 
than the (+) i somers in tests for anal ges i c  act i v i ty ( Pearl  and Harri s ,  
1 96 6 ;  Harris  et �. , 1 969) , i n  effects on sched u l e-control l ed behav i or 
(McMi l l a n  and Harr is , 1 972 )  a nd i n  anticonvu l s a nt acti v i ty ( Cowan et 
�. , 1 979 ) . The potency rati os for the pa i rs of i somers in these sys­
tems vary from reports that the i s omers are nearly· equi potent to reports 
that the ( - )  i somer is 400 t imes more potent than the (+) i somer . 
I n  Experiment IV we found that the (+ )  i somer o f  N-al l yl normetazoc i ne ,  
a nother opi ate o f  the benzomorphan series , was respons i b1 e for the PCP-
1 i ke d i scriminative  s timul us  properti es of N-a l l yl normetazoc i n e  in both  
rats  and  s qu i rrel monkeys .  On  the  other hand , i n  both spec i es the  ( - )  
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FIGURE 21 
Chemical  structure of cycl azoc i ne . 
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i somer was mOre potent than the ( + )  i somer i n  ove�a1 1 response rate 
su ppress ion . 
C l i n ical stud i es have i nd icated that the ( + )  i somer of various 
op io ids  produce su bj ective  effects wh ich  are  qual i tatively di fferent 
form their  compl imentary ( - )  i somers . H i g h  doses o f  dextromethorphan 
and ( + ) - pentazoc ine  produced nervousnes s ,  anxi ety and psychotomimeti c  
effects i n  man ,  whereas ( - ) -pentazoc ine  and 1 evomethorphan produced a 
morphi ne-1 i ke sedation ( Ja s i nski , et �. , 1 97 1 ; Bel l v i l l e  and Forres t ,  
1 968 ) .  Racemic  cycl azoc ine  has al so been s hown to produce a nx i ety , 
dysphoria a nd psychotomimetic  symptomatol ogy i n  man (Marti n ,  1 967 ; 
Haertzen , 1 97 0 ) . 
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I n  add i tion , stud i es have suggested s im i l a r i t i es i n  the  d i scrim i ­
nat ive  stimul us  effects of ketam ine  or PCP a n d  dextrorphan i n  the p ig eo n  
( Herl i n g  � �. , 1 980 ) , rhesus monkey ( Young e t  �. , 1 980)  a n d  rat 
( Ho1�zman , 1 980 )  whereas the 1 - i somer of dextrorphan ,  1 evorphano1 , 
resul ted i n  sal i n e-appro priate respond i ng i n  p i geons  tra� ned to d i s ­
crimi nate dextrorphan from sal i ne ( Young e t  �. , 1 980 ) .  Rats tra i ned 
to d i scrimi nate morph i n e  from sal i n e  general ize  compl etely to 1 evorphano1 
but not ev en part ia l l y  to dextrorphan ( I·li nter , 1 97 5 ;  Shannon a nd Hol tzma n ,  
1 97 6 )  . 
Experiment V I  was d esi gned to further i nves t i gate the overl a p  i n  
t he  d i scriminative  stimu l u s  propert i es o f  cyc l azoc i n e  and PCP .  I n  the  
l i ght  of the ster eospec i f i c i ty of many of the pharmacol ogica l  act i v i t i es 
o f  cycl azoc i n e ,  we tested both  the ( + )  and  ( - )  i somers and racemic  
cycl azoc i n e  for general i zat ion  to  PCP i n  squ irrel mon keys tra i ned to  
d i scrimi nate PCP  from sal i n e .  
B . . Methods 
Subj ects 
The s ubj ects were the s i x  adu l t  ma l e  s qu i rrel monkeys ( Sa im ir i  
s C i ureus_ ,Sa nta Cruz ,  Bo l i v i a , Primate Imports , Port Hashi ngton , New 
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Yor k )  wh ich  had prev ious ly  been used i n  a study of the di scriminative  
st imu l u s  properti es of N-a1 1 y1 normetazoc ine  ( Exper iment I V ) . The  an ima l s 
were mai nta i ned at constant weights ( 0 . 8  to 1 . 0 kg ) throughout the 
experiment by adjusted post- sess ion  feed i ngs . They were i ndiv i dua l l y  
housed i n  standard primate caging  where they had unl imi ted access to 
water . 
Procedure -----
The procedure for tra i n i ng the squi rrel monkeys to d i scriminate PCP 
from sa l i ne has been descr i bed in more deta i l  i n  the methods section o f · 
Experiment I I .  The s ubj ects were tra i ned to respond on a fixed-rat io  32 
( FR32 )  schedu l e  of food presentation . Thi rty-�i n sessi ons were con-
ducted s even days a week . Each  an imal received a n  i nj ection of ei ther 
phys i o l o gical sal i ne or 0 . 1 6  mg/kg PCP on a doubl e a l ternation schedu l e ,  
i . e .  two days of PCP i njections fo l l owed by two days of sal i ne i n jections , 
etc . The an imal was i nj ected whi l e  i n  the primate cha i r ,  5 mi n pre-
ses s i o n .  The cha i r  was immed i a tely pl aced i n  the cubicl e .  The on ly  
source  o f  l i ght vias the  four stimu l u s  l i ghts · a bove the l evers whi ch  I�ere 
i l l umi nated at the i n i ti ation  of the ses s i on . For three animal s ,  the 
l eft l ever was rei nforced on PCP days and the ri ght l ever was rei nforced 
on s a l -i ne days . The l ever cond i tion  were reversed for the other three 
s u bj ects . Responses on the i ncorrect l ev er reset the FR contingency for 
rei nfor·ced res pond i ng the correct 1 ever . 
I n i t ia l l y ,  every third s ess ion  began with a 2-mi n period dur i n g  
wh i c h  respond i ng wa s not rei nforced , a fter whi ch  t h e  animal was cont i n u ed 
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a s  usual  on  the FR 32  schedu l e  for the rema i n i ng 28 mi n .  When an  a n ima l  
had  performed 85 percent or more responses on the  appropri ate l ev er 
d u r i n g  four  consecutive exti nction probes , test sessi ons were begun . 
The effects of substi tut ing vari ous doses of PCP ,  ( ± ) -cyc 1 azoc i n e  
( + ) -cyc 1 azoc i ne ,  a nd ( - ) -cyc 1 a zoci ne for the 0 . 1 6  mg/kg dos e  o f  PCP were 
d etermi ned on test days . Test sessi ons were conducted every t h i rd day 
i f  the a nimal compl eted the fi rst FR on the a ppropr i ate l ev er on the 
control day precedi ng the test day .  Test sessi ons cons i sted o f  a 2 -m i n  
exti ncti on period a fter whi c h  the an imal s were returned . to thei r home 
· cages .. The doubl e a l ternation  cont i nued on control days .with  the test 
s es s i ons i nterspersed such  that a PCP and a sal i ne tra i n i ng day preceded 
eac h  success i ve  test day . 
For each  drug , three anima l s rece ived the doses i n  ascend i ng order , 
and  three anima l s  received the doses i n  descend i ng order . The PCP dose­
r es ponse  determi nati on was conducted fi rst in a l l s ubj ects . The other 
drugs were admi n i stered in random order . Tes ts were conducted w ith  f ive  
doses  of PCP  ( 0 . 04-0 . 64 mg/kg) and four  doses ( ± ) -cyc1 azoc i n e  ( 0 . 003- 0 . 1  
mg/kg ) ,  ( - ) -cyc1 azoc i ne ( 0 . 001 - 0 . 03 mg/kg)  a nd (+ ) -cyc 1azoc i ne ( 0 . 1 -3 .0 
mg/kg ) . The doses were chosen to cover a range from no effect to nearly 
compl ete suppress ion  o f  res ponse rates dur i ng the ·2- m i n  test s e s s i ons . 
Al l doses of each of the cycl azoc i ne compounds were tested twic e  i n  eac h  
a n ima l ; o ne  determination  was preceded by a PCP tra i n i ng day a n d  the 
s econd determination  wa s preceded by a sal i ne tra i ni ng day . Al l doses  
o f  a g i v en drug were · adm i n i stered to a subj ect before testi n g  the  next 
dru g .  A vehi cl e test was conducted at  the end of each dose-response 
determ i nat ion .  
Da ta -Ana lys i s  
The analys is  of t h e  data wa s performed i n  an  i dentical · manner to 
that descri bed i n  the methods section of Experiment I I .  
Drugs 
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PCP was suppl i ed by B io  Ceutic  La borator ies ( S ernyl an ) .  Al l three 
forms o f  cycl azoc i n e  were suppl i ed by Sterl i ng-W inthrop Res earch I nst itu t e .  
P C P  wa s d i l u ted w i t h  steri l e  sal i ne t o  a concentration  that resul ted i n  
a n  i nj ection vol ume o f  0 . 2  ml / kg .  The cyc l a zoc ine  compounds were di ssol ved 
i n  hydrochl oric  a c i d  ( l  . 35 mg HCl per 1 0  mg cyc l a zo c i ne )  and d i l uted 
wi th s teri l e  sal i ne to a concentration that resul ted in an i nj ection 
vol ume o f  0 . 2  ml / kg .  For PCP,  v ehi cl e i nj ections were 0 . 2  ml / kg o f  0 . 9  
percent sal i ne .  For cycl azoc i ne compounds , the vehi cl e i nj ections were 
0 . 2  m l / kg of the most concentrated hydrochl oric  ac id-sal ine  sol ution  
neces sary to  keep the hi ghest dos e  of the drug  tested i n  sol ution . 
C .  Resul ts 
The tra i ni ng dose of PCP ( 0 . 1 6  mg/kg ) produced a pproximately 95 
percent drug-l ever a ppropri ate res pond i n g  ( Fi gure 2 2 , u pper l eft panel ) .  
A h i g her test dose o f  PCP ( 0 . 32 mg/kg ) produced an  even h i gher per­
centage of drug- l ever a ppropri ate cho i ces whereas 0 . 64 mg/kg compl etel y 
el imi nated respond i ng on ei ther l ever .  O f  the cycl azoci ne compounds , 
on ly  { + ) - cyc1 a zoc i ne produced a dose-rel a ted i ncrea s e  i n  the percent o f  
responses made on  t h e  PCP-appropriate l ev er ( Fi gure 2 2 ,  l ower l eft 
panel ) .  The 3 . 0  mg/kg dose produced 1 00 percent drug-l ever a ppro priate  
respondi ng in  those  s ubj ects who responded . There was no  s i gn if icant 
d i fference (p � 0 . 05 )  between test days fol l owing  sa l i ne  tra i n i ng days 
a nd test days fo l l owing  PCP tra i n i ng days for the same dose of ( + ) ­
cycl azoc i ne .  For both PCP a nd { + ) -cyc l azoc i n e ,  the s l opes o f  the l i nes 
for percent drug-l ever appropriate res pond i n g  were rel atively s i m i l a r  
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FIGURE 22 
Grou p  dose-response curves for PCP ,  ( ± ) -cycl azoc ine , ( + ) -cyc l a ­
zoc i ne a nd ( - ) -cyc l azoci ne for s uppres s i on of  operant respond i ng and for 
percent drug-l ever appropriate res pond ing  in the squ irrel monkey . The 
mea n percent drug-l ever appropri ate respond i ng ± S . E . M .  averaged across 
an ima l s  ( sol i d  l i nes ) and the mean percent control response rate ± S . E . M  
averaged across an imal s (das hed l i nes ) are o n  the ord i nate wi th the 
correspondi ng drug dose on the absci ssa . Veh i cl e rates were cal cul a ted 
over the 2-min test session  with  vehi cl e pretreatment at the end of each 
drug dose-response determi nat i o n .  
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(Ta bl e 8 ) . Ne i ther racemic  cycl azoc i ne nor the ( - )  i somer produced o v er 25 per­
cent PCP-a ppropr iate respond i ng at any of :the doses tested ( Fi gure 2 2 ,  
ri ght  panel s ) . 
Overa l l  response rates for each an imal  remai ned fai rly s ta bl e 
throughout the experiment .  Response rates for the two sal i ne tes t  days 
before the PCP dose-response determina tion and the sa l i ne test day a ft er 
the  PCP dose-respons e d eterm i nation  were averag ed and used as the PCP 
" veh i c l e rate and as  the control rate for al l of the drugs and for the 
cycl azocine  veh icl e i nj ect ion .  Thes e average val ues ± S . E . M .  for eac h  
s u bj ect were 1 . 2 ± . 20 ,  . 8 9  ± . 0 5 ,  2 . 3  ± . 2 2 ,  1 . 9 ± . 31 , 1 . 5 ± . 1 6 ,  1 . 03 
± . 1 1  responses per sec . Response rates after cycl azoc i ne  v ehi cl e 
i nj ecti ons d i d  not d i ffer much from control response rates . Al l fou r  
compounds produced a dose- dependent decrease i n  res ponse rates . At t h e  
h i gher drug doses , some a nimal s d i d  not res pond at  al l .  Tes t days for 
wh ich  an an imal ' s  response rates were l ess  tha n 0 . 05 response per sec 
for the 2-m i n  ext i nction period were not i ncl uded in  the percent drug­
l ever a ppropri ate respond i ng tabul at ion .  The s l opes of the  l i nes for 
response rate suppress ion  are s im i l a r  for a l l  four compounds ( Ta bl e 8 ) . 
A dose of 0 . 1 6" mg/kg PCP a nd 1 . 0 mg/kg ( + ) -cyc1 azoc ine  resul ted i n  
greater than 8 0  percent PCP-l ev er a ppropri ate responses wi th  on ly  
m i n ima l  effects on response rates . For ( ± ) -cyc1 azoc i ne  and ( - ) -cyc1 a zoc i ne ,  
dos es " o f  . 003 mg/kg or l a rger d ecreased response rates during  the test 
sess ions wi th  no evi dence of g eneral i zation  to the PCP cue .  
Ta bl e 8 s hows the ED50 val u es for percent drug-l ever respond ing a nd " 
for suppress i on of operant r espond i ng for al l four compounds . PCP wa s 
a p proximatel y 8 t imes more potent than the ( + )  i somer of cyc lazoc ine  i n  







{ ± ) -Cycl a zoc ine  
{ + ) -Cycl azoc i ne 
{ - ) -Cyclazocine  
TABLE B 
POTENCY OF PCP AND CYCLAZOCINE  FOR STIMULUS GENERALIZATION AN D SUPPRESSION OF 
ED50* Ra tio  
Drug-Lever to 
Res �ond i ng PCP 
. 07 1 . 0 
( . 06- . 08 )  
. 57 8 . 1  
( . 34- . 89 )  
OVERALL RES PONSE RATE 
. 
ED50*** Rat i o  
Response Rate to 
Sl ope** Su��ress ion PCP Sl o�e** 
1 46 . 3 1  1 . 0  -86 
( . 03- . 34 )  
. 01 2  0 . 04 -58 
( .  001 - . 02 )  
84 . l . 9 6 . 1  -88 
( 1 . 5 -3 . 9 ) 
. 008 0 . 03 -68 
( . 004- . 01 ) 
ED50s for Response 
Rate Su ppression 
Drug-Lever Respond ing 
4 . 4  
3 . 3  
* Dose  (mg/kg of base )  resul t i ng i n  50% drug-l ever a ppropriate respond i ng as  determi ned by l i near regression and 
95% confidence l imits  in parenthes i s .  
** In  l og dose (�g/ kg) - percent effect u n i ts .  
***Dose (mg/kg of base )  resul ting  i n  a 50% decrease  i n  response rates a s  determi n ed by l i near regression and 
95% confidence l imits i n  parenthes i s .  
su ppress i on of operant respond ing  was :  ( - )  i somer > racem ic  mixture 
> PCP > (+) i somer . S i nce racem ic  cyc l a zoc i ne was 3/4 as potent as the 
( - )  i somer for res ponse rate suppress ion , t h i s  is roughly cons i s tent 
wi th an add it ive  effect of the i somers on  response rate suppress ion . 
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For both PCP and ( + ) -cyc l azoc ine ,  the dose necessary to suppress operant 
respond i ng to 50 percent of vehi cl e rates wa s 3-4 times l arger tha n the 
E D50 dose for drug-l ever a ppro priate respond i ng . 
D .  Di scuss ion  
Our resul ts i nd icate that there i s  stereospec if ic ity in  the PCP­
l i ke s ti mu l us propert ies o f  cycl azoc i n e .  I n  th i s  study , the ( + )  i somer 
of cyc l a zo c i ne produced PCP-appropri ate respond i ng in squi rrel monkeys 
trai ned to d i scrimi nate PCP  from sal i ne ,  whi l e  the ( - )  i somer and the 
racemi c mi xture did not .  However ,  the ( - )  i somer and the racemic  m ix­
ture  of cycl a zoc i ne were not behav iora l l y  i nacti v e .  They were extremely 
potent in response rate di sruption a nd i n  producing  observabl e effects 
on behav ior .  I n  t h i s  sens e ,  o ur  study supports the  l i terature i n  d eter­
mi ni ng that the stereo i somers of cyc l a zocine  have d i fferent spectra 
of p harmacologi cal acti v i ty .  
There i s  some di screpa ncy i n  the l i tera ture concerni ng the rel at ive  
potency of the  stereo i somers of cycl a zoc i ne for d i sruption of operant 
respond i n g .  McMi l l a n  a nd Harr i s  ( 1 977 )  fou nd ( - ) -cyc l a zocine  to be 
a p proximatel y 3 times more potent tha n ( +} -cyc l azoc i ne in d ecrea s i ng 
, the ra te o f  respondi ng i n  p i geons tra i ned u nder a mul t i pl e FR schedu l e 
of food presentation . R�centl y ,  Teal and Hol tzman ( 1 980b) reported that 
the ( - )  i somer o f  cyc lazoc ine was 1 00 times more potent than the ( + )  
i somer i n  di srupti ng opera nt respond i ng i n  squi rrel monkeys . I n  our ' 
study ,  ( - ) -cyc l a zocine  was 200 times more potent than (+ ) -cycl a zoci ne 
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i n  respo nse rate s uppress ion .  Whi l e  there have been no stud i es com­
par i ng the effects of s tereo isomers of cycl azocine  on operant perfor­
mance i n  rodents , Pearl rt �. ( 1 968 ) reported that whi l e  ( + ) -cycl azoc i ne 
wa s 1 50 times l ess  active  than the ( - )  i somer i n  the rat ta i l  fl i c k  
tes t ,  i t  wa s o n l y  1 6  times. l es s  potent i n  di sru pting  rotarod performance 
in  m ice  and 6 .8  times l ess potent i n  decrea s i ng motor acti v i ty in  m ice . 
Thi s i s  cons i stent �Ji th the fact that rodent bioassays hav e  been found 
to u nderestimate the �otency of s ev eral benzomorphan opi ates in primates 
( Ta ber et �. , 1 964 ; Pearl and Harri s ,  1 966 ) . I t  seems l i ke ly  tha t  the 
behavi oral effects of cycl azoc i ne i somers are not only stereosel ectiv e  
b u t  a l so s peci es-spec i f i c .  Thi s i nterest ing area warrants further 
i nvesti gati o n .  
A n  i nterest ing  d i screpancy between t h i s  study and some earl i er work  
l i es i n  the  fa i l ure o f  ( ± ) -cycl azocine  to  general i ze to  PCP i n  our  
s tudy . I t  has  been reported that rats  ( Tea l and Hol tzma n ,  1 980a ) and 
p i geons ( Herl i ng ,  1 980)  tra i ned to d i scr im i nate ( ± ) -cyc1 azoc i ne from 
s a l i ne genera l i ze to PCP .  Futhermore ,  Hol tzman ( 1 980 ) found that  rats 
trai ned to d i scriminate PCP from sal i ne genera l i zed to ( ± ) -cycl azoci n e .  
I t  i s  pos s i bl e  that the spec i es d i fference i n  t h e  effects o f  cycl a zoc i ne 
i s omers on operant respond ing  cou l d  expl a i n  the d i sagreement between our 
s tudy a nd the  prev ious  wor k .  Because  t h e  ( - )  i somer of cycl azoci ne i s  
m u c h  more potent re 1 a t ive  t o  t h e  ( + )  i somer i n  s.u ppres s i ng operant res­
pond i ng in  s q u i rrel monkeys , any dose of ( ± ) -cyc 1 a zoc i ne whi ch conta i ned 
enough of the ( + )  i somer to produce PCP-a ppropr i ate res pond i ng wou l d  
a l so have enough o f  the . ( - )  i somer to compl etely su ppress respondi ng : 
I f  the rel at ive  potency of the stereoi somers for d i s rupting  operant 
behav i or i n  rats is c l oser to that found by 11cNi l l a n  a nd Harr i s  ( 1 971 ) 
for pi geons , than i t  woul d be poss i bl e  to fi nd a dose of ( ± ) - cyc1 azoci ne 
whi ch  cou l d  produce a PCP- l i ke d i scriminative cue wi thout compl ete ' 
d i sruption of respond i n g .  
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In a recent s tudy ,  Teal a nd Hol tzman ( 1 980b )  conducted genera l i ­
zation  testing  with  ( + )  a nd ( - ) -cycl azoc i ne ' i n  squi rrel monkeys tra i ned , 
to d i scrimi nate between sal i ne and ei ther ( - ) -morphi ne or racemic  cycl a zo c i ne .  
Whi l e  both i somers substi tuted for the tra i n i ng dose o f  cyc l azoci ne i n  
the  cyc l a zoci ne-tra i ned group ,  the genera l i zation  o f  the ( - )  i somer and 
racemic  mi xture coul d be bl ocked by nal trexone whereas the genera l i -
zat ion  produced by the ( + )  i somer coul d not .  I n  add i tion , the ( + )  
i Somers of l evorphanol , methadone , and l evomethorphan a l l  produced 
cyc l a zoci ne- l ever a ppropriate respond i ng whi l e  the ( - )  i somers al l 
general i zed to morph ine .  They suggested that  the effects of the  ( +) 
i s omer of , cyc l azocine  and other op iates are not med iated by opiate  
receptors . They a l so fou nd t,hat ( - ;- cycl azoc i ne wa s 1 00 times more 
potent than ( + )  -cycl a zoci ne in produc'i ng ( ± ) -cycl azoc i ne-appropriate 
respond i ng .  Because  o f  thi s ,  they concl uded that in  the squirrel 
monkey ,  the ( - )  i somer i s .  for the most par t .  respons i bl e  for the 
d i scrimi native' st imul us  properti es of racem ic  cycl azoc i ne . Thi s  i s  
cons i s tent w ith the fa i l ure o f  racem ic  cycl azoc i n e  and ( - ) -cycl azoc i ne 
to general i ze to PCP i n  the present study. 
In Marti n ' s  ( �Iarti n g �  . . 1 975 )  theory o f  three opiate receptor 
types ba s ed on the effects of vari ous op iates i n  the chronic  s p i nal  dog . 
( ± ) -cycl azoc i ne is reported to be an ago n i s t  o f  the sigma receptor a s  
wel l a s  other op io id  receptors . The effects of PCP i n  the chron ic  
sp i nal  dog  are  al so very s im i l ar to  those of the prototypic  s igma agoni s t , 
( ± ) - N-a l l yl normetazoc i ne ( Va upel and Jasinsk i . 1 979 ) . I n  Experiment I V .  
w e  s howed that N-al l ynormetazoc i ne h a s  a very s i mi l ar separat ion  o f  
acti v i ty i n  the behavi oral pharmacol ogy o f  i ts opti cal i somers a s  does 
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cyc l a zoc i ne .  I n  both rats a nd  squ irrel monkeys tra i ned to  d i scrimi nate 
PCP from sa l i n e ,  the (+1 i somer general i zed to PCP whi l e  the · ( - I  i somer 
d i d  not .  The present study reemphas i zes the need to further i nvesti gate  
t he  s tereospec if i c i ty of the s igma receptor .  
I n  concl u s i o n ,  ( +I -cycl azoc i ne general i zed to  PCP i n  a dose-depen­
dent fas h ion  in squ i rrel monkeys tra i ned to d i scrimi nate PCP from 
sa l i n e .  Nei ther ( ± I - cycl azoc i ne nor ( - I -cycl azoci ne general i zed to PCP 
at a ny o f  the doses tested . Al l four compounds produced a dose-depen­
dent d ecrease in response rates . The ( - I  i somer was 300 times more 
potent than the ( + 1  i somer for response rate su ppress ion and the 
potency of the racemic  mi xture is cons istent wi th add i ti on of the ( + 1  
a nd ( - I  i somers . Th i s  study suggests two v ery d i s t i nct pharmaco l o g i ca l  
profi l es for t h e  stereoi somers of cycl azoc i n e .  
V I I I .  F I NAL DI SCUSS I ON 
Phencycl i d i ne appears to bel ong to a u n i q ue  cl ass  of drugs which  
have a vari ety of chemi ca l  s tructures . The studi es presented in  this  
d i s s ertation i nd i cate many s i m i l ar it ies  between the effects o f  PCP a nd 
several structura l l y  s imi l ar and d i s s imi l ar compounds on a vari ety of 
behav i oral measures . 
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In genera l , our findi ngs are in agreement with the l i terature 
concerning  the acute effects of PCP and PCP-l i ke compounds on schedu1 e ­
control l ed behavior .  I n  pi geons (Weng er , 1 976 ) , m i ce  (Wenger a nd Dews , 
1 97 6 ) , ra ts ( Murray , 1 978 ) , rhesus monkeys ( Ba l s ter a nd Cha i t ,  1 97 6 )  and 
squ i rrel monkeys ( Cha i t  and Bal s ter , 1 97 7 ,  1 978 , 1 97 9 ) . it  has been 
reported tha t  l ow dos es of PCP cause response rate i ncreases . When 
assessed , these response rate i ncrea ses have  been shown to be consi stent 
wi th  the  rate-dependency hypothes is  ( Dews , 1 958 ) in the sense that l ow 
bas.e1 i ne rates of respond i ng are i ncreased more than h i g h  basel  i ne rates 
of res pond i ng a fter PCP a dmi n i stration  . 
. I n Experiment I Jle found tha t  PCP a nd three s tructural ana  1 ogues 
( PC E , ·  TCP and ketam i n e )  had qual i tative ly  s im i l a r  effects i n  rhesus 
monkeys tra i ned to l ever press o n  a fixed- i nterval ( FI )  schedu l e o f  food 
pres entation . Low doses o f  a l l  four compounds i ncreased the l ow rate 
respond i ng at the beg i nning  of the FI  and decreased the h i g h  rate 
respond i ng at  the end o f  the Fl . H i g h  doses of a l l four compounds 
decreased respondi ng in a l l  parts of the Fl . 
C ha i t  and Bal ster ( 1 97 7 ,  1 978 , 1 979 )  have reported tha t  i n  squ i rrel  
monkeys , l ow doses of PCP produced sma l l i ncreases i n  response rates of 
schedul e-control l ed performances whi l e  h i g her doses produced dose­
dependent decreases in response rates . I n  our squi rrel monkey s tu d i es 
( Experiments I I ,  I I I ,  I V .a nd V I ) ,  we found a s imi l ar effect o f  PCP and  
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a l l  of the PCP-l i ke compounds . Every drug whi ch  general i zed to PCP i n  
the  d i scriminative  s timul us  exper iments produced smal l but con s i s tent 
response rate i ncreases a t  some l ow doses in  a l most  ev ery subj ect . I n  
ma ny cases , these response rate i ncreases were not ev ide�t i n  the dose­
response  curves because  they occurred at di fferent doses for di fferent 
a n imal s ,  so when the data for d i fferent an imal s was averaged they wer.e 
not v i s i bl e . These response rate i ncreases were not stati st i cal l y  
s i gn i ficant .  
I n  contra s t ,  our rat stud i es ( Exper iments IV and V)  show l i ttl e 
i nd i cat ion  of a trend towards response rate i ncreases at l ow doses o f  
P C P  or a ny o f  t h e  drugs tested . Al though l ow doses of PCP and sev eral 
other drugs occas i onal ly produced response rate i ncreases , these were 
not nearly as consi stent as i n  the squ i rrel monkey stud i es .  Thi s i s  i n  
contrast  with  much o f  the l i terature reporti ng  response rate i ncreases  
in  s chedul e-control l ed performa nce in  rats a fter l ow doses of PCP  and 
PCP a nal ogues ( Murray , 1 978 ;  Mel i s ka and Trevor , 1 97 8 ;  Gl i ck  et �. , 
1 97 9 ) � Th i s  d i s crepancy cou l d  be due  to d i fferent control rates of 
res pond i n g  produced by schedul es u s ed in  the exper iments . The FR 
sc hedu l e  used i n  our experiments generated fa i rl y  h i g h  res pons e  rates 
( > 1 responses per s ec None of the stud ies reporti ng  res ponse  rate 
i ntreases i n  rats used a FR schedu l e .  
I n  Experiments I I  through V I , w e  demonstrated that a vari ety of 
compounds , some s tructural l y  s im i l ar to PCP and some structura l l y  
d i s s i mi l ar to PCP,. coul d produce drug-l ever appropr i a te respond i ng i n  
squi rrel monkeys a nd/or rats '�ra i ned to d i scriminate PCP from sal  i n e .  
Genera l i zations i n  t h e  druG d i scrim i nat ion  parad i gm have cons i s tently 
been s hown to occur between drugs wi th  a s i mi l ar s pectra of pharmaco l o g i ca l  
properti es , but genera l l y  not between drugs of di fferent drug cl asses 
a nd pharmacol ogi cal properti es ( Barry , 1 974;  Schuster and Bal ster , 
1 97 7 )  . 
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I n  Experiment I I ,  we demonstrated the s pec i f i c i ty of the PCP cue  by 
test i ng PCp- tra i ned s qu i rrel monkeys for general i zation  to morph i ne ,  
ketocyc l azocine  and mesca l i ne .  None of these drugs produced PCP-a ppro­
priate  respondi n g .  Other i nv esti gators ( Jarbe e.t �. , 1 975 ;  Pol i ng et 
�. 1 979 ;  Shanno n ,  1 979 )  have reported no general i zation  wi th a- y-ar-;-;D�_thy�-�-­
o f  o ther psychoactive  compounds i ncl uding  69-THC ,  LSD ,  morphi ne and  
mesca l i ne in  rats tra i ned to  d i scrimi nate PCP  from sal i ne .  I t  seems 
c l ea r ,  therefore , that the drug d i scrimination  parad igm i s  a fa ir ly  
s pecif ic  assay for PCP-l i ke behav ioral act i v i ty .  This  makes i t  espec-
i a l l y  i nteresting  when compounds which  are structural l y  d i s s im i l ar to 
PCP ,  such  as d exoxadrol , etoxadro l , ( ± )  and ( + ) - N-al l yl normetazoci n e ,  
a n d  (+) -cycl azoc i ne g eneral i ze to PCP . 
One i nteresting  poi nt whi ch  shoul d be addressed concerns the l a c k  
of general i zation  of ketocyc l a zoc i ne to P C P .  We chose t o  test thi s 
drug because i t  i s  consi dered to be the protototyp ic  agon i st of the  
� receptor in  Marti n ' s  ( �larti n et �. , 1 976 )  op iate receptor theory . 
Ketocycl azoc i ne ,  l i ke cyc l azoc i ne ,  i s  a benzomorphan op io i d .  I n  
Experiment V I  w e  found that ( + ) -cyc l azoc i ne but not ( - ) -cycl a zoc i ne o r  
( ± ) -cyc l a zoc ; ne genera l i zed to PCP i n  squ irrel monkeys tra i ned to d i s ­
crimi nate PCP from sal i n e .  I t  i s  pos s i bl e that ( + ) -ketocycl azoc ine  
wou l d  al so genera l i ze to PCP, but on ly  the  racem ic  mixture was tested 
i n  t h i s  study . 
I n  a l l drug d i s crimi nation stud i es ,  an imal s are tra i ned to perform 
d i fferent tas ks under d i fferent drug cond i ti ons . In our experiments , a 
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l eft l ev er press was rei nforced under the PCP or sal i ne state and a 
r i ght l ev er press wa s rei nforced u nder the oppos i te state . Many drug 
d i s cr i m i nation experiments use  the c ho i ce between two arms of a T-maze 
as the tas k  to be performed d i fferent ial l y  under d i fferent drug cond i ­
t ions . Regardl ess of t h e  tas k  i nvol ved , i t  i s  pos s i bl e  to obta i n  some 
measure of non- s pec i fi c  behav ioral d i sru pti on  from the same tas k  by 
measur ing  response rate s uppress ion , runway l atency , or some other 
i nd i cation  of non-spec i fi c  impa i rment .  Measures of response-rate d i s ­
rupti on  and drug general i zation a r e  i ndependent of each other . For 
exampl e ,  i n  our stud i es �e saw response rate decreases at dos es of ( ± ) ­
cyc l a zo c i n e ,  ( - ) - N-a1 1 ynormeta zoc i ne and ( - ) -cyc1 a zo c i ne whi c h  d i d  not 
produce drug-appropri ate respond i ng a bove sal i ne l ev el s .  
I n  most of the drug d i s cr im ination  l i terature ,  response rates are 
not reported . Whi l e  drug d i scrim i nation  is  an i nval uabl e tool in  
measur ing  some v ery spec if ic  properties  of psychoactive compounds , i t  
ma kes s ense  to ga i n  whatever add i tiona l i nformation i s  poss i bl e  from 
th i s  same tas k .  For drugs whi ch  genera l i ze to each other , it is i nter­
esti ng to compare potency for general i zation to potency for behav i oral  
di srupti o n .  I n  o u r  exper iments , w e  measured respons e rate suppres s ion  a s  
wel l a s  drug-l ev er a ppropr iate res pond i ng duri ng the test peri ods . We 
then cons tructed dose- effect curves for both performances . By a l i near 
regress ion o n  these dose-response curves , ' a n  ED SO do s e  ( effecti ve dose 
50 )  for both measures wa s determi ned . Thi s i nformation enabl ed us to 
compare our test compounds to PCP with  regard to the s l o pes of the dos e­
effect curves for general i zation  and drug-l ever appropri ate respond i ng 
as wel l as the potency for response rate su ppressionand the potency for 
drug-l ev er appropr iate respond i n g .  We fou nd that the sl opes of the 
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dose-response curv es for general i zation and response rate su ppress ion  
were  s imi l ar for al l of the drugs  which  genera l i zed to  PCP . I n  add i t i o n ,  
i n  nearly every case these drugs were 3 to 8 times more potent i n  
produc ing  drug-l ever a ppropr i ate respond i ng than i n  respons e rate 
su ppres s ion . For most compound s ,  doses cou l d  be found whi ch produced 
over 7 0  percent drug-l ever a ppropr i ate respond i ng wi thout decreas i ng 
response rates bel ow sal i ne control l ev el s .  
For s ev eral drug s , however , the potency ratio for res ponse rate 
suppres s i o n  and general i zati on  was co nsi stentl y sma l l er tha n for the 
majori ty of the compounds whi ch  general i zed PCP . One of these excep­
tions was ( ± ) -N-al lyl normetazo c i n e .  For this compound , the potency 
ratio  for response rate suppress ion to drug general i zation wa s 1 . 7 i n  t h e  
squ i rrel monkey and 2 . 8  i n  t h e  rat .  Thi s i s  proba bly because o n l y  the  
( + )  i s omer produces PCP- l ever appropri ate respond i ng whi l e  the  ( - ) 
i somer i s  fa i rly potent i n  the response rate su ppression . For ( - ) and 
( + ) - ketami ne i n  rats , there i s  a l so a rel ati v el y  sma l l  d i fference be­
tween the E DSO for response rate suppression and the EDSO for drug-l ever 
a ppropri ate respond i n g .  The reason for thi s  is not cl ea r .  
Con s i deri ng the apparent sens i ti v i ty o f  the drug d i scrimination 
tas k  for PCP- l i ke compounds ,  i t  is  of i nterest that most of the compounds  
wh i c h  g eneral i zed to  PCP  produced smal l but  cons i s tent response rate 
i ncrea s es at  doses whi ch  d i d  not produce drug-l ever a ppropri ate re­
s pondi ng above sal i ne l eve l s .  I t  wou l d  be i nteresti ng to determine . i f  
these response rate i ncreases represent behavioral  acti v i ty of PCP-l i ke 
compounds at doses whi ch  are not d i scriminabl e from sal i ne .  I t  i s  
pos s i bl e  that these doses are , i n  fact , di scr iminabl e from sal i ne i n  
a n ima l s trai ned to d i scrimi nate l ower doses o f  PCP from sa l i n e .  W e  pl a n  
to i nv esti gate thi s poss i bi l i ty by progres s i v el y  l oweri ng  the tra i n i ng 
dose  of PCP i n  squi rrel monkeys tra i ned to d i scrimi nate 0 . 1 6 mg/kg PCP 
from sa l  i ne then constructing  PCP dose-response curves  at thes"e l ower 
tra i n i ng doses . 
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It has been s uggested tha t there may be some correl ati on  between 
the eas e  with whi ch  a drug can serve as  a di scrim i native  s t imul u s  
( "d i scrimi nabi l i ty" ) a nd t h e  abuse l i a bi l i ty of a d r u g  (Overto n ,  1 97 1 ) .  
Overton a nd Batta ( 1 977 )  i nv esti gated the rel ations h i p  between the a bu s e  
l i abi l i ty a n d  degree of di scriminabi l i ty of a vari ety of drugs . They 
used the number of tra i n i ng sessions requ i red to establ i s h  d i s cr i m i ­
n a t i v e  respond i ng i n  rats tra i ned i n  a T-maze d r u g  d i scr im i nation  tas k  
a s  a n  i ndex o f  d i scrimi na b i 1 i ty .  They d i d  not fi nd a usefu l l y  h i g h  
correl at ion between a bu se  1 a i bi 1 ity a n d  d i scriminabi l i ty as measur ed by 
thi s procedure . Perha ps u s i ng an o perant tas k  a nd the rat i o  of potency 
for d i scrimi nation  to res ponse rate su ppres s ion as an i ndex of d i scrim i ­
nabi l i ty ,  a d i fferent pattern wou l d  resul t .  I n  a ny case , there i s  meri t 
i n  measuring  a nd reporti ng some measure of behav iora l d i sruption  i n  drug 
d i scrimi nation tas ks for use  in  compar ing  drugs wi thi n  a c l ass  and i n  
compar i ng d i fferent cl asses o f  drugs . 
Experiments I I I ,  I V ,  V a nd VI were desi gned to i nvesti gate the 
newl y emer"g i ng overl ap  i n  the pharmacol ogies of PCP a nd the psycho­
tomimeti c op io ids , particul arly the s igma receptor agoni sts . I n  Exper i ­
ment I I I ,  w e  demonstrated that dexoxadro1 and etoxadrol ,  two compounds 
wh i c h  are structural l y  d i s s im i l ar to PCP , genera l i zed to PCP i n  the 
squ i rrel monkey tra i ned to di scrimi nate PCP from sal i ne .  Prior to our 
report of this f i nd i ng  ( Brady and Ba l ster , 1 980b) , the on ly compound 
other than the structural anal ogues of PCP which  had been r eported to 
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general i ze to PCP wa s the psychotomimetic  op io i d ,  N-al lyl normetazoc i n e  
( S hanno n ,  1 979) . Dexoxadrol a n d  �toxadrol a r e  o f  parti cu l ar i nterest 
because  the former wa s i nvesti gated for use  as a n  a na l ges i c ,  but has 
psyc hotomimeti c s i de-effect� in �a n  at  doses whi ch  produced a na l ges i a  
( S imopou l os et �l . ,  1 970 ;  Lasagna and Pearso n ,  1 965 ) ,  whi l e  etoxadrol 
was i nvesti gated for use as  an anesthet ic  ( Fredricksoin 2t �. , 1 976 ) . 
Thes e two compounds are v ery s im i l ar  to each o ther i n  structure ( Fi gure 
1 1 )  but d i ss imi l a r  from the aryl cycl oal kyl ami nes ( PCP ,  Figure 8 )  and  the  
benzomorpha ri op io ids  ( N-a l l yl normeta zoc i ne ,  Fi gure 1 3 ) .  Further 
i nvestigation  of the chemical  and pharmacol og ica l  commona l i ti es among 
these three groups of compounds wi l l  be a us eful approach to further 
research  concerni ng the PCP-op io id  ov erl a p .  
I n  Experiment I V ,  we found that i n  both squi rrel monkeys a n d  rats 
the  PCP-l i ke di scrimi native stimul us  propert i es o f  N-a l l yl normetazoc i n e  
were i n  the ( + )  i somer , wh i l e  t h e  ( - ) i somer wa s much more potent i n  
ov era 1 1  res ponse rate su ppress ion . The racemi  c m i  xture i s , therefore , 
actual ly  a mixture of two active  compounds wi th  d i fferent behav-
iora l pharmacol og ies . This  i s  especi a l l y  s i gn i ficant i n  v i ew of the  
fact  that N-al lyl normetazoci ne  is  consi dered the  prototypic s igma ago­
n i s t  i n  Marti n ' s  (Mart i n  � �. , 1 976 )  theoret i ca l  proposal of three 
op i ate receptors based on  the pharmacol ogical  profi l e  of various o p i a te s  
i n  t h e  c hron i c  s p i na l  dog . Consi dering  the marked stereosel ecti v i ty o f  
the  actions of a l l  opi ates coupl ed wi th t h e  pecu l i a r  s eperation  of 
pharmaco l ogical  ·acti v i ty between the stereoi somers of opioids  in  the 
benzomorphan ser ies ( V i l l arreal , 1 970 ) , it  seems part icu lar ly  important 
to use pure s tereoi somers in further i nvesti gation  of the op io i d  s igma 
receptor .  
Our  s tudy i nv est igating  the d i scr iminativ e stimu l u s  properti es o f  
-1 65-
cycl a zo c i ne in PCp- tra i ned squi rrel monkeys ( Experiment V I ) demonstrates 
that for another benzomorphan op io id  whi ch  has been found to general i ze 
to PCP ( Tea l and Hol tzman , 1 980a ; Herl i ng et {L, 1 98 0 ;  Hol tzman , 1 980 )  
the  PCP- l i ke d i scr im inative  stimul us properti es res i de  i n  the  ( + )  i somer . 
I n  our s tudy ,  the (- ) i somer was approximatel y 200 times more potent 
then the ( + )  i somer in response rate suppres s i o n .  Thi s  potency ratio  
i s  cons i s tent wi th the l arge potency di fference reported by Teal and  
Ho l tzman ( 1 980 )  for the effect of cycl azoc ine  s tereo i somers on operant 
behav ior  i n  the squi rrel monkey , but marked ly  'd i fferent from the only 3 to 
4 -fol d potency d i fference reported by McMi l l a n  and Harri s ( 1 971 ) ' for t he  
effects o f  cyc lazoc ine  s tereo i somers on  operant behavior  i n  t he  p i geo n .  
The potency di fference between the stereo i somers o f  cycl azoc i n e  for 
response rate suppress i on i n  the squi rrel monkey proba bly expl a i ns the 
fact that racem ic  cycl azoc ine did not genera l i ze to PCP i n  our study . 
I t  woul d  be imposs i bl e  to get a 'h i g h  enough  dos e  o f  the (+)  i s omer i n  
t h e  racemi c m ixture t o  produce PCP-appropri ate res pond ing  wi thout a dose 
of the  ( � ) i somer whi ch  wou l d  compl etely suppre�s responding . 
The s tud i es wi th enantiomers of N-a l l ynormetazoc i ne and cycl a zoc i n e  
( Experiments I V  a n d  V I ) c l earl y su pport t h e  i dea that t h e  ( + )  and ( - )  
i s omers i n  the benzomorphan seri es are , often two di fferent drugs wi th 
v ery d i fferent spectra o f  pharmacolog ical  acti v i ty .  I t  a l so a ppears 
that the (+) i somers of cycl azoc i ne and N-al l ynormetazoci ne are respons i bl e 
for the PCP- l i ke properti es of these compounds . It wou l d  be i nteres t i ng 
to i nvesti gate the stereo isomers of these compounds i ndi v idua l l y  i n  the 
chron i c  s p i na l  dog to see if the (+)  i somer i s  in  fact respon s i bl e for 
the s igma profi l e  of acti v i ty i n  the chron ic  s p i na l  dog . It wou l d  a l so  
be of i nterest to use  pure  stereoi somers o f  these compounds i n  wh ich  
i nvest igations of spec i fic  b inding  s i tes for PCP and i n  expl ori ng s igma 
op i ate receptor b ind i ng . In th is  regard , I am currently tra i n i ng rats  
to d i scriminate ( + ) -N-a1 l yl normetazoc i ne from sal i ne because  we bel i ev e  
that th i s  compound may prove t o  b e  a better prototype s igma receptor 
a go n i st than the racem ic  m ixtur e .  We have been successful in tra i n ing  
the d i scr imination and pl an  to  test  var ious  aryl cycl oal kyl amines  and 
benzomorphans  for genera l i zation . The ( + ) -N-al l yl normetazoc ine  cue  may 
prove to be an  excel l ent behav ioral model for s igma a gon ist  act i v i ty .  
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I n  Exper iment IV , we demonstrated that high  doses  of nal oxone d id  not 
, a ntagon ize  the d i scrm i native sti mul us  properti es of the (+)  i somer or 
the response rate su ppress ion  produced by the (- )  i somer of N-a 1 1 yl nor ­
metazoc ine  i n  rats or s qu irrel monkeys . Al though some i nvestigators 
report antagonism of some of the effects of N-al l y1 normeta zoc i ne  by h i g h  
doses of opiate a ntagoni sts (Mart i n  et �. , 1 976 ; Iwamato , 1 97 9 ) , 
i nvestigations of the effects of N-al l yl normetazoc i ne on operant perfo r ­
mance ( Harr i s , 1 980 ) ,  a s  an  ant iconvul sant ( Cowan e t  �. , 1 979 ) , or  a s  
a d i scriminative stimul u s  (Tea l a n d  Hol tzma n ,  1 980c ) i nd icate that these 
effects are not antagon ized by nal oxone . It ' i s  a l so of i nterest  i n  thi s 
context that Tea l and Hol tzman ( 1 980b) found that the drug-l ever a ppro­
priate respondi ng produced by ( - )  and ( ± ) -cycl azoc ine  i n  squ irrel monkeys 
tra i ned to d i scr im inate ( ± ) -cyc 1 a zoc ine  from sal i ne wa s bl ocked by h i gh  doses 
o f  na loxone whi l e  the drug-l ever a ppropri ate res pond i ng produced by the (+) 
i somer wa s not . In add i tion , Teal and Hol tzman ( 1 979 )  reported tha t  i n  
rats tra i ned to d i scriminate cycl a zoc i ne wa s bl ocked by nal oxone wh i l e  the 
general i zation of PCP and ketamine  to cycl azoc i n e  was not . I t  i s  l i kel y that 
the d i scrimi native stimu l u s  cue  of cycl azoc i ne refl ects the d i fferent 
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pharmaco l ogica l  properti es of both the ( + )  a nd ( - )  i somers . I t  a l so 
s eems cl ear that some of the biol og ical act i v i t i es of racemic m i xtures 
o f  cyc l a zoc ine and N-a1 1 y1 normetazocine are not antagoni zed by na l oxone  
a nd therefore proba bl y  not  med i ated by opi ate receptors . I t  i s  pos s i bl e 
tha t t he  ( + )  i somers are respons i b l e  for the non-opi o i d  act i v i ty o f  
t h e s e  compounds . If t h i s  i s  the case ,  then the pharmacol ogical  overl a p  
betwe21i the aryl cyc l oa1 kyl amines and the s igma agonists may l i e  i n  t he  
non -opioid  s pectra of activ i ty of these s igma a gon i sts . Thi s a l so 
s uggests that the psychotomimet i c  s ide  effects produced by some cl i n i ­
ca l l y u s ed benzomorphans (e . g .  pentazoc ine )  may b e  el imina ted by remov i n g  
t h e  ( + )  i somer wi thout affecting  t h e  effi cacy of the dru g .  
Experiment V was desi gned to determine  i f  the stereosel ect iv i ty o f  
t h e  PCP- l i ke d i scrimi nat i ve  stimu l u s  properti es of the opioids  wa s a l s o  
fou nd i n  an  ary1 cyc l oa l kyl amine with  a ch ira1  center . The resu l ts  
i ndi cate that both s tereo i somers of ketamine  are approximately  equ i ­
potent i n  producing  drug-l ever a ppropri ate respond i ng and i n  response 
rate su ppres s ion hi rats tra i ned to discrim i nate  PCP from sal i ne . Thi s 
i s  cons i s tent wi th much of the l i terature wh ich  i nd i cates quantitative  
a nd qual i tat ive  s i m i l ar it ies in  the effects of stereoi somers of ketami ne 
i n  a vari ety of procedures ( Mari etta � !l. , 1 97 7 ;  Ryder et �. , 1 978 ; 
Me1 i s ka et !l. , 1 979 ) . I t  i s  poss i bl e  that other aryl cyc1 a l kyl amines  wHh 
ch ira 1  centers wi l l  be more us eful i n  expl oring  the s tereospeci fi c i ty o f  
the effects of th i s  group  of compounds . 
I n  conc l u s i on , PCP- l i ke drugs have proved to be a v ery fas c i nati ng  
a nd u n i qu e  cl ass  of compounds . The overl a p  between PCP and the psycho­
tomimetic  opioids  is  espec ia l l y  i nterest i ng .  Further exp lorat ion  i n  
th i s  d i rection cou l d  prov ide i nformation  o f  va l ue  i n  improv i ng the  
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therapeut i c  usefu l ness of  bot h  cl asses o f  compou nds and i n  add i ng to' 
the body of knowl edge concern i n g  psychotomimetics  and psyc hotic  behav i o r . 
The research reported i n  th i s d i s serta t ion  ha s contr i buted towards 
these . a ims . 
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